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ABSTRACT 
Rational design, synthesis and characterization of amide functionalized pyridine and 
benzimidazole transition metal complexes 
Samuel S.K. Asem 
December 14, 2011 
This study expands our efforts to make a new class of Pt (II) compounds analogous 
to cisplatin and its derivatives using sterically hindered ligands. Pt compounds in this 
series have been synthesized using specially designed pyridine and benzimidazole 
ligands. These heterocycles, amide functionalized at position 2 with aryl and alkyl 
pendants, rapidly change their mode of coordination depending on the pH of the medium. 
These ligands, synthesized using condensation chemistry, also coordinate to Co(II), 
Ni(H), Cu(lI), and Zn(1I) generally as anionic bis-chelates through the benzimidazole 
nitrogen and the carbonyl oxygen, creating a four-coordinate complex with the exception 
of an unusual trigonal bipyramidal Zn(H) complex. I H NMR temperature studies reveal 
that these ligands interconvert between imide and amide isomers and that electron 
withdrawing pendants favor amide isomers. Crystal structures of Co(II) and Ni(1I) 
complexes of N-( I-methylbenzimidazol-2-yl)cyclohexanecarboxamide, for example, 
show two ligands bind per metal ion when reacted with acetate and nitrate salts. The bis-
chelates of these Ni(1I) complexes also show expansions of their coordination spheres 
v 
from four to five-coordinate. Furthermore, these Ni(II) bis-chelated complexes possess 
square planar or distorted 4-coordinate geometries. 
The synthesis and properties of several new Pt (II) complexes containing these 
ligands will be presented. A second generation and novel complex class containing 
metal-binding, linker and recognition domains is reported. Both classes of Pt complexes 
were obtained using a synthetic methodology which favors the cis isomers. The second 
generation complex crystallizes in the monoclinic space group P2dn with lattice 
dimensions a = 17.7393(5) A, b = 11.4632(3) A, c = 19.3959(5) A and ~ = 99.794(3)°. 
These complexes have been characterized using physical methods that include X-ray 
crystallography, IH &13C NMR, Mass spectrometry, UV and IR spectroscopies. 
Complexes similar in structure to cisplatin and carboplatin show varying cytotoxic 
properties toward different cancer cell lines. Additionally, some of these new Pt 
complexes show comparable and promising cytotoxicity against prostate cancer cell 
lines. 
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Metalloenzymes and metalloproteins have been of intense interest partly because 
of their enormous ability to enhance rates of reactions that are orders of magnitude 
unparalleled by the best chemical catalysts [1-3]. As a result, they have found utility in 
biofuel production and pharmaceutical processes such as vaccine production and biocells 
[4-9]. These enzymes are able to enhance reaction rates by utilizing one or a combination 
of six mechanisms; proximity and orientation effects, acid-base catalysis, covalent 
catalysis, electrostatic catalysis, preferential binding to the transition state complex and 
metal ion catalysis[I-3, 10-14]. 
The discrimination and preference of ~-D-glucopyranose over other pyranoses as 
a substrate of hexokinase in glycolysis is an example of an enzyme that uses proximity 
and orientation effects. That is, hexokinase's ability might be because ~-D-glucopyranose 
is the only monosaccharide with all its hydroxyl groups in the equatorial position. As 
such, it is able to engage in hydrogen bonding with all the hydroxyl groups of the 
monossacharide. Thus, the binding of glucose for phosphorylation requires the 
cooperative interactions of all the hydroxyl groups with specific amino acid residues 
located in and around the active site of the enzyme. The alignment or orientation of these 
bulky groups might also be critical for both substrate docking at the active site and 
stabilization [1, 15]. 
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Another mechanistic approach involves the allosteric binding of co-factors to 
these enzymes. Through these interactions, co-factors are able to induce activation or 
deactivation of the enzyme by either causing global or local changes. The binding in 
allosteric sites causes conformational changes resulting in re-positioning of residues in 
close proximity to the binding site or within the active site. Consequently, residues that 
once helped to stabilize a substrate will no longer be there resulting in an alteration of the 
enzyme's activity. That is, subsequent substrates are prevented from docking. An enzyme 
that uses this approach is ribonucleotide reductase which converts ribose to deoxyribose. 
The binding of adenosine triphosphate (ATP) to an allosteric site of a subunit of 
ribonucleotide reductase brings the phenolic side chain of tyrosine within reach for a 
radical reaction with the Fe(III)-O-Fe(III) cluster. This initiates a cascade of events that 
converts ribose to deoxyribose via abstraction of hydrogen. The binding of A TP to a 
different allosteric site deactivates the enzyme. Through these interactions, up-regulation 
and down regulation of pathways in biological systems are achieved [1]. 
Metal ion catalysis usually involves transition and p-block metal centers such as 
Mn, Fe, Ni, Zn and Cu [1, 16-17]. In Cu, Zn-superoxide dismutase for example, the two 
metals are bridged and bound by the imidazole of the amino acid residue histidine. 
Superoxide dismutase catalyzes the conversion of superoxide into hydrogen peroxide and 
oxygen [14, 18-25]. Without the action of superoxide dismutase and a cascade of 
enzymes, the build up of superoxide, generated during the production of ATP, leads to 
oxidative stress. Left unchecked, essential components of the cell like the cell membrane 
are damaged. A damaged cell membrane impairs cell homeostasis, the cell's ability to 
2 
regulate flow of nutrients and waste to maintain optimal conditions necessary for 
cytoplasmic enzymes. 
The general structure of these metalloproteins could be described as having 
primary and secondary coordination spheres. The first coordination sphere, for discussion 
in this work, refers to the metal binding site, while the second coordination sphere refers 
to the portion of the enzyme that can participate in substrate stabilization and 
functionality[26]. The ability of metalloenzymes to perform their respective tasks is 
largely due to hydrogen bonding, as evident in hexokinase and other non-covalent 
interactions among side chains of amino acid residues. Desiraju et. al. defines the 
hydrogen bond, X-H···Y-Z, as an attractive interaction in which an electropositive H 
atom intercedes between two electronegative species X and Y(X,Y = F, 0, N) and brings 
them closer together [27-28]. The strength of these interactions are not only dependent on 
the electronegativity of X and Y, but also the directionality or angle of contact [27-28]. 
These interactions have energies between 0.5 to 40 kcal mor l [27] and play key roles in 
the eventual structure and function of these metalloenzymes. They also affect the 
primary, secondary and tertiary folding of these enzymes, and in some cases also help 
stabilize substrate and transition state intermediates of the reactions they catalyze. 
Interactions between amino acid residues are also utilized in substrate recognition, 
selectivity and specificity [29]. Additionally, weaker hydrogen bond interactions 
involving X= C, 0, Nand Y= 0, N, CI, M-CI have been reported to play important roles 
in the stabilization of solid-state structures [27-28, 30]. Models to study these enzymes 
have involved imidazole-transition metal complexes partly because of the numerous 
histidine bound metalloenzymes [14,31]. However, these complexes do not show the 
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same selectivity or secondary coordination environment. Furthermore, imidazole 
complexes are relatively difficult to synthesize compared to benzimidazole [32]. 
Benzimidazoles bind in a similar fashion as imidazoles and also offer steric bulk that can 
be used to shape the secondary coordination environment. Chapter III will examine the 
complexation of novel functionalized benzimidazole derivatives to selected first row 
transition metals under basic condition. 
Increasingly, transition metals are being studied not only for their catalytic 
properties [33-34] but also for their role in therapeutics as cures for diseases and 
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Figure 1.1: Chemical structures of the most important anticancer metal drugs [45]. 
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Vanadium complexes are being investigated for their insulin-like properties as 
treatments for diabetes [46]. Copper [47-54], ruthenium, rhodium, palladium, osmium 
and iridium are all under investigation for their anti-tumor properties based on the 
success of platinum compounds such as cisplatin (diamminedichloroplatinum(II)) [45, 
55]. 
For nearly 40 years, the biological activity of cis-diamminedichloroplatinium(II), 
known as cisplatin, and its derivatives (e.g. carboplatin) have been the focus of extensive 
investigation in an attempt to elucidate their mode of action toward a variety of human 
malignancies [45,56-58]. Cisplatin is an effective therapeutic toward testicular cancer, 
and is used to treat ovarian, head and neck, esophageal, cervical, and non-small cell lung 
cancer, as well as melanoma, bladder carcinoma, and neuroblastoma [44-45, 59-62]. A 
major drawback associated with the use of cisplatin and other Pt (II) compounds is renal 
toxicity [45, 59], which can be mitigated by hydration and diuresis therapy. In addition, 
cisplatin and carboplatin have limited solubility in water and are administered 
intravenously. Of the thousands of platinum compounds synthesized, only a few have 
reached clinical trials and still fewer have received approval for clinical use. Newer 
derivatives have attempted to exploit steric hinderance of associated bulky ligands in 
retarding thiol coordination; a process believed to playa central role in the deactivation 
of Pt drugs [45,63-65]. Other studies have focused on developing orally active Pt 
compounds containing Pt (IV), which is more inert to ligand substitution compare to Pt 
(II). The Pt (IV) species are thought to be activated by reduction to Pt (II) by intra- and 
extra-cellular agents prior to reaction with DNA[66]. 
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Cisplatin is believed to be activated within the cell by the substitution of both 
chlorides with water. The substitution within the cell is partly predicated on the decrease 
in chloride concentration. Figure 1.2 shows such an activation. Cisplatin's cytotoxic 
effects comes from binding to N7 of guanine in nuclear DNA [14, 55-57, 62, 67-80] and 
an in depth discussion of the mode of action of cisplatin can be found in Chapter IV. 
Figure 1.2: Activation of cisplatin. 
However, undesirable interactions such as reaction of cisplatin with His19 of 
CU,Zn superoxide dismutase [81], ubiquitin [82], albumin [83-85], hemoglobin [86], 
transferrin [87-89] and other proteins [90-91]; all lead to deactivation and contribute to 
drug resistance. Furthermore, 65 to 98% of cisplatin administered intravenously after a 
day is bound to blood plasma proteins with most of the Pt (50-61 %) bound to albumin 
[85]. The binding of cisplatin to these proteins, in many cases, interfers with metabolic 
pathways and accounts for numerous side-effects including hyperzincuria [85] and 
hypozincemia [85], associated with cisplatin chemotherapy. Thus, the need for more 
effective and less toxic drugs. To date only KP1019 (indazolium trans-
[tetrachlorobis(lHindazole) ruthenate(III)], FFCI4a) [92] and NAMI-A (imidazolium 
trans-[tetrachloro(DMSO) (imidazole) ruthenate(lII)] [93] have entered clinical 
evaluation[ 45]. 
A major challenge for most platinated complexes as potential antitumor 
compounds is reaching their target (nuclear or mitochondrial DNA). This may be due to, 
in addition to the afore mentioned, the low intracellular concentration attributable to 
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either low influx or high efflux, and deactivation by thiols. This challenge may be 
addressed by making the ligands of these platinated compounds more non-polar thereby 
facilitating diffusion across the cell membrane. Such an approach would also circumvent 
the reliance on transport proteins that mayor may not be present in cell membranes of 
both small and large cancer cells. Although this approach does not address water 
solubility, injection of these "compounds" directly into tumors, for instance, makes their 
water solubility less critical. Additionally, development of new drug delivery systems and 
the incorporation of these "compounds" into delivery vessels such as lyposomes 
circumvents water solubility. It should be noted that the incorporation of peptide linkages 
in the second generation of Pt complexes presented in this work and discussed later in 
this chapter would enhance the water solubility of some of these novel compounds. 
Chances for Pt-DNA adduct formation are enhanced during the S-phase of cell 
division when DNA is unwound and separated from proteins such as histones into double 
or single strands. The "exposed" DNA strands are now susceptible to reactions with 
activated platinated di-aqua species, resulting in Pt- DNA adduct formation. The 
formation of Pt-DNA adducts prevents a cascade of enzymes from "decoding" the DNA 
and subsequent production of mRNA; a template for the production of amino acids, the 
building blocks of proteins/enzymes. That is, adduct formation, monofunctional or 
bifunctional, prevents transcription, translation and replication. As a result, apoptosis is 
triggered. 
Cancerous cells go through the S-phase of cell division more frequently than 
normal cells, so with more precise targeting, side effects like kidney failure associated 
with the administration of these platinated species can be minimized. Out of thousands of 
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platinum compounds synthesized over the years, only a few have been clinically useful 
(Figure 1.1). Although many compounds have been found to exhibit more potent 
cytotoxic activity against cancerous cell lines in the lab, none has translated into a 
comparable or more potent candidate in clinical trials. This is partly because these 
compounds lack specificity and are unable to differentiate between normal cells and 
cancerous cells and therefore are not clinically useful. 
Reedijk and colleagues have introduced a new class of platinated compounds that 
are tagged with fluorophores [94]. These compounds are activated in vivo through the 
action of esterases. This approach serves two fundamental purposes. The first of which is 
to be able to track the platinated compound through the cell. However, this has proven to 
be more challenging than previously thought because of the limitations of current 
technology. That is, current technology does not allow the confirmation of the attachment 
of the platinum component in vivo to the activated fluorophore, making it difficult to 
ascertain the pathway and mechanism of the platinated compound. However, 
accumulations of fluorophores are in agreement with previous pathways of the action of 
cisplatin [68]. The second rationale behind this approach is to use the fluorophore as 
agents of intercalation (between the bases in the DNA helix), thereby facilitating the 
orientation and binding of the compounds to DNA[68, 95-98]. 
The framework and design of our platinated compounds shows more flexibility 
and promise than any other benzimidazole moieties seen in literature [13,99-107]. The 
addition of peptidic and in some cases lipophilic features, are all aimed at exploiting the 
properties of the cell membrane and increasing cellular concentrations of the platinated 
species. Futhermore, the peptidic sites provide hydrogen bonding sites, similar to 
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cisplatin, enabling the compounds to bind to DNA. Also, the peptidic sites add water 
solubility, a property most of these compounds lack. This approach also circumvents the 
reliance on transport proteins that mayor may not be present in both small and large 
cancer cells. Additionally, the sterics of the ligands minimize interactions and reactions 
with thiols like glutathione [108-111]. 
Two types of ligands are presented in this work (Figure 1.3). Ligands of Type 1 
are a direct coupling of an acyl chloride moiety to the benzimidazole. As, shown in 
Figures 1.3 and 1.4, ligands of type 2 have a linker between the metal binding domain 
and the recognition domain. 
o ' 
0-1. N:+ N H 
/ 
R2 = -{CH2).CHo, -(CH2),.CH3 
R1= H, Me 
Figure 1.3: Types 1 & 2 of the proposed ligand system 
Additionally, the proposed ligand system lends itself to modifications such as 
substitution of the binding domain with an imidazole or pyridine for example, the 
9 
recognition domain with an amino acid, a polypeptide, dye, antibody or a specific 
sequence of oligonucleotides. These variations will shed light on membrane permeability 






Figure 1.4: Type 2 of the proposed ligand system; showing the three domains; a platinum 
binding domain, spacer-linker domain and a recognition domain. 
Reactions involving transition metals, to a large extent are governed by the 
number of electrons in the d-orbital. Platinum(II), a d8 ion, preferably forms square planar 
compounds. It is the most studied with regards to substitution chemistry due to its slow 
reactivity compared to other d8 ions; Pd(II), Au(III), Rh(I) and Ir(I). These reactions 
usually proceed with retention of stereochemistry at the metal center and are affected by 
factors that include trans effect, trans influence, type of ligand (nucleophilic or 
electrophilic), cis effect or steric effects and solvent type (coordinating or non 
coordinating) [112]. 
The most considered and utilized factor in the synthesis of cisp1atin analogs is the 
trans effect. This is evident in the choice of tetrachloroplatinate(II) as starting 
material[54, 59, 63-64, 75,113-115]. Trans effect can be defined as the ability of a bound 
ligand to weaken the metal-ligand bond trans to it.This ability to weaken a bond is also 
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affected by any pi-back bonding the bound trans ligand may be engaged in with the metal 
[116]. Consequently, the incoming ligand substitutes at the site of the weakest bond. It 
should be noted that the extent to which each factor exerts its influence is dependent on 
the conditions [112, 117-120]. Figure 1.5 shows the trans effect. 
I - 1-CI Br Br 
CIII" " Pt- NH3 
+Br +Py 




CI CI Py 
1- Br 1- Br CI 
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2. CI,,, ,· Pt- Py 
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I 
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+NH3 +Br .. CIII "" Pt- Py .. CIII "" Pt- Br 
-CI 
, -Py , 
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Figure 1.5: Substitution of Pt(ll) , the trans effect. 
The first reaction series of Figure 1.5 shows the substitution of a chloride ion by a 
bromide and pyridine. This illustrates the effect of one of the chloride ions and bromide 
ion directing the incoming nucleophile to the trans position. The second step shows the 
bromide ligand having a larger trans effect than the chloride. Subsequent reactions also 
show the effects of bromine and pyridine ligands. It is worth noting that in the first two 
reaction series, both halides are cis to each other whereas a trans product is obtained in 
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the latter. Thus, the stereochemistry of a product can be controlled by the order in which 
ligands/nucleophiles are introduced in the reaction and the starting material. The ranking 
of the trans effect of several species/ligands is shown below. 
- - - - - --
CO, CN , C2~ > PR3 H > CH3 > C6HS , N02, I , SCN > Br , CI > Py,NH3 
,OH , H20 [112]. 
It can be seen from the ranking that iodine posseses a higher trans effect than 
chlorine. As a result, one protocol for the synthesis of cisplatin analogues presented in 
this dissertation utilizes this property. Thus, the starting material tetrachloroplatinate(II) 
is converted to tetraiodoplatinate(1I) prior to its reaction with desired ligands. The pros 
and cons of this reaction route is also presented in Chapter IV. 
This dissertation evaluates the synthesis of novel amide functionalized 2-amino 
benzimidazole ligands and their reactivity with selected biologically relevant first row 
transition metals and platinum. It highlights the successful synthesis of a novel dipeptidic 
platinum moiety, the first in a series and a framework aimed at facilitating Pt -DNA 
adduct formation and the minimization of Pt- thiol interactions. The dissertation also 
examines the packing arrangements of these metal complexes in an attempt to elucidate 
the types of interactions within their crystal lattice, their second coordination 
environment, and their potential as biological models. Furthermore, the cytotoxic profiles 
of selected platinated moieties contained in this series are compared to cisplatin, the 
leading drug against cancer. 
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CHAPTER II 
SYNTHESIS, CHARACTERIZATION, AND ANALYSIS PROCEDURES 
This chapter deals with the synthesis, characterization and analysis of the 
compounds used in this dissertation. Ligands prepared for this work, with the exception 
of a pyridine analog, have either a 1-methylbenzimidazole or 1-H-benzimidazole repeat 
motif. Although some compounds were prepared with similar protocols, they have been 
kept separate because of differences in reaction time and yield. 
A: Procedures for Physical data collection: 
1. Mass Spectrometry (MALDI-TOF) 
Data for all the compounds reported in this dissertation, were collected on a PE 
Biosystems Voyager DE-Pro mass spectrometer with an average laser shot of 70 in the 
positive mode with 2,5-dihydroxy benzoic acid as the matrix of choice. Laser intensities 
were varied for each sample to make sure that resultant peaks were not due to laser 
assisted reactions. The experimental peaks reported in this work are isotopomeric peaks 
with the highest peak intensity in a given cluster. 
2. X-ray Crystallography 
X-ray crystal structures were determined by Dr. Mark Mashuta at the X-ray 
diffraction laboratory, Department of Chemistry, University of Louisville. A complete 
listing of data collection, cell parameters, atomic coordinates, bond lengths and angles 
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are located in the appendix. A single X-ray quality crystal was mounted on a 0.05 mm 
CryoLoop with Paratone oil. CryoLoop was mounted on a Bruker SMART APEX CCD 
diffractometer, with the loop under a stream of liquid nitrogen to reduce the temperature 
to 100 K. A monochromated Mo Ka radiation source (0.71073 A) was used as an X-ray 
source, and frame co-scan exposures were collected using the SMART software package. 
Frame data was processed using the SAINT program to determine the final unit cell 
parameters. The SADABS program was used to correct independent reflections for 
absorption. 
Once data were processed, structures were solved by either direct methods or 
Patterson Methods, and structures were refined by least-squares methods on F2. This was 
done using SHELXL-97, which is incorporated into the SHELXTL suite of programs. 
Non-hydrogen atoms were refined anisotropically, unless they were being modeled for 
disordered. Hydrogen atoms attached to carbon atoms were generally placed in a 
geometrically ideal position and refined as a riding model. Hydrogen atoms attached to 
nitrogen or oxygen atoms were allocated difference maps and refined isotropically, unless 
the heavy atom was modeled for disorder. 
3. KBr-IR Data Acquisition 
Infrared data were acquired on a Mattson Galaxy series 5000 FTIR using the 
diffuse reflectance Infrared Fourier transform Spectra mode (32 scan cycles). Pellet 
samples were prepared by grinding approximately 0.500g KBr (oven dried), with 150mg 
of the complex. 
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4. NMR Data Acquisition 
The NMR data were acquired on a three-channel Inova 500 MHz spectrometer 
with pulse-field capability. Sample preparation for IH NMR identification spectra were 
generally performed by dissolving approximately 5 mg of sample in 0.5 mL of deuterated 
solvent. IH NMR spectra were typically acquired by combining 8, 16 and 32. Spectra 
were acquired with a 45 degrees pulse and an average of two seconds delay. 13C NMR 
spectra were acquired using standard methods over a 14 hour period. The stars in the 
spectra in this work represent solvent peaks. 
5. NMR Experiments 
The general procedure for NMR experiments involves dissolving a measured 
amount of a purified complex in a solvent system of deuterated acetonitrile and 
deuterated water (2: 1 v) in an NMR tube. A IH NMR spectrum is collected before any 
other reactant was added. Sample tubes were shimmed and data was collected overnight 
at regular time intervals. For insoluble compounds of this system, deuterated chloroform 
was used. Temperature based experiments were carried out in deuterated 
dichloromethane from -80 0 C - 2SOC at 100 intervals. 
6. UV -vis Titration 
UV-vis spectrophotometric data was obtained using a Varian Cary 50 Bio UV-
visible spectrophotometer. Scanning was done at a medium rate from 1100 nm to 200 
nm. "'max were determined from aliquots of samples dissolved in 0.5 mL deuterated 
chloroform placed in 10 mL quartz cuvette containing 3 mL dichloromethane. 
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7. Bioassay 
Bioassays were performed in Dr. Paula Bates laboratory by Lavona K. Casson at 
the Brown Cancer Center of the University of Louisville. 150 ilL of culture media, -
1000 cells was pippetted into individual wells of a 96 well plate. The culture contained 
Dulbecco's Modification of Eagle's Medium supplemented with 10% heat inactivated 
fetal bovine serum, 100 U/mL penicillin and 100 Ilg/mL streptomycin. 95 out of the 96 
wells were incubated for 24 hours at 37°C with 5% CO2. After this incubation period, the 
culture plates were treated with compounds of varying concentration in a 0.1 % DMSO in 
water (by volume) solvent. Sample plates were treated with similar concentrations of 
cisplatin in the same solvent, for standard comparison. The sample plates were analyzed 
for remaining cells after five days of incubation using the MTT method. This method 
uses a digestible dye, MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium 
bromide], to quantify the number of living cells present in a given culture medium. 
16.7 ilL of a 0.5 % solution of MTT in buffer solvent was added to each well, and 
the plates were allowed to incubate for 4 hours to allow cells time to digest the dye. 83.3 
ilL of 0.01 M HCI in a 10% sodium lauryl sulfate solution, a lysing agent, was added to 
each well to halt dye digestion. 
The relative concentration of MTT in each well was measured using a mUlti-path 
UV -vis spectrophotometer set at 570 nm. The absorbances of prepared blanks (cell 
cultures with no cytotoxic material) were also measured. Since this method does not 
directly determine number of cells, relative cell numbers are calculated by using the 
absorbance of the control wells (cell cultures with no cytotoxic material added) as 0% 
growth inhibition, and the absorbance of the blank as 100% growth inhibition (complete 
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cell death). The percent growth inhibition of the cytotoxic compound is given by the ratio 
of the percentages of the absorbances of treated wells to control wells. 
B: Materials 
The following is a list of chemicals purchased for the development of this dissertation. 






2-amino-l-methylbenzimidazole, 95%, purified by recrystallization in hot ethyl acetate 
Zinc(II) nitrate hexahydrate, Zn(N03h . 6 H20 
Zinc(II) acetate dihydrate, Zn(C2H30 2h . 2 H20 
Nickel(II) nitrate hexahydrate, Ni(N03h . 6 H20 
Cobalt(II) nitrate hexahydrate, Co(N03h . 6 H20 
Copper(II) nitrate hexahydrate, Cu(N03h . 6H20 
Copper(II) chloride dihydrate, CuCh . 2H20 








N,N' -dicyc1ohexyl carbodiimide (DCC), 99% 


















Deuterated dimethyl sulfoxide 
Acetyl anhydride 
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C: List of Compounds and Nomenclature 
Compound 
1. N-(N' -1-methylbenzimidazol-2-yl)hexadecanamide (Hmbhda) 
2. N-(N'-1-methylbenzimidazol-2-yl)decanamide (Hmbda) 
3. N -(benzimidazol-2-yl)cyclohexanecarboxamide (Hbchca) 
4. N-(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamide (Hmbchca) 
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5. N-(N'-1-methylbenzimidazol-2-yl)benzamide (Hmbba) 
6. N-(benzimidazol-2-yl)benzamide (Hbba) 
7. N -(N' -1-methylbenzimidazol-2-yl)N" -boc-2-amino-2,2-dimethylacetamide 
(Hisoba) == L boc 
8. N-(N' -1-methylbenzimidazol-2-yl)-2-N' -phthalimidylacetamide (Hmbpha) 
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9. N-(N' -1-methylbenzimidazol-2-yl)-2,2-dimethylpropanamide (Hdmmbp) 
crJ Ok I );-N, ---~ N H 
10. N-(N'-I-methylbenzimidaz-2-yl)acetamide (Hmba) 
11. N-(N'-I-methylbenzimidaz-2-yl)-2,2,2-trichloroacetamide (Hmbtca) 
12. N-(benzimidazol-2-yl)-2,2-dimethylpropanamide (Hdmbp) 
H 0 
cr~ k I );-N, ---~ N H 









Compounds 14- 23 
Compound Ligand(L) Rl R2 M Formula 
15 2 Me (CH2)gCH3 Cu ML2 
16 4 Me C6HII Ni ML2 
17 4 Me C6HII Co MLz 
18 6 H C6HS Zn ML3 
19 9 Me C(CH3)3 VO MLz 
20 2 Me (CH2)8CH3 Ni ML2 
21 1 Me (CH2)14CH3 Ni ML2 
22 4 Me C6H II Zn ML2 
23 10 Me CH3 Zn ML2 
24. CU2(OAc)4(Paph [Pap = N-2-pivaloylamino pyridine] 




r'>-~-;: ~~ 0 




Ij '\ N/-f. 
- \ 
H 
26. trans-Bis[(N-pyridin-2-yl)-2,2-dimethylpropanamide]Pt(II) diiodide 
t(PaphPtI2 
~~ t , 
\.-~ NII ·~ 
N\ 0 









28. cis-Bis[(N-pyridin-2-yl)-2,2-dimethylpropanamide]Pt(II) dichloride 
c(PaphPtCh 
o-~-« N 0 











CI-Pt - CI 
I 0 
o-N ~ .. , '/ " N/ ~ - \ H 
Compounds 30 - 45 
Compound Ligand Rl R2 Formula 
30 2 Me (CH2)gCH3 PtL2 
31 4 Me C6H" PtLzI2 
32 4 Me C6H" PtL2 
33 4 Me C6H" PtL2CI2 
34 1 Me (CH2)' 4CH3 PtL2 
35 9 Me CCCH3)3 PtL2I2 
36 9 Me CCCH3)3 PtL2 
37 9 Me CCCH3)3 PtL2CI2 
38 12 H CCCH3) 3 PtL2I2 
39 12 H CCCH3) 3 PtL2CI2 
40 3 H C6H" PtL2I2 
41 13 Me CH2CH3 PtL2CI2 
42a 5 Me C6H5 PtL2CI2 
42b 5 Me C6H5 PtL2CI2 
42c 5 Me C6H5 PtL2CI2 
42d 5 Me C6H5 PtLz 
46 7 Me LbOc PtL2CI2 
D: Synthesis of Compounds 
1. N-(N' -1-methylhenzimidazol-2-yl)hexadecanamide (Hmhhda) 
Triethylamine (1.60rnL, ll.5 mmol) and (3.00 rnL, 9.89 mmol) palmitoyl chloride were 
added to (1.46 g, 9.92 mmol) 2-amino-l-methylbenzimidazole (amb) dissolved in 100 
rnL anhydrous tetrahydrofuran. The reaction was left stirring under a blanket of nitrogen 
in a capped round-bottom flask for 5 days. The solvent was stripped using a rotary 
vacuum evaporator. The product (1.44 g) was extracted with 60 rnL ether. Isolation of the 
product was achieved via evaporation of the solvent using a rotary vacuum evaporator. 
Yield: 3.74 mmol, 37.5 %; Calcd mass: 385.31 glmol, exptl mass: mlz (%) [Mt: 386.64 
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(l00) [(Hmbhda)Ht, 408.58 (55) [(Hmbhda-H)Nat; I H NMR (CDCh): 8: 7.23 (4H, m, 
benzimidazole), 3.79 (3H, s, N-CH3), 2.50 (4H, t, -CHz-, J = 7.5 Hz), 2.38 (2H, t, -CH2-, 
J = 7.5 Hz), 1.76 (4H, t, -CH2-, J = 7.0 Hz), 1.68 (2H, broad-t, -CH2-), 1.26 (l6H, broad-
m, -CH2-), 0.887 (3H, t, -CH3, J = 7.0 Hz). 
2. N-(N' -1-methylbenzimidazol-2-yl)decanamide (Hmbda) 
Method A: (0.789 g, 5.36 mmol) amb was dissolved in 70 mL anhydrous CH2Ch. After 
45 minutes, (l.40 mL, 10.0 mmol) Et3N and (1.20 mL, 5.78 mmol) decanoyl chloride 
was added to the reaction flask. The reaction was left stirring under a blanket of nitrogen 
in a capped round-bottom flask for 7 days. The solvent was stripped via rotary vacuum 
evaporation and the product (1.40 g) was obtained after extraction with 60 mL diethyl 
ether and evaporation of the diethyl ether. (Yield: 4.66 mmol, 86.9 %) 
Method B: (0.904 g, 6.14 mmol) amb was dissolved in 42 mL anhydrous 
dichloromethane. Decanoyl chloride (1.30 mL, 6.26 mmol) was added together with 
(1.20 mL, 8.61 mmol) Et3N to the round-bottom reaction flask. The reaction was allowed 
to stir at room temperature for 24 hours after blowing nitrogen gas for one minute to 
create a blanket. The reaction was rotavaped and reconstituted with 20 mL 
dichloromethane. The solution was treated with a saturated sodium chloride solution. 5 
mL diethyl ether was added after a second rotary vacuum evaporation. 1.05 g of product 
was isolated. (Yield: 3.49 mmol, 56.8 %); Calcd mass: 301.22 glmol, exptl mass: mlz (%) 
[Mt: 301.04 (48) [Hmbdat, 322.92 (20) [(Hmbda-H)Nat; IH NMR (CDCh): 8: 7.28 
(4H, m, benzimidazole), 3.66 (3H, s, N-CH3), 2.51 (2H, t, -CH2-, J = 7.5 Hz), 1.75 (2H, 
q, -CH2-, J = 7.5 Hz, J = 15.0 Hz), 1.30, 1.38 (12H, broad-m, -CH2-), 0.893 (3H, t, -CH3, 
J = 7.0 Hz) 
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3. N-(benzimidazol-2-yl)cyclohexanecarboxamide (Hbchca) 
A solution of cyclohexyl carbonyl chloride (2.72 mL, 20.0 mmol) in 10 mL dry dimethyl 
formamide) was added dropwise to a stirring solution of (1.33 g, 10.0 mmol) 2-
aminobenzimidazole (ab) and triethylamine (5.58 mL, 40.0 mmol) in dry DMF (10 mL). 
The solution was stirred at room temperature for 2 hours and refluxed for 6 hours. It was 
then allowed to cool to room temperature and added dropwise to 350 mL distilled water. 
The resulting precipitate was filtered and washed with 10 mL water. The solid was 
insoluble in methanol and chloroform and was recrystallized in acetone after 5 minutes of 
heating. 1.38 g of product was recovered. 
Yield: 5.68 mmol, 56.8 %, Calcd mass: 243.13 g/mol, exptl mass: m/z (%) [Mt: 243.26 
(100) [Hbchcat; IH NMR (DMSO-d6): 8: 12.02 (1H, s, N-H), 11.38 (lH, s, N-H), 7.42 
(2H, s, benzimidazole), 7.06 (2H, dd, 1 = 4.0 Hz, 1 = 2.5 Hz, benzimidazole), 1.83 (2H, 
d, 1 = 12.0 Hz, cyclohexyl), 1.75 (2H, d, 1= 13.0 Hz, cyclohexyl), l.64 (2H, d, 1 = 11.0 
Hz, cyclohexyl), 1.43 (2H, m, cyclohexyl), 1.24 (2H, m, cyclohexyl) 
4. N -(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamide (Hmbchca) 
Cyclohexyl carbonyl chloride (1.00 mL, 7.36 mmol) was added to a 70 mL solution of 
anhydrous dichloromethane containing (1.20 mL, 8.61 mmol) triethylamine and (1.08 g, 
7.35 mmol) ambo The reaction was stirred under a blanket of nitrogen for 3 days. The 
reaction solvent was stripped under vacuum (rotavap). 1.50 g of desired product was 
isolated after extraction with diethyl ether followed by rotary vacuum evaporation. Yield: 
5.83 mmol, 79.3 %; Calcd mass: 257.15 g/mol, exptl mass: m/z (%) [Mt: 258.48 (68) 
[(Hmbchca) Ht, 280.45 (56) [(Hmbchca-H) Nat, 296.36 (76) [(Hmbchca) Kt ; IH 
NMR (CDCh): 8:12.22 OH, s, N-H), 7.23 (4H, m, benzimidazole), 3.65 (3H, s, N-CH3), 
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2.42 (lH, t, J = 11.0 Hz, cyclohexyl), 2.02 (2H, d, J = 12.0 Hz, cyclohexyl), 1.80 (2H, d, 
J = 11.0 Hz, cyclohexyl), 1.68 (2H, d, J = 10.5 Hz, cyclohexyl), 1.53 (2H, dd, J = 12.5 
Hz, J = 11.5 Hz cyclohexyl), 1.34 ( 2H, m, cyclohexyl) 
5. N-(N'-1-methylbenzimidazol-2-yl)benzamide (Hmbba) 
Benzoyl chloride (0.356 mL, 2.53 mmol) was added to a stirring solution of (0.451 g, 
3.06 mmol) amb in 15 mL tetrahydofuran. Triethylamine (491 ilL, 3.52 mmol) was added 
to the mixture. The solution was stirred at room temperature for four days. 0.557 g of 
product was isolated after extraction with diethyl ether followed by rotary vacuum 
evaporation. Yield: 2.22 mmol, 87.7 %; Ca1cd mass: 251.11 g/mol, exptl mass: m/z (%) 
[Mt: 251.20 (100) [Hmbbat, 273.04 (22) [(Hmbba-H) Nat 289.02 (19) [(Hmbba-H) 
Kt; IH NMR (CDCh): 8: 12.40 (1H, s, amide proton), 8.38 (2H, d, J = 7.0 Hz, ortho-
benzoyl), 7.48 (3H, m, J = 7.0 Hz, para, meta-benzoyl), 7.30 (4H, m, benzimidazole), 
3.78 (3H, s, N-CH3) 
6. N-(benzimidazol-2-yl)benzamide (Hbba) 
A solution of benzoyl chloride (2.32 mL, 20.0 mmol) in 10 mL dry dimethylformamide 
was added dropwise to a stirring solution of (1.33 g, 10.0 mmol) ab and triethylamine 
(5.58 mL, 40.0 mmol) in dry DMF (10 mL). The solution was stirred at room temperature 
for 2 hours and refluxed for 6 hours. It was then allowed to cool to room temperature and 
added dropwise to 350 mL distilled water. The resulting precipitate was recrystallized in 
chloroform. 1.05 g of product was recovered. 
Yield: 4.43 mmol, 44.45 % Ca1cd mass: 237.09 g/mol, exptl mass: m/z (%) [Mt: 238.39 
(69) [(Hbba) Ht ; IH NMR (DMSO-d6): 8: 12.23 (lH, s, amide proton), 8.11 (2H, d, J = 
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7.0 Hz, ortho-benzoyl), 7.58 OH, t, J = 7.0 Hz, para-benzoyl), 7.51 (2H, t, J = 7.0 Hz, 
meta-benzoyl), 7.44 (2H, s, benzimidazole), 7.12 (2H, s, benzimidazole) 
7. N -(N' -1-methylbenzimidazol-2-yl)-N" -boc-2-amino-2,2-dimethyl acetamide 
(Hisoba) or L boc 
Method A: N-boc-2-aminoisobutyric acid (NBAB) (0.481 g, 2.37 mmol) and (0.288 g, 
1.40 mmol) N,N' -dicyclohexylcarbodiimide (DCC) was poured into a round bottom flask 
. 25 mL anhydrous CH2Ch was added to the reaction flask and the reaction was left to run 
overnight. Amb (0.348 g, 2.36 mmol) was added to the reaction mixture. After 7 days, 
the mixture was filtered and the precipitate was washed with methanol and acetone. The 
subsequent solvent of the filtrate was removed under reduced pressure and the product 
(0.339 g) was extracted from the precipitate using 40 mL ether. (Yield: 1.02 mmol, 
43.2%) 
Method B: (0.832 g, 4.09 mmol) NBAB and (0.414g, 2.01 mmol) N,N'-dicyclohexyl 
carbodiimide (DCC) were poured into a round bottom flask. Anhydrous CH2Ch (40 rnL) 
was added to the reaction flask and the reaction was left to run overnight. A white 
precipitate was observed. Amb (0.301 g, 2.05 mmol) was added to the reaction mixture. 
The mixture was filtered after 3 more days and the precipitate was washed with 15 mL 
methanol and 15 mL acetone. The solvent of the filtrate was then removed under reduced 
pressure and the desired product (0.0635 g) was extracted from the precipitate with ether. 
Yield: 0.191 mmol, 9.3 %; Calcd mass: 332.18 g/mol, exptl mass: mlz (%) [Mt: 333.56 
(100) [(Hisoba)Ht, 355.50 (78) [(Hisoba-H)Nat; 'H NMR (CDCh): b: 7.254 (4H, m, 
benzimidazole), 6.20 OH, s, N-H), 3.68 (3H, s, N-CH3, benzimidazole), l.65 (6H, s, 
CH3), 1.48 (9H, s, tert-butyl) 
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8. N-(N' -1-methylbenzimidazol-2-yl)-2-N' -phthalimidyl acetamide (Hmbpha) 
Anhydrous dichloromethane (10 mL) was added to amb (0.196 g, 1.33 mmol). CHCh 
(1.0 mL) and Et3N (0.200 mL, 1.43 mmol) were added to the mixture. The resulting 
solution was combined with phthalylglycyl chloride (0.355 g, 1.59 mmol) dissolved in 
3.0 mL anhydrous dichloromethane. Nitrogen gas was blown over the reaction flask for 
approximately 2 minutes. The solution turned yellow and a precipitate started forming 
after 5 minutes of stirring. 0.245 g of product was isolated via filtration. Yield: 0.733 
mmol, 55.1 %; Calcd mass: 334.11 g/mol, exptl mass: mlz (%) [Mt: 334.93 (100) 
[Hmbphat, 357.93 (11.73) [(Hmbpha)Nat; lH NMR (DMSO-d6): 8: 12.46 (1H, s, N-H), 
7.91 (4H, d, aromatic), 7.42 (2H, s, aromatic), 7.21 (2H, m, aromatic), 4.40 (2H, s, -CH2), 
3.44 (3H, S, N-CH3) 
9. N -(N' -1-methylbenzimidazol-2-yl)-2,2-dimethylpropanamide (Hdmmbp) 
Amb (0.751 g, 5.10 mmol) was dissolved in 40 mL anhydrous CH2Cb. Et3N (1.00 mL, 
7.17 mmol) was added to the solution. Pivaloyl chloride (0.700 mL, 5.53 mmol) was 
added after 15 minutes and the reaction was left for 5 days. 
Purification: A slurry of NaCl, 9.03 g NaCI in 20 mL H20, was added to a separating 
funnel that had 30 mL of the product solution. The mixture was shaken vigorously and 
allowed to equilibrate. The aqueous layer was drained off and 70 mL CH2Cb was added 
to the organic layer. 20 mL H20 was added to the undissolved NaCI and added to the 100 
mL CH2Cb, shaken for a few minutes and drained. The organic layer was transferred into 
a round bottom flask and the solvent stripped via rotary vacuum evaporation. 
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Yield: 1.15 g, 4.99 mrnol, 97.8%; Calcd mass: 231.14 g/mol, exptl mass: m/z (%) [Mt: 
232.43 (100) [(Hdmmbp)Ht; IH NMR (CDCh): 8: 7.26 (4H, m,benzimidazole), 3.64 
(3H, s, N-CH3), 1.30 (9H,s, t -butyl) 
10. N-(N'-I-methylbenzimidaz-2-yl)acetamide (Hmba) 
Amb (0.733 g, 4.98 mmol) was dissolved in 2 mL chloroform. Acetyl anhydride (l.0 mL, 
10.6 mmol) was added to the reaction flask. 0.449 g of product was isolated after rotary 
evaporation and ether extraction. Yield: 2.37 mmol, 47.7 % ; Calcd mass: 189.09 g/mol, 
exptl mass: m/z (%) [Mt: 190.62 (100) [(Hmba)Ht, 212.44 (81) [(Hmba-H) Nat, 
228.39 (64) [(Hmba-H)Kt; IH NMR (CDCh): 8: 12.24 (lH, s, N-H ), 7.28 (4H, m, 
benzimidazole), 3.66 (3H, s, N-CH3), 2.28 (3H, s, -CH3). 
11. N-(N' -1-methylbenzimidaz-2-yl)-2,2,2-trichloroacetamide (Hmbtca) 
Amb (1.05 g, 7.12 mmol) was dissolved in 50 mL anhydrous THF. 2,2,2-trichloroacetyl 
chloride (1.20 mL, 10.8 mmol) and Et3N (1.20 mL, 8.61 mmol) was added to the reaction 
flask. The reaction was stirred under a blanket of nitrogen for 6 days. A white precipitate 
that weighed 1.05 g was obtained after filtration. The solid was dissolved in 25 mL 
EtOH. The solution was heated for 5 minutes to reduce the volume of the solvent. The 
solvent was allowed to evaporate and 0.825 g of white crystals were obtained. 
Yield: 2.84 mmol, 39.8 %; Calcd mass: 290.97 g/mol, exptl mass: m/z (%) [Mt: 289.51 
(95) [(Hmbtca-H)t, 290.48 (60) [Hmbtcat; IH NMR (CDCh): 8: 11.67 (lH, s, N-H), 
7.28 (4H, m, benzimidazole), 3.78 (3H, s, N-CH3). 
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12. N -(benzimidazol-2-yl)-2,2-dimethylpropanamide (Hdmbp) 
Ab (0.549 g, 4.12 mmol) was dissolved in 40 mL anhydrous DMF. Pivaloyl chloride 
(0.659 mL, 5.08 mmol) and Et3N (3.0 mL, 21.5 mmol) was added to the reaction flask. 
An additional 20 mL DMF was added after 30 minutes and the reaction was left for 9 
days. 0.215 g of product was isolated after precipitation in water followed by 
recrystallization using ethanol. Yield: 0.990 mmol, 24.0%, Calcd mass: 217.12 g/mol, 
exptl mass: m/z (%) [Mt: 217.34 (100) [Hdmbpt, 239.24(38) [(Hdmbp)Nat, 
255.13(18) [(Hdmbp)Kt; 'H NMR (CD30D): 8: 7.37 (2H, d, benzimidazole, 1= 8.5Hz), 
7.07 (2H, d, benzimidazole, 1= 9.5Hz), 1.25 (9H, s, t-butyl) 
13. N-(N'-I-methylbenzimidaz-2-yl)propanamide (Hmbpa) 
Amb (0.706 g, 4.80 mmol) was dissolved in 10 mL chloroform. Propionic anhydride (1.0 
mL, 7.80 mmol) was added to the reaction flask and the reaction was stirred at room 
temperature for four days. The reaction solvent was removed under reduced pressure. 
0.170 g of product was isolated following extraction with diethyl ether and rotary vacuum 
evaporation. Yield: 0.837 mmol, 17.4 %; Calcd mass: 203.11 g/mol, exptl mass: mlz (%) 
[Mt: 203.99 (100) [Hmbpat 
15. Bis[N-(N'-I-methylbenzimidazol-2-yl) decanamido]copper(II) Cu(mbdah 
Copper(II) nitrate hexahydrate (0.237 g, 1.26 mmol) was dissolved in 2 mL methanol. A 
solution containing N-(N' -1-methylbenzimidazol-2-yl)decanamide (0.482 g, 1.60 mmol) 
in 5 mL methanol was added dropwise to the stirring copper nitrate solution. The copper 
nitrate solution turned green upon addition of ligand. A green precipitate formed 
immediately upon addition of triethylamine (0.029 mL, 0.208 mmol). The precipitate was 
31 
isolated by vacuum filtration. X-ray quality crystals (green needles/rods) were obtained 
by dissolving the precipitate in 1 mL dichloromethane, layered with 5 mL methanol. 
Yield: 0.263 g, 0.396 mmol, 31.4 %; Calcd mass: 663.34 g/mol, exptl mass: m/z (%) [Mt 
: 663.20 (40) [Cu(mbdaht, 302.42 (70) [(Hmbda)Ht; KBr-IR (cm -I): VC-H = 3129, 
3058, 2957, 2920, 2853 Vc = C = 1621 
16. Bis[N -(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamido ]nickel(II) 
Ni (mbchcah 
Nickel(1I) nitrate hexahydrate (0.0502 g, 0.173 mmol) was added to a 5 mL MeOHlIO 
mL CH2Clz solution containing N-(N' -1-methylbenzimidazol-2-yl)cyclohexanamide 
(0.119 g, 0.463 mmol). A pale blue color was observed after 1 minute of addition of the 
Nickel(II) nitrate hexahydrate. Triethylamine (0.0500 mL, 0.359 mmol) was added to the 
blue solution resulting in a pale blue precipitate after 1 minute. 5 mL H20 was added to 
the mixture. The product was recovered after vacuum filtration. Crystals were obtained 
from via layering using a CH2Clz / ether combination. Yield: 0.0747 g, 0.131 mmol, 
75.7%; Calcd mass: 570.22 g/mol, exptl mass: m/z (%) [Mt: 576.87 (100) 
[(mbchcahNit, 892.30 (50) [(mbchca)3Ni2t; IH NMR (CDCh): 8: 9.24, 5.01, 2.23,1.72, 
1.54,1.33; KBr-IR (cm-I): VN-H = 3435, VC-H = 3120, 3053, 2930, 2859 vc=c = 1617 
17. Bis[N -(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamido ]cobalt(II) 
Co(mbchcah 
N-(N' -1-methylbenzimidazol-2-yl)cyclohexanamide (0.119 g, 0.463 mmol) was 
dissolved in 10 mL CH2Clz and added dropwise to a stirring solution of cobalt(1I) nitrate 
hexahydrate (0.0671 g, 0.231 mmol) dissolved in 5 mL methanol. Triethylamine (0.05 
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mL, 0.359 mmol) was added to the reaction vessel. The resulting precipitate was 
recrystallized in 2 mL acetone I 2 mL ether. Yield: 0.0412 g, 0.0721 mmol , 15.6 %; 
Calcd mass: 571.22 glmol, exptl mass: mlz (%) [Mt: 573.89 (95) [((mbchcahCo)H2t; 
258.45 (100) [(Hmbchca)Ht, 281.43 (20) [((Hmbchca)H)Nat, 471.21 (62) 
[(Hmbchca)(DBA-matrix)Cot; KBr-IR (cm -I): VC-H = 3063, 2930, 2813 vc=c= 1622 
18. Trans-Bis[ N-(benzimidazol-2-yl)benzamidoHN-(benzimidazol-2-yl) 
benzamide ]zinc(II) Zn(bbah(Hbba) 
Zinc(II) nitrate hexahydrate (0.132 g, 0.444 mmol) was dissolved in 5 mL methanol. A 
solution containing N-(benzimidazol-2-yl)benzamide (0.211g, 0.888 mmol) in 5 mL 
methanol was added dropwise to the zinc nitrate solution with stirring. Triethylamine 
(0.140 mL, 1.38 mmol) was added to the solution. The resulting mixture was filtered and 
the solvent of the filtrate was allowed to slowing evaporate yielding x-ray quality 
crystals. Yield: 0.0466 g, 0.0603 mmol, 13.6 %; Calcd mass: 773.18 glmol, exptl mass: 
mlz (%) [Mt: 539.26 (35) [Zn(bbaht; IH NMR (CDCh): 8: 7.98 (6H, ortho-benzoyl) 
7.16 (9H, meta, para-benzoyl), 7.55, 7.38, 7.20 (l2H, benzimidazole) ; KBr-IR (cm-I): 
VN-H = 3322 VC-H = 3062, 2974, 2755 vc-o, C = C = 1764, 1662 
19. trans- Bis[2,2-dimethyl-N -(N' -1-methylbenzimidazol-2-yl)propanamido] 
vanadium(IV) oxide VO(dmmbph 
Vanadyl acetyl acetonate (0.0560 g, 0.211 mmol) was dissolved in 1.0 mL methanol. 
Excess N-(N' -1-methylbenzimidazol-2-yl)-2,2-dimethylpropanamide dissolved in 
methanol was added. An instant color change, blue-green solution to purple solution was 
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observed. A purple precipitate followed and was filtered via vacuum filtration. The 
precipitate was allowed to dry, weighed and recrystallized from methylene chloride and 
methanol. Yield: 0.0659 g, 0.125 mmol, 59.2 %; Calcd mass: 527.20 glmol, exptl mass: 
mlz (%) [Mt: 528.27(100) [(VO(dmmbph)Ht; KBr-IR (em-I): VC-H = 3057, 2960 vc=c 
= 1618 
20. Bis[N -(N' -1-methylbenzimidazol-2-yl)decanamido ]nickel(II) Ni(mbda)z 
N-(N' -1-methylbenzimidazol-2-yl)decanamide (0.482 g, 1.60 mmol) was dissolved in 10 
mL methanol. Nickel(II) nitrate hexahydrate (0.224 g, 0.770 mmol) dissolved in 5 mL 
was added to the ligand. The solution became cloudy after the addition of triethylamine 
(0.200 mL, 1.40 mmol). A pale green precipitate was isolated via vacuum filtration 
(0.670 g, 1.02 mmol). Purple needle crystals were obtained by dissolving the pale green 
powder in 3 mL diethyl ether. The crystals dissolved upon exposure to air. 
Yield: 1.02 mmol, 63.45 %; Calcd mass: 658.35 glmol, exptl mass: mlz (%) [Mt: 302.42 
(30) [(Hmbda)Ht; 659.24 (100) [((mbdahNi)Ht; IH NMR (CDCh): 8: 8.58,5.76,3.48, 
2.77,2.15,1.56,1.30,1.21; KBr-IR (em-I): VC-H = 3153, 3057, 2904, 2857 vc=c = 1618 
21. Bis[N -(N' -1-methylbenzimidazol-2-yl)hexadecanamido ]nickel(II) 
Ni(mbhda)z 
Nickel(II) nitrate hexahydrate (0.0457 g, 0.157 mmol) was added to a 5 mL MeOH/ 5 mL 
CH2Clz solution containing N-(N' -1-methylbenzimidazol-2-yl)hexadecanamide (0.122 g, 
0.317 mmol). A pale blue color was observed after 1 minute of addition of the Nickel(II) 
nitrate hexahydrate. Triethylamine (0.0438 mL, 0.314 mmol) was added to the blue 
solution resulting in a pale blue precipitate. 5 mL H20 was added to the mixture. The 
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product was recovered after vacuum filtration. Yield: 0.0418 g, 0.505 mmol, 32.2 %; 
Calcd mass: 826.53 glmol, exptl mass: mlz (%) [Mt: 827.40 (100) [(Ni(mbhdah)Ht, 
386.57 (28) [(Hmbhda)Ht; IH NMR (CDCh): 8: 8.658 (8H, s, benzimidazole), 5.722 
(6H, s, N-CH3), 2.876, 2.202,1.547, 1.285 (28H,s, -CH2-), 0.886 (6H,s, -CH3) ; KBr-IR 
(cm-I): VC-H = 3145, 3056, 2917 (broad) Vc=c= 1618 
22. Bis (N -(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamido )zinc(II) 
Zn(mbchcah 
Zn(N03h·6H20 (0.0469 g, 0.158 mmol) was dissolved in a 5 mL methanol I 5 mL 
dichloromethane. N -(N' -1-methylbenzimidazol-2-yl)cyclohexanamide (0.104 g, 0.153 
mmol) was added to the flask. After 30 minutes, Et3N (0.044 mL, 0.316 mmol) was 
added. 2 mL CH2Ch and 4 mL ethanol was added to the reaction mixture. It was then 
heated for 10 minutes and filtered. The precipitate was weighed 0.0126 g. Yield: 0.0219 
mmol, 13.8%; Calcd mass: 576.22 glmol, exptl mass: mlz (%) [Mt; 150.44 (64) 
[(amb)Ht ; 257.74 (66) [(Hmbchca)Ht: 578.21 (100) [(Zn(mbchcah)H2t: 726.24 
(14 )[Zn(mbchcah(C6H II )COt 
23. Bis[N -(N' -1-methylbenzimidazol-2-yl)acetamido ]zinc(II) Zn(Hmba h 
N-(N'-I-methylbenzimidazol-2-yl) acetamide (0.0290 g, 0.153 mmol) was dissolved in 
5mL methanol. Zn(N03h· 6H20 (0.0217 g, 0.729 mmol) was added to the stirring 
solution. Et3N (0.021mL, 0.151 mmol) was added to the solution after 30 minutes. An 
instant white precipitate was observed. The reaction was allowed to continue for 20 
minutes after which the precipitate was filtered and washed with 10 mL water. The 
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precipitate was recrystallized in chloroform. Yield: 24.3[,lmol, 33.4%; IH NMR (CDCh): 
8: 7.26,7.25,7.15 (8H, benzimidazole), 3.79(6H, s,N-CH3), 2.30 (6H, s, -CH3) 
24. Trans -Bis[ (N -pyridin-2-yl)-2,2-dimethylpropanamide) ] (f,1-tetrakisacetatocopper ) 
copper(II) 
A stirring solution ofN-2-pivaloylamino pyridine (0.415 g, 2.33 mmol) in acetone (10 
mL) was combined with a solution of Cu(CH3COOh . H20 (0.232 g, 1.16 mmol) in 
methanol (20 mL). The reaction was refluxed for an hour and stirring was continued for 
24 hours at room temperature. The reaction mixture was filtered and the solvent of the 
filtrate was removed via rotary evaporation. The resulting solid weighed 0.194 g and the 
desired product was extracted and reconstituted in diethyl ether for recrystallization. 
Dark green crystals weighing 0.113 g were obtained. 
Yield: 0.157 mmol, 13.5 %; Calcd mass: 718.13 glmol, exptl mass: mlz (%) [Mt: 583.73 
(15) [ CU2(OAc)(Paph 0] + ; 242.76 (100) [CuPapt; KBr-IR (cm-I): VO-H = 3394 VN-H = 
3213,3201 VC-H = 3139, 3086, 2981, 2873 Vc-o = 2550, 2359, 2011, 1866 
25. Cis-Bis[ (N -pyridin-2-yl)-2,2-dimethylpropanamide ]platinum(II) diiodide 
c(PaphPtI2 
KI (1.34 g, 8.09 mmol) was added to K2PtCl4 (0.419 g, 1.01 mmol) dissolved in 5 mL 
H20. The solution was stirred for 40 minutes and added dropwise to N-2-
(pivaloylamino )pyridine (0.360 g, 2.02 mmol) dissolved in 5 mL methanol in a 25 mL 
Erlenmeyer flask. Upon addition of 3 mL methanol and 3 mL water to the reaction flask, 
an instant yellow precipitate was observed. The reaction was maintained at 50°C and 
allowed to run for 1 hour 18 minutes. The yellow precipitate was filtered and washed 
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with 10 mL H20. The product was recovered after vacuum filtration. Yield: 0.532 g, 
0.661 mmol, 65.4 %; Calcd mass: 804.99 glmol, exptl mass: mlz (%) 680.77 (70) [M-It. 
IH NMR (CDCh): 8 10.64 (2H, s, N-H), 8.41 (2H, d, 1= 4.25 Hz, pyridine), 8.16 (2H, 
dd, 1= 2.5 Hz, 1= 1.00 Hz, pyridine), 7.74 (2H, t, I = 7.5 Hz, I = 1.5 Hz, pyridine), 6.95 
(2H, t, 1= 6.0 Hz, 1= 1.5 Hz, pyridine), 1.62 (18H, s, tert-butyl); KBr-IR (cm- I ): VN-H = 
3306, VC-H = 2969, 2871 vc-o = 1713 
26. Trans-Bis[ (N -pyridin-2-yl)-2,2-dimethylpropanamide ]platinum(II) diiodide 
t(PaphPtl2 
N-2-(pivaloylamino)pyridine (0.435 g, 2.44 mmol) was dissolved in 6 mL acetonitrile. 
K2PtCl4 (0.506 g, 1.22 mmol) was dissolved in 5 mL H20. KI (1.62 g, 9.75 mmol) was 
added to the flask containing potassium tetrachloroplatinate(II). The resulting solution 
was added dropwise to the 6 mL solution of ligand and allowed to stir for 30 minutes. 8 x 
68 !lL 3.93 M KOH was added to the yellow solution after 53 minutes. The resulting pale 
yellow precipitate was vacuum filtered after an hour. The yellow precipitate weighed 
0.249 g and was later identified as the bis chelated amido form. The filtrate was 
transferred into a vial and layered with CH2Ch and ethanol (1: 1 v). Golden crystals were 
obtained after a few days. Yield: 0.364 g, 0.452 mmol, 37.1 %; Calcd mass: 804.99 glmol, 
exptl mass: mlz (%) [Mt: 678.33 (65) [M-It. IH NMR (CDCh): 8 10.19 (2H, s, N-H), 
8.54 (2H, dd, 1= 24.0 Hz, la,l b= 5.0,8.5 Hz, pyridine), 7.75 (2H, t, 1= 7.5 Hz pyridine), 
7.03 (2H, t, 1= 6.0 Hz, pyridine), 1.60 (18H, s, tert-butyl); KBr-IR (cm- I ): VN-H = 3300, 
VC-H = 2963, 2871 Vc-o = 1713 
37 
27. Trans-Bis[ (N -pyridin-2-yl)-2,2-dimethylpropanamido ]platinum(II) t(Pap hPt 
Method A: KI (2.31 g, 13.9 mmol) was added to a 25 mL Erlenmeyer flask containing 
K2PtCI4 (0.721 g, 1.74 mmol) dissolved in 6 mL H20. An additional5mL H20 was added 
to the flask. N-2-(pivaloylamino)pyridine (0.619 g, 3.47 mmol) dissolved in 12 mL 
acetonitrile was added dropwise to the reaction flask after 26 minutes of stirring. 4 x 572 
!!L 3.93M KOH was added after 46 minutes. The resulting pale yellow precipitate was 
vacuum filtered and washed with 25 mL H20 after an hour and 41 minutes. 0.444 g of 
product was obtained. The sample was purified by recrystallization using chloroform as 
solvent. (Yield: 0.808 mmol, 46.5 %). 
Method B: (0.103 g, 0.128 mmol) PapPtI2 was added to 12 mL acetonitrile / water 
solution (3: 1 v). The resulting slurry was put on a hot plate at 85°C. 80 !!L 3.93M KOH 
was added in increments of 0.010 mL. The mixture became clear after the addition of 
0.030 mL of the potassium hydroxide. The solvent was stripped in vacuo after an hour. 
The yellow solid was reconstituted in a mixture of 2 mL CH2Ch / 6 mL MeOH. (Yield: 
20.0 %) 
Method C: (Pap hPtCh (0.198 g, 0.317 mmol) was added to 10 mL acetonitrile / 5 mL 
water solution. The resulting slurry was put on a hot plate at 85°C. 0.105 mL of 3.93M 
KOH was added to the mixture. A light green / yellow solution was observed after 15 
minutes of addition of base. After 1 h 30 min, the reaction was allowed to cool to room 
temperature (10 minutes). A yellow solid (0.0274 g) was recovered after filtration. 
Yield: 0.0499 mmol, 15.8 %; Calcd mass: 549.17 g/mol, exptl mass: m/z (%) 551.49 
(100) [MH2t. IH NMR (CDCh): 0: 8.82 (2H, d, J = 5.5 Hz, pyridine),7.67 (2H, t, J = 7.5 
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Hz, pyridine), 7.11 (2H, d, J = 9.0 Hz, pyridine), 6.87 (2H, t, J = 6.0 Hz, pyridine), 1.26 
(I8H, s, tert-butyl); KBr-IR (cm -I): VC.H = 3121, 3093 vc.o = 1616 
28. Cis-Bis[ (N -pyridin-2-yl)-2,2-dimethylpropanamide ]platinum(II) dichloride 
c(PaphPtCh 
(2-pivaloylamino)pyridine (0.185 g, 1.04 mmol) dissolved in 10 rnL methanol, was 
added dropwise to an orange K2PtCl4 solution (0.213 g, 0.514 mmol) K2PtCl4 dissolved 
in 6 mL H20. The reaction was maintained at 50°C. The solution became cloudy after 30 
minutes and intensified through the course of the reaction. Stirring of the reaction was 
discontinued after two hours. The pale yellow precipitate was filtered, washed with 8.4 
mL water, dried and weighed (0.107 g, 0.172 mmol). The filtrate was returned onto the 
hot plate after 10 minutes and stirred at 50°C for an additional 6 hours 35 minutes. The 
solvent of the filtrate was stripped via rotor vacuum and 0.152 g of product was 
recovered. Both samples were combined and recystallized in chloroform. Yield: 0.245 
mmol, 81.31 %; Calcd mass: 621.12 g/mol, exptl mass: m/z (%) 588.8 (95) [M-Clt. IH 
NMR (CDCb): 810.66 (2H, s, N-H), 8.33 (2H, d, J = 4.0 Hz, pyridine), 8.09 (2H, s, 
pyridine), 7.76 (2H, t, J = 7.0 Hz, pyridine), 6.89 (2H, t, J = 6.0, Hz pyridine), 1.57 (I8H, 
s, tert-butyl) KBr-IR (cm -I): VN-H = 3294, VC-H = 3106,2951 Vc-o = 1700 
29. Trans-Bis[(N-pyridin-2-yl)-2,2-dimethylpropanamide]platinum(II) dichloride 
t(PaphPtCh 
Trans-Bis[(N-pyridin-2-yl)-2,2-dimethylpropanamido]platinum(II) (0.403 g, 0.733 
mmol) was dissolved in 33 mL anhydrous dichloromethane. HCI gas, from a sulfuric acid 
- sodium chloride generator, was bubbled through the solution for 18 minutes. The 
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reaction was stirred for 14 hours 12 minutes. A pale yellow precipitate was observed at 
the end of the reaction. The precipitate was filtered and weighed. A weight of 0.0211 g of 
mixed product was obtained. The solvent of the filtrate was stripped (in vacuo) and 0.130 
g of desired product was recovered. Yield: 28.6%; Calcd mass: 62l.12 g/mol, exptl mass: 
m/z (%) 587.83 (58) [M-Clt. IH NMR (CDCh): 8 10.43 (2H, s, N-H), 8.60 (2H, s, 
pyridine), 8.43 (2H, d, J = 4.0 Hz, pyridine), 7.82 (2H, t, J = 8.0 Hz pyridine), 7.08 (2H, 
t, J = 6.0 Hz pyridine), 1.56 (18H, s, tert-butyl); KBr-IR (cm -I): VN-H = 3336, VC-H = 
3140, 2969 Vc-o = 1700 
30. Bis[N -(N' -1-methylbenzimidazol-2-yl)decanamido ]platinum(II) Pt(mbdah 
A dark purple solution containing KI (1.02 g, 0.766 mmol) and potassium 
tetrachloroplatinite(II) (0.318 g, 0.766 mmol) dissolved in 5 mL H20, was added 
dropwise to a 10 mL acetonitrile solution of N-(N' -1-methylbenzimidazol-2-
yl)decanamide (0.461 g, 1.53 mmol). A pale yellow precipitate (0.591 g) was isolated via 
filtration after the addition of two equivalence of 3.93 M KOH. Yield: 0.741 mmol, 96.7 
%; Calcd mass: 797.40 g/mol, exptl mass: m/z (%) [Mt: 795.55 (20) [«mbda)zPt)-H2t, 
302.57 (20) [(Hmbda)Ht; 340.46 (10) [(Hmbda)Kt; IH NMR (CDCh): 8: 7.15 (2H, d, J 
= 7.5Hz, benzimidazole), 7.03 (2H, t, J = 7.5 Hz, benzimidazole), 6.67 (2H, t, J = 7.5 Hz, 
benzimidazole), 6.37 (2H, t, J = 8.5 Hz, pyridine), 3.77 (6H, s, N-CH3), 2.53 (4H, t, J = 
7.5 Hz, -CH2-), 1.82 (4H, dd, h = 14.5 Hz, h = 8.0Hz, -CH2-), 1.61 (8H, s, -CH2-), 1.44 
(4H, m, -CH2-), 1.36, 1.29 (12H, broad, -CH2-), 0.881(6H, t, -CH3); KBr-IR (cm-
I) : VC-H 
= 2952, 2880 v c=c = 1615 
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31. Bis[N -(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamide ]platinum(II) 
pte cyclohexylamb hI2 
KI (0.513 g, 3.09 mmol) was added to potassium tetrachloroplatinite(II) (0.152 g, 0.365 
mmol) dissolved in 5 mL H20. The dark purple solution was combined with a 10 mL 
solution of acetonitrile containing N-(N' -1-methylbenzimidazol-2-yl)cyclohexanamide 
(0.243 g, 0.946 mmol). A yellow precipitate was observed. 0.275 g of product was 
isolated after suction filtration. Yield: 286 ""mol,78.4 %; Calcd mass: 963.08 g/mol, exptl 
mass: mlz (%) [Mt: 965 (13) [((mbchcahPtI2)H2] +,258.46 (l00) [(mbchca)Ht; IH 
NMR (CDCh): 8: 9.73 (2H, s, N-H), 7.55 (2H, d, J = 8.0 Hz, benzimidazole), 7.15 (6H, 
m, benzimidazole), 3.67 (6H, s, N-CH3), 2.80 (2H, t, J = 3.25 Hz, cyclohexyl), 2.45 (4H, 
d, J =12.5 Hz, cyclohexyl) , 2.29 (4H, d, J = 12.5 Hz, cyclohexyl), 1.96 ( 4H, t, J = 3.5 
Hz, cyclohexyl) , 1.500 ( 4H, m, cyclohexyl), 1.395 ( 4H, t, cyclohexyl); 13C NMR 
(CDCh): 8: 174.84(C=O), 144.82, 136.83, 132.76, 124.06, 123.74, 122.79, 117.00, 
111.38, 110.02, 108.87(C=C), 48.42, 45.70,32.27,29.22,28.28, 25.97(Csp3-) 
32. Bis[N-(N' -1-methylbenzimidazol-2-yl)cyclohexanecarboxamido ]platinum(II) 
Pt(mbchca)z 
KI (0.513 g, 3.09 mmol) was added to potassium tetrachloroplatinite(II) (0.152 g, 0.365 
mmol) dissolved in 5mL H20. The dark purple solution was combined with a 10 mL 
solution of acetonitrile containing N-(N' -1-methylbenzimidazol-2-yl)cyclohexamide 
(0.243 g, 0.944 mmol). A yellow precipitate (0.275 g), identified later as the cis-diiodo 
product, was observed. The mixture was filtered and (4 x 71""L) 3.93M KOH was added 
to the filtrate. 0.0139 g of product was isolated after filtration. 
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Yield:0.0197 mmol, 5.40 %; Ca1cd mass: 707.25 g/mol, exptl mass: m/z (%) [Mt: 
708.13 (100) [((mbchcahPt)Ht, 258.35 (46) [(Hmbchca)Ht; lH NMR (CDCh): 8: 7.14 
(2H, d, J = 4Hz, benzimidazole),7.02 (2H, t, J = 7.0 Hz, benzimidazole), 6.66 (2H, d, J = 
8.0 Hz, benzimidazole), 6.38 (2H, d, J = 4.25 Hz, benzimidazole), 3.65 (3H, s, N-CH3), 
2.54 (2H, tt, cyc1ohexane), 2.11 (4H, t, J = 16.5 Hz, cyc1ohexane), 1.83 (4H, t, 
cyc1ohexane), 1.70 (2H, t, cyc1ohexane), 1.63 (2H, t, cyc1ohexane), 1.57 (2H, s, 
cyc1ohexane), 1.36 (2H, m, cyc1ohexane); KBr-IR (cm-1 ): VC-H = 3059, 2925, 2852 Vc = 
C = 1615 
33. Bis[N-(N' -1-methylbenzimidazol-2-yl) cyclohexanecarboxamide ]platinum(II) 
dichloride Pt(mbchcahClz 
K2PtCl4 (0.161 g, 0.388 mmol) dissolved in 5 mL H20 was added dropwise to a slurry of 
5 mL MeOH/ 5 mL MeCN / 6 mL CHCh / 10 mL CH2Cb and N-(N' -1-
methylbenzimidazol-2-yl)cyc1ohexanecarboxamide (0.200 g, 0.777 mmol) on a hot plate. 
The temperature of the mixture was adjusted from 95°C to 60°C after 5 minutes. The 
temperature was raised to 75°C, 30 minutes into the reaction. 5 mL MeOH was added 
after 2.25 hours. A yellow homogenous solution was observed. The solvent of the 
solution was removed by rotary evaporation after 30 minutes. The resulting solid, 0.208 
g, was washed with 40 mL H20 and recrystallized in 5 mL CHCh. Yield: 0.267 mmol, 
68.7%; Ca1cd mass: 779.21 g/mol, exptl mass: m/z (%) [Mt: 745.37 (35) 
[((mbchcahPtCI)Ht, 258.48(100) [(Hmbchca)Ht, 280.46 (10) [HmbchcaNat; lH NMR 
(CDCh): 8: 10.05 (2H, s, N-H),7.19 (8H, m, benzimidazole), 3.62 (6H, s, 
benzimidazole), 2.68 (2H, s, -CH2-), 2.31 (2H, s, -CH2-), 2.15 (2H, s, -CH2-), 1.55 (22H, 
m, -CH2-) 
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34. Bis [N -(N' -1-methylbenzimidazol-2-yl) hexadecanamido ]platinum(II) 
Pt(mbhda)z 
K2PtCl4 (0.156 g, 0.377 mmol) was added to a 15 mL (2: 1 v) acetonitrile/ water solution. 
The mixture was stirred for 30 minutes after which potassium iodide (0.500 g, 0.301 
mmol) was added. After 30 minutes, N-(N' -1-methylbenzimidazol-2-yl) hexadecanamide 
(0.290 g, 0.754 mmol), dissolved in 5 mL acetonitrile, was added to the solution. A 
yellow precipitate was observed after the addition of two equivalents of 3.93 M KOH. 
The product was isolated via suction filtration. Yield: 152 !lmol, 40.4% Calcd mass: 
965.58 g/mol, exptl mass: m/z (%) [Mt: 964.18 (30)[(Pt(mbhdah)-Ht, 386.45(100) 
[(Hmbhda)Ht, 735.43(88) [Pt(mbhda)(matrix-DBA)t . 
35. Cis-diiodo-Bis[2,2-dimethyl-N -(N' -1-methylbenzimidazol-2-
yl)propanamide ]platinum(II) Pt(Hdmmbp )zI2 
K2PtCl4 (0.146 g, 0.351 mmol) was added to a 5 mL (2: 1 v) acetonitrile/ water solution. 
The mixture was stirred for 30 minutes after which potassium iodide (0.486 g, 2.93 
mmol) was added. After 30 minutes, two equivalents of 2,2-dimethyl-N-(N' -1-
methylbenzimidazol-2-yl)propanamide. An instant yellow precipitate was observed. A 
weight of 0.300 g of product was isolated from filtration and drying (in vacuo). Yield: 
0.329 mmol, 93.8 %. IH NMR (CDCh): 8: 9.91 (2H, s, N-H),7.47 (2H, d, J = 8.0 Hz, 
benzimidazole), 7.17 (4H, s, benzimidazole), 7.13 (2H, s,benzimidazole), 3.68 (6H, s, N-
CH3), l.67 (I8H, s, tert-butyl). 
43 
36. Bis[2,2-dimethyl-N -(N' -1-methylbenzimidazol-2-yl)propanamido ]platinum(II) 
Pt(dmmbp)z 
10 mL acetonitrile I water solution (2: 1 v) was added to (0.300 g, 0.329 mmol) 
pte dmmbp hI2 in a 25 mL Erlenmeyer flask. Four aliquots of 71 [.tL of 3.93 M KOH was 
added to the mixture under stirring. A color change (yellow to pale yellow) of the solute 
was observed. The pale yellow precipitate was filtered and dried after 2 hours. 0.180 g of 
product was recovered. Yield: 0.274 mmol, 83.2 % IH NMR (CDCb): 7.14 (2H, d, J = 
8.0 Hz, benzimidazole), 7.02 (2H, t, J = 7.5 Hz, benzimidazole), 6.68 (2H, d, J = 7.5 Hz, 
benzimidazole), 6.40 (2H, d, J = 8.0 Hz, benzimidazole), 3.75 (3H, s, N-CH3), 1.36 (I8H, 
s, tert-butyl); KBr-IR (cm-l ): VC-H = 3061, 3047, 2964, 2871 vc-o = 1708 
37. Cis - Bis[2,2-dimethyl-N-(N'-1-methylbenzimidazol-2-
yl)propanamide ]platinum(II) dichloride Pt(Hdmmbp )ZCh 
Method A: Pt(dmmbp)z(0.180 mg, 0.274 mmol) was dissolved in 25 mL of 
dichloromethane. HCl gas (from a conc. H2S0JNaCl generator) was bubbled through the 
stirring solution for 15 minutes. The light yellow solution became more intensely yellow 
over the 15 minutes. The solvent was evaporated (in vacuo) after 6 hours of stirring. The 
residue was recrystallized in 2 mL CH2Clzi 2 mL ether. Yellow crystals weighing 0.193 g 
were obtained. (yield: 0.265 mmol, 96.9 %) 
Method B: K2PtCl4 (0.925 g, 0.223 mmol) dissolved in 5 mL H20 was added dropwise to 
a stirring solution of N-(N' -1-methylbenzimidazol-2-yl)-2,2-dimethylpropanamide (0.103 
g, 0.446 mmol) in 5 mL ethanol. The reaction was maintained at 50°C. A yellow 
precipitate started forming after 4 hours. The reaction was stopped after 8 hours 35 
minutes. 0.106 g of product was isolated after recrystallization in 2 mL CH2Clzi 2 mL 
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diethyl ether. Yield: 0.146 mmol, 65.4 %. Calcd mass: 727.18 g/mol, exptl mass: mlz (%) 
[Mt: 731.80 (8) [(Pt(HdmmbphCb)H4t, 232.59 (100) [(Hdmmbp)Ht; IH NMR 
(CDCh): 8: 10.39 (2H, s, N-H), 7.19 (6H, m, benzimidazole), 7.11 (2H, d, 
benzimidazole), 3.72 (6H, s, N-CH3), 1.64 (I8H, s, tert-butyl) ; KBr-IR (cm-
I ): VN-H = 
3267,3218 VC-H = 3063,3047,2964,2871 vc-o = 1708 
38. Cis -Bis[ (N -benzimidazol-2-yl)-2,2-dimethylpropanamide ]platinum(II) diiodide 
Pt(Hdmbp hI2 
K2PtCl4 (0.258 g, 0.622 mmol) and potassium iodide (0.798 g, 4.81 mmol) dissolved in 5 
mL water, was added dropwise to (N-benzimidazol-2-yl) 2,2-dimethyl propanamide 
(0.261 g, 1.20 mmol) in 14 mL acetonitrile I 10 mL methanol. A yellow precipitate was 
observed and suction filtered after 7 hours. Yield: 0.172 g, 0.195 mmol, 31.3%.Calcd 
mass: 883.02 glmol, exptl mass: mlz (%) [Mt: 888.49 (26.92) [(Pt(HdmbphI2)Hst, 
218.86 (100) [(Hdmbp)Ht; KBr-IR (cm -I): VN-H = 3325 (broad), VC-H = 2965, 2870 Vc-o 
= 1708 
39. Cis - Bis[ (N -benzimidazol-2-yl)-2,2-dimethylpropanamide ]platinum(II) 
dichloride (Hdmbp hPtCh 
K2PtCl4 (0.416 g, 1.00 mmol) dissolved in 10 mL water was added dropwise to a 10 mL 
tetrahydrofuran solution of (N-benzimidazol-2-yl)-2,2-dimethylpropanamide. An instant 
precipitate was observed upon the dropwise addition, disappearing after a minute. The 
orange solution was maintained at 50°C overnight. The yellow precipitate was filtered 
and dried. A weight of 0.0324 g of desired product was obtained. 
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Yield: 0.463 mmol, 46.3%; Calcd mass: 699.14 glmol, exptl mass: mlz (%) [Mt: 665.58 
(40) [(Pt(HdmbphCl)Ht, 219.04 (100) [(Hdmbp)H2t; IH NMR (CDCh): 0: 11.33 (2H, 
s, amide protons), 10.44 (2H, s, benzimidazole), 8.20 (2H, s, benzimidazole ), 7.39 (2H, 
d, J = 4.5 Hz, benzimidazole), 7.32 (4H, t, J = 7.5 Hz, benzimidazole), 1.48 (l8H, tert-
butyl) 
40. Bis[ N-(benzimidazol-2-yl) cyclohexane carboxamide] platinum(II) diiodide 
(HbchcahPth 
Potassium iodide (1.16 g, 6.98 mmol) was added to K2PtC14 (0.383 g, 0.923 mmol) 
dissolved in 5 mL water under stirring. The resulting purple solution was added dropwise 
to a slurry of N-benzimidazol-2-yl cyclohexanecarboxamide (0.442 g, 1.74 mmol) in 10 
mL methanol. 10 mL acetonitrile and 5 mL water was added to the mixture. A yellow 
precipitate was observed after 1 h 45 minutes. A weight of 0.724 g of product was 
recovered and recrystallized using dimethylformamide and ethanol. Yield: 0.774 mmol, 
83.9 %; Calcd mass: 935.05 glmol, exptl mass: mlz (%) [Mt: 808.12(43.98) 
[((HbchcahPtI)-Ht, 244.88 (l00) [(Hbchca)Ht, 266.96 (24) [Hbchca Nat, 282.73 (8) 
[HbchcaKt; \3C NMR ((CD3hCO): oem): 123.15, 122.45 (d), 118.86 ( s ), 111.94 ( 2H), 
44.77 (s), 35.23 (s), 26.53 (s), 26.53 (s), 25.44(s), 25.19(s); KBr-IR (cm-I): VN-H = 3312, 
VC-H = 3058, 2929, 2853 vc-o = 1708 
41. Cis - Bis[N-(N'-I-methylbenzimidazol-2-yl)propanamide]platinum(II) dichloride 
(Hmbp)PtCh 
K2PtCl4 (0.0879 g, 0.212 mmol) was dissolved in 5 mL water and added to a stirring 
solution of N-(N' -1-methylbenzimidazol-2-yl)propanamide (0.0866 g, 0.424 mmol) in 
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5mL methanol. The reaction was allowed to continue for 17 hours. The yellow precipitate 
was filtered, washed with 5 mL H20 and recrystallized in chloroform. Yield: 0.101 g, 
0.150 mmol, 70.9%, Calcd mass: 671.11 g/mol, exptl mass: m/z (%) [Mt: 637.23 (17.91) 
[(Pt(HmbphCI)H2t, 204.82 (100) [(Hmbp)Ht, 600.33 (30) [Pt(Hmbpht; IH NMR 
(CDCh): 8: 10.20 (2H, s, amide), 7.17, 7.08 (8H, m, benzimidazole), 3.74 (6H, s, N-
CH3), 1.21 (4H, -CH2-), 0.815 (6H, t, -CH3); KBr- IR (em-I): VN-H = 3251, 3145 VC-H = 
2978,2941 Vc-o = 1732, 1699 
42. N-(N'-1-methylbenzimidazol-2-yl) benzamide] platinum(II) and platinum(IV) 
complexes 
K2PtCl4 (0.146 g, 0.351 mmol) was added to as mL (2: 1 v) acetonitrile/ water solution. 
The mixture was stirred for 30 minutes after which (0.486 g, 2.93 mmol) potassium 
iodide was added. After 30 minutes, two equivalents of N-(N' -1-methylbenzimidazol-2-
yl)benzamide, Hmbba, were added. A yellow precipitate was observed. A weight of 
0.300 g of product was isolated from filtration and drying (in vacuo). A 10 mL 
acetonitrile-water solution (2: 1 v) was added to (0.300 g, 0.330 mmol) Pt(HmbbahI2 in a 
25 mL Erlenmeyer flask. Four aliquots of 71 ilL of 3.93M KOH were added to the 
mixture under stirring. A color change (yellow to pale yellow) of the solute was 
observed. The pale yellow precipitate, 0.180 g, was filtered and dried after 2 hours. 
(0.180 g, 0.274 mmol) Pt(mbbah was dissolved in 25 mL of dichloromethane. HCI gas 
(from a cone. H2SOJNaCI generator) was bubbled through the stirring solution for 15 
minutes. The light yellow solution became more intensely yellow over the 15 minutes. 
The solvent was evaporated (in vacuo) after 2 hours of stirring. 
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46. Cis - Bis[N'-boc-2-amino-2,2-dimethyl (N-(N"-l- methylbenzimidazol-2-
yl)acetamide]platinum(II) dichloride (isoba) Pt(LboChCh 
K2PtCl4 (0.0403 g, 0.971 mmol) was dissolved in 5 mL water and added to a stirring 
solution of N' -boc-2-amino-2,2-dimethyl(N-( 1- methyl benzimidazol-2-yl)acetamide 
(0.0645 g, 0.194 mmol) in 10 mL methanol. The reaction was stirred at 80°C for 24 hrs 
and allowed to stir at room temperature for nine days. The yellow precipitate was filtered 
and washed with 5 mL H20. 0.0631 g of desired product was obtained. 
Yield: 67.86 )..lmol, 69.9 %; Calcd mass: 929.27 g/mol, exptl mass: m/z (%) [Mt: 933.02 
(23) [(Pt(Hisoba)ZClz)H4t; IH NMR (CDCh): 8: 10.59 (4H, s, amide), 7.17 (8H, m, 




TRANSITION METAL COMPLEXES 
A: Background Discussion 
The interest in first row transition metals is partly due to an effort to understand 
their vital biological roles in metalloproteins and their potential in medicinal chemistry. 
Ions such as Co 2+/3+[ 17] , Fe 2+/3+ [1, 17], Cu 2+ and Zn 2+ [18, 25] can be found in the 
active sites of such enzymes as glutamase mutase and methionine synthase for cobalt, 
hemoglobin and cytochromes for iron, superoxide mutase and tyrosinase for copper, and 
carbonic anhydrase for zinc, just to name a few. Vanadium(IV) compounds for example 
are being investigated for their insulin-like and anti-tumor activities [17,46]. 
Unlike the s-block metals, transition metals have varying oxidative states. In 
addition to the varying oxidative states, transition metals, because of partially filled d-
orbitals and comparatively low energy barriers between their d-orbitals, are able to 
promote electrons resulting in low or high spin states. Additionally, different 
coordination numbers result for the same oxidative state depending on the ligand field. 
For example, Fe(II) ion in hemoglobin, transitions between a five coordinate 
(deoxyhemoglobin) and a six coordinate complex when bound to O2 without the 
oxidation of the iron center, allowing the transfer of oxygen from the lungs to inner 
tissues in the human body [121]. In cytochrome c however, the iron is used in the 
transfer of electrons in the synthesis of ATP in the mitochondria and cycles between +2 
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and +3 oxidation states [122-125]. Carboxypeptidase has at its core a Zn(II) ion, a p-
block metal with filled d-orbitals, has a N202 donor set with a water molecule 
coordinated in the fifth position. The nitrogens are from histidine residues, while the 
oxygen atoms are from a glutamate residue [17]. This enzyme hydrolyzes peptidic bonds 
without a change in the oxidative state of the metal. Other biological roles of these metals 
include involvement in catalytic pathways, electrochemical processes and radical 
chemistry as evident in methylation during methionine synthesis, proton gradient 
formation during ATP synthesis, or the synthesis of RNA by RNA polymerase. 
In an effort to gain more insight into transition metal behavior, ligands containing 
2-aminobenzimidazole and 2-amino-I-methylbenzimidazole were functionalized into 
amides and complexed to selected biologically relevant metals. This chapter examines the 
coordination modes, coordination numbers and crystallacttice packing arrangements of 
these complexes, synthesized using a 1:2 metal-ligand ratio. 
B: Synthesis and Characterization of Ligands 
Dee 
+ 
Scheme 1: Reaction protocol of 2-amino-I-methylbenzimidazole ligands. 
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Scheme 1 shows some standard reactions that can be used to functionalize an amine into 
an amide. Some of the reaction routes that lead to amide formation involve a Fischer acid 
esterification of a carboxylic acid, followed by reaction with a primary amine. Another 
involves the reaction of an anhydride with a primary amine. A third method usually 
employed is the reaction of an acyl chloride with the primary amine under basic 
conditions. The acyl chloride could be generated by reacting a carboxylic acid and 
thionyl chloride or could be commercially obtained. Generally, acyl chlorides gave 
comparatively higher amide product yields than either anhydrides or esters. Therefore 
reaction routes involving anhydrides or esters were employed only when their respective 
acyl chlorides were not commercially available. Compounds 1-6 and 8-12 were 
synthesized by reacting either 2-amino-l-methylbenzimidazole or 2-amino 
benzimidazole with the respective acyl chloride. Compounds 3 and 6 were synthesized 
using published procedures of Rastogi et ai. [126]. Compound 7 was synthesized by the 
generation of the anhydride (in situ) via DCC coupling, followed by reaction with 2-
amino-l-methylbenzimidazole. Compound 9 was synthesized based on established 
procedures by Philip Bauer [32]. 
The initial solubility of 2-amino-l-methylbenzimidazole crystals is low in 
methylene chloride (-10 mg in 10 mL). However, its solubility is enhanced with the 
addition of triethylamine (usually 1.5 molar equivalence). The use of a solvent such as 
methylene chloride in the synthetic route provides the advantage of the separation of 
triethylammonium chloride from the product solution by simple filtration. The excess 
triethylamine is removed by treatment of the product solution with brine solution in a 
separating funnel. The methylene chloride is then stripped via rotary evaporation. The 
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product is extracted using diethyl ether followed by stripping of the solvent via rotary 
evaporation. Thus, chromatography is avoided. 
Unlike its 1- methyl derivative, 2-aminobenzimidazole has two sites for 
amidation (Nl and 2-amino). Consequently reactions done at room temperature are likely 
to produce mixed products. Additionally, 2-aminobenzimidazole is not soluble in 
methylene chloride. As a result, reactions involving 2-aminobenzimidazole were carried 
out in dimethylformamide according to published protocols by Rastogi et al. with four 
equivalence of triethylamine and six hours of reflux [126]. The product solution is poured 
into a beaker of water (-350-500 mL) upon cooling to room temperature, and the desired 
product is recovered using filtration. The change in solvent and subsequent work-up 
introduces two potential problems, the first of which is the possible protonation of the 
N3, the site necessary for metal-ligand complexation. This is only problematic when 
dealing with platinum complexation discussed in the next chapter. The second potential 
problem involves pi-stacking of these ligands due to hydrophobicity. 
A. IH NMR and Mass Spec. Analysis of Ligands 
Table 3.1 below displays the mass spectrometric data for ligands used in this work. 
Reported below are the exact masses of the most intense isotopomers in selected peak 
clusters. The spectra of these compounds can be located in the appendix. Examination of 
the data reveals agreement of the calculated masses and the experimental masses. 
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Table 3 l ' Mass soectrometric data of ligands 
Compd Calcd. Mass Expt' l mass mJz (peak intensity%) peak characterization 
(ReI. ab 'dance %) 
1 385.31 (75) 386.64 (100) [(Hmbhda)Ht, 408.58 (60) [(Hmbhda)Nat 
2 301.22 (81) 301.04 (46) [Hmbdat, 322.92 (20) [(Hmbda)Nat, 340 (10) [(Hmbda)Kt 
3 243 .14 (84) 243 .26 (100) [Hbchcat 
4 257 .15 (83) 258.48 (68) [(Hmbchca)Ht, 280.45(56) [(Hmbchca) Nat, 296.36 (76) 
[(Hmbchca)Kt 
5 251.11 (83) 251.20 (100) [Hmbbat, 273.04 (22) [(Hmbba-H) Nat, 289.02 (19) [(Hmbba-H)Kt 
6 237.09 (84) 238.39 (69) [(Hbba)Ht 
7 332.18 (81) 333.56 (100) [(Hisoba)Ht, 355 .50 (75) [(Hisoba-H) Nat, 372.36 (46) [(Hisoba) Kt 
8 334.11 (80) 334.93 (100) [Hmbpa t, 357.93 (10) [(Hmbpa)Nat 
9 231.14 (85) 232.43 (100) [(Hdmmbp)Ht 
10 189.09 (88) 190.62 (100) [(Hmba)Ht, 212.44 (82) [(Hmba) Nat , 228.39 (64) [(Hmba)Kt 
II 290.97 (38) 289.51 (95) [(Hmbtca)-Ht, 290.48 (60) [Hmbtcat, 174.41 (55) 
[(methylbenzimidazole)C=Ot 
12 217.12 (86) 217.34 (100) [Hdmbpt, 239.24 (38) [(Hdmbp-H)Nat, 255.13 (18) [(Hdmbp-H)Kt 






i.' ' •.. 'I"" i Ii II iii i. ii, I. iii ii I iii ,. i i "'1 i Ii • 'I 
1 ) 12 11 10 • 7 -0 -1 ppa 
Figure 3.1: IH NMR spectrum of compound 1 in CDCl) 
The I H NMR spectrum of compound 1, Figure 3.1, reveals a multiplet centered at 
7.23 ppm and corresponds to the four aromatic protons of the benzimidazole. The peak at 
3.79 ppm corresponds to the methyl protons attached to the nitrogen (Nl) of the 
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benzimidazole. Peaks appear as triplets at 2.50 ppm, 2.38 ppm, 1.76 ppm, 1.68 ppm and 
0.886 ppm, corresponding to protons of the aliphatic palmitoyl pendant and are in the 
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Figure 3.2: IH NMR spectrum of compound 2 in CDCl3 
The IH NMR spectrum of compound 2 in CDCI3, Figure 3.2, displays a multiplet around 
7.28 ppm that represents the aromatic protons of the benzimidazole moiety. The peak at 
3.66 ppm corresponds to the methyl protons of N1 of the benzimidazole. The peak at 2.51 
ppm, a triplet, corresponds to the two protons of the carbon, ( Ca ), alpha to the carbonyl 
carbon. The peaks at l.75 ppm and 0.893 ppm appear as a quartet and triplet respectively. 
They represent Cp- protons and the terminal methyl protons. The broad peak at 1.38 ppm 
integrates to twelve - CH2- protons. 
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Figure 3.3: 'H NMR spectrum of compound 3 in DMSO-d6 
The IH NMR of compound 3 in deuterated dimethyl sulfoxide (DMSO-d6), shows two 
single peaks at 12.02 ppm and 11.38 ppm.These peaks correspond to the amide and 
benzimidazole protons respectively. The aromatic peaks of the benzimidazole appear at 
7.42 ppm and 7.06 ppm. The peaks at 1.834 ppm, 1.75 ppm, 1.64 ppm and 1.43 ppm 
appear as doublets and multiplets and correspond to the ortho and meta protons. The para 
protons appear as a multiplet at 1.24 ppm. The ipso proton peak is masked by the water 
peak, a common impurity in DMSO-d6, at 2.50 ppm. It ' s I-methylbenzimidazole 
derivative, compound 4, has a similar IH NMR spectrum with the aromatic region having 
a multiplet at 7.23 ppm corresponding to the four aromatic protons of the benzimidazole. 
An amide peak appears at 12.22 ppm. A singlet with a chemical shift of 3.65 ppm 
corresponds to the methyl substituent of the benzimidazole moiety. Cyclohexyl protons 
of compound 4 appear at 2.42 ppm (t), 2.02 ppm (d), 1.80 ppm (d), 1.68 ppm (d), 1.53 










Figure 3.4: IH NMR spectrum of compound 5 in CDC)3 
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Figure 3.4 shows the IH NMR spectrum of compound 5 in CDCh. The singlet displayed 
at 12.40 ppm represents the amide proton. The doublet centered at 8.38 ppm (J = 7.0 Hz), 
represents the two ortho protons of the phenyl, whilst the multiplet at 7.48 ppm 
corresponds to the three protons at the para and meta positions of the phenyl group. A 
multiplet at 7.28 ppm, corresponds to the four aromatic protons of the benzimidazole. 
The singlet with a chemical shift of 3.80 ppm represents the methyl substituent of the 
benzimidazole moiety. The 2-aminobenzimidazole derivative, compound 6, has a similar 
proton spectrum with chemical shifts, in DMSO-d6, at 12.23 ppm (s), 8.11 ppm (d), 7.12 
ppm (d), 7.58 ppm (m), 7.51 ppm (m) and 7.44 ppm (m). The multiplets at 7.58 ppm, 
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Figure 3.5: IH NMR spectrum of compound 7 in CDC)3 
Figure 3.5 displays the IH NMR spectrum of compound 7, N-(N'-l-methylbenzimidazol-
2-yl)-N"-boc-2-amino-2,2-dimethylacetamide (Hisoba), in CDCh. A multiplet at 7.25 
ppm represents the four aromatic protons of the benzimidazole. The peak at 6.20 ppm 
represents the amide proton (boc). Peaks at 3.68 ppm, 1.65 ppm and 1.48 ppm represent 
the methyl group of the I -methylbenzimidazole, dimethyl of the acetyl group and the tert-
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Figure 3.6: 'H NMR spectrum of compound 8 in DMSO-d6 
The IH NMR of compound 8 in DMSO-d6 is displayed in Figure 3.6. The spectrum 
shows an amide peak at 12.46 ppm. The aromatic region displays a doublet, singlet and 
multiplet at 7.91 ppm, 7.42 ppm and 7.21 ppm with an integration ratio of 4H: 2H: 2H 
respectively. The peaks at 4.40 ppm and 3.44 ppm correspond to the two protons of the 
acetyl group and the methyl group of the benzimidazole respectively. Figure 3.7 shows 
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Figure 3.7: 'H NMR spectrum of compound 9 in CDCI3 
The multiplet at 7.26 ppm corresponds to the four aromatic protons of the 2-amino-l-
methylbenzimidazole. The singlet at 3.64 ppm represents the methyl protons of the N 1 
atom (benzimidazole). The nine tert-butyl protons appear as a singlet with a chemical 
shift at 1.30 ppm. Similarly, compound 10 has a multiplet around 7.28 ppm 
corresponding to the benzimidazole protons. Additional peaks at 12.24 ppm,3.66 ppm 
and 2.28 ppm represents an amide, N-methyl and acetyl protons respectively. The IH 
NMR of compound 11 in CDCh, Figure 3.8, shows an amide peak at 11.67 ppm. 
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Figure 3.8: 'H NMR spectrum of compound 11 in CDCI3 
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The four aromatic protons of the benzimidazole appear as a multiplet at 7.28 ppm. The 
methyl substituent of the benzimidazole appears as a singlet at 3.78 ppm. The peak at 
1.50 ppm is a water peak impurity commonly found in CDCb [127]. 
c 
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Figure 3.9: IH NMR spectrum of compound 12 in CD30D 
The IH NMR spectrum of compound 12 in CD30D, Figure 3.9, shows two doublets 
centered at 7.37 ppm and 7.07 ppm with coupling constants of 8.50 Hz and 9.50 Hz 
respectively. Both doublets integrate to four protons and represent the aromatic protons 
of the 1H-benzimidazole. The peak at 1.25 ppm represents the tert-butyl group. Both the 
amide peak and the hydrogen attached to the nitrogen of the benzimidazole are absent 
and might be due to rapid proton exchange with the solvent or tautomerization. However, 
they do show up in CD2Ch at -80DC at 12.15 ppm and 11.51 ppm respectively (spectrum 
in appendix) . Additionally, the aromatic protons appear as singlets in the ratio 1: 1:2 with 
chemical shifts of 7.57 ppm, 7.35 ppm and 7.21 ppm. The tert-butyl peak appears at 1.26 
ppm. 
The IH NMR of the ligands performed in CDCb, 2-amino-1-
methyl benzimidazole derivatives, compounds 1,2,4,5, 7,9 and 10, show broad amide 
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proton peaks with little or no peak intensity. In some cases, amide peaks are not visible. 
From a 1 H NMR data interpretation view point, the absence of an amide peak is 
problematic. However, the aromatic proton signals of the 2-amino-l-
methylbenzimidazole aggregate into a single multiplet peak when the primary amine is 
coupled to the carbonyl carbon of the acyl chloride. This can be used as a diagnostic tool 
for this system. The variation in amide peak intensity might be due to rapid proton 
exchange with the solvent or conversion between tautomeric conformers in solution. The 
tautomeric and resonance forms (1, 2 and 3) for the acetyl and benzamide derivatives in 
both solid and solution are shown in Figure 3.10 [128-135]. 
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Figure 3.10: Tautomeric and resonance forms of acetyl and phenyl derivatives adapted and modified [32] 
Furthermore, the tendency of these ligands to exist as imides, ((2) in Figure 3.10), is 
directly proportional to the electron withdrawing strength of the attached amide coupling 
group [32]. The dominance of the imide form over the amide, may be due to resonance 
assisted hydrogen bonding [134-135]. Out of the seven IH NMR spectra obtained in 
CDCh, only compound 11, the most electron withdrawing of the series, shows a sharp 
amide peak. What this suggests is that compound 11 has either a comparatively slower 
proton exchange with solvent at room temperature or a preference of one tautomer over 
the other in solution, unlike the acetyl derivative or the tert-butyl derivative (compound 
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9). To investigate this phenomenon, lH NMR temperature experiments from -80 °C to 25 
°C were carried out in CD2Clz using compounds 3, 4, 9 and 11. Figures 3.11- 3.13 display 
the stacked plots for these experiments. 
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Figure 3.11: Stack plot of compound 3 in CD2Ch; showing the broadening of the amide peak with rise in 
temperature. H is tautomeri zed proton. 
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Figure 3.12: Stack plot of compound 4 in CD2CI2 ; showing the broadening of the amide peak with rise in 
temperature. 
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Figure 3.13: Temperature stack plot of compound 11 in CD2Cl2 
At -80 °C, the tautomeric process is slow to a point where the amide peaks of all 
three compounds (3,4 and 11) can be seen. As the temperature is increased, the amide 
peaks of compounds 3 and 4 begin to broaden as a result of an increase in the rate of 
interconversion between imide and amide isomeric forms . The amide peak of compound 
11, however, remains sharp at all the temperatures (-80 °C to 25 °C), indicating a lack of 
interconversion between isomeric forms . The implication and significance of this in terms 
of property and tendency towards metal chelation will be explored in the next chapter. 
Additionally, proton exchange with the solvent can be ruled out since dichloromethane is 
a non-coordinating solvent and therefore cannot engage in the traditional (Bronsted) 
acidlbase proton exchange with molecules in this series. It should be noted that 
compound 9 displays a temperature profile similar to that of compounds 3 and 4. 
Compound 9 has been extensively investigated in our laboratory. 
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Figure 3.14: Drawing of compound 9 
Work done by Philip Bauer shows a preference for the imide isomer in the solid 
state [32]. Furthermore, theoretical calculations for the isomeric form 3 of compound 9, 
(Figure 3.10), show that the energy barrier is too high, making this form not easily 
accessible. This however does not preclude this state as a possible intermediate step in its 
binding to metals. Furthermore, additional stability is gained through resonance in some 
2-acylamido forms of similar heterocyclic moieties [132-133] . The pKa and coordination 
f d 9 C 2+ N' 2+ C 2+ d Z 2+ · h' . o compoun to 0 , 1 , U an n IOns, avmg acetate or mtrate as 
counterions, has also been investigated [32]. In his study, the pKa of compound 9, 
Hdmmbp, was determined as 4.25, lower than acetic acid (4.74). Thus, the conjugate base 
of acetic acid should be able to deprotonate Hdmmbp, transforming it into a bis chelate 
anion, consequently promoting metal complex formation using metal acetate salt as 
starting material. Based on the experimental data, it was shown that the binding 
properties of Hdmmbp was pH dependant. Thus, the ligand has a propensity of forming 
predominantly neutral four coordinate complexes with the aforementioned first row 
transition metals (Figure 3.15) [32]. 
64 
M = Co, Ni, Cu, Zn 
Figure 3.15: Metal complexes of compound 9 
The above study has been extended to include vanadium and is discussed later in 
the chapter. Additionally, a similar study involving the pyridine analog of compound 9, 
2- pivaloyl amino pyridine, purchased from Sigma-Aldrich is discussed in more detail in 
the next chapter. 
B: Synthesis and Characterization of Metal Complexes 
Based on findings from previous studies, benzimidazole metal-complex derivatives 
were synthesized using metal nitrate salts and base. The preference of nitrate salts over 
acetate salts was primarily driven by an effort to increase yield. Except for the vanadyl 
complex, all metal complexes were obtained with a metal to ligand ratio of 1 : 2. Excess 
ligand was used in the case of vanadium to drive the reaction towards the formation of 
the bis chelated complex (diamido form). 
Color changes were observed upon the combination of the dissolved metal salt and 
ligand methanol solutions of Cu2+, Co2+ and Ni2+. These findings are consistent with 
similar 2-aminobenzimidazole complexes [32]. The color change occurs with the 
formation of the monodentate intermediate of the respective ligand, occuring through the 
coordination of the nitrogen of the benzimidazole, designated as N3, to the metal [32] . 
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An attempt to generate similar four coordinate complexes of the pyridine analog of 
compound 9 for comparison, failed using the same synthetic method. This is consistent 
with the findings of Nonoyama et al. using an acetyl pyridine analog, N-(2-pyridyl) 
acetamide [136]. Nonoyama et al. concluded that the deprotonation of this ligand under 
alkaline conditions was facilitated only by Pd(II), hence the successful synthesis of the 
bis chelated square planar Pd(lI) complex. However, copper, nickel and cobalt 
precipitated their respective hydroxides regardless of the starting metal salts used (Cl- , 
Br-, N03-, NCS- ) [136]. 
Scheller-Krattiger et. al. have reported two bis-chelated forms of the ligand with 
Ni(lI) and Zn(1I) using nitrate salts of the metal as starting material. Unlike the Pd(lI) 
complex, the axial positions are occupied by water, making the complex octahedral 
[137]. In an effort to obtain the bis-chelated copper (II) complex in our lab, a second 
approach involving the reflux of the ligand in a copper acetate solution for one hour 
followed by stirring at room temperature for 24 hr was employed, resulting in compound 
24. 
C: FT -IR Analysis of Metal Complexes 
Infrared spectroscopy helps elucidate functional groups in a complex. Amide 
complexes have characteristic absorption peaks around - 3200 cm- I and -1700 cm- I 
indicative of amide proton and carbonyl stretching frequencies respectively. Figure 3.16 
displays the KBr-IR absorption spectrum of compound 15. The spectrum displays a broad 
stretching frequency peak in a region usually associated with the O-H stretch of water or 
an alcohol moiety. 
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Figure 3.16: IR spectrum of compound 15. 
However, this is absent from the IR spectrum of compounds 16, 17 and 36, all bis-
chelates. This suggests that this peak is due to an impurity, possibly water. 
Furthermore, the peaks at 3129 cm- I and 3058 cm- I are similar to those seen in the 
spectra of compounds 16 and 17, and are indicative of Csp2-H stretching frequencies. 
These peaks correspond to the aromatic proton stretches of the benzimidazole. Csp3-H 
stretching frequencies for compound 15 appear at 2957 cm- I , 2920 cm- I and 2853 cm-
I. The C = C stretching frequency of compound 15 appears at 1621 cm- I . The absence 
of an intense stretching peak at 1700 cm- I confirms an absence of a carbonyl. The 
absence of both the carbonyl and amide stretching frequency peaks suggest that the 
ligand, N-(N' -1-methylbenzimidazol-2-yl)decanamide, is chelated to the metal and is 
in its anionic form. Table 3.2 contains selected IR data for compounds 15-17 and 36 
with their respective metal ions. It should be noted that compounds 16 and 17 have 
the same ligand, N-(N' -1-methylbenzimidazol-2-yl)cyc1ohexanecarboxamide . 
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Table 32' Selected absorotion oeaks for comoounds 15-17 and 36 ..
Compound Metal Cspz-H Csp3-H C=C 
15 Cu 3129 cm-\ 3058 em-I 2957 cm- J , 2920 em-I, 2853 em-I 1621 em-I 
16 Ni 3120 cm- ,3053 cm- J 2930 cm- , 2859 cm- 1617 cm- J 
17 Co 3063 em-I 2930 em-I, 2813 cm- J 1622 em-I 
36 Pt 3061 cm-J 2960 cm- ,2936cm- ,2863 cm- 1618 cm- J 
The KBr-IR absorption spectrum of compound 17 is similar to compounds 16 and 36 
(table 3.2). However, unlike compound 16, only one Cspz-H stretch with doubled 
intensity is seen for compound 17. Taken together, both the intensity and type of 
stretching frequencies present for the same ligand in compounds 16 and 17 suggests a 
slightly different coordination environment and hence geometry. This is comfirmed by 
the X-ray crystallographical data discussed later in this chapter. CsprH stretches, for 
compound 17 appear at 2930cm- I and 2813 cm- I . The absence of a carbonyl and N-H 
stretching frequencies confirms an anionic form of the chelating ligand, N -(N' -1-
methylbenzimidazol-2-yl)cyclohexanecarboxamide for both complexes. 
i ... 
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Figure 3.17: IR spectrum of compound 18. 
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The KBr-IR absorption spectrum of compound 18, Figure 3.17, displays a spectrum 
different from the other bis-chelated complexes of this series. This suggests more 
variations in the coordination mode of the ligand to the metal. The crystallographic data, 
discussed later in this chapter, shows a five coordinate complex with ligands in both 
anionic and neutral modes. This is confirmed by the additional stretching frequencies 
seen in the infra-red spectrum. The N-H stretch appears at 3322 cm- I and is similar to 
values reported by Garnovskii et al. [138]. Csp3-H and Csp2-H stretches appear at 3062 
cm- 1, 2974 cm- I and 2755 cm-I • The carbonyl stretch appears at 1764 cm-I and has a 
lower stretching frequency usually seen for this series. A C = C stretch appears at 1662 
and is a lower stretching frequency compared to the previous bis-chelated complexes. 
The carbonyl and additional stretches in the 1000 cm-1 - 2000 cm-1 region also suggest 
the presence of both protonated and anionic forms of the ligand. This is confirmed by the 
N-H stretch at 3322 cm- I . 
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Figure 3.18: IR spectrum of compound 19. 
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Figure 3.18 displays the IR absorption spectrum of compound 19. This trace is also 
similar to compound 36. The absence of a N-H stretch and carbonyl stretch suggests an 
anionic form of the ligand, 2,2-dimethyl-N-(N' -1-methylbenzimidazol-2-yl)propanamide. 
Absorption stretches at 3057 cm-I and 2960 cm-I confirm Csp2-H and Csp3-H stretches. 
Also, a stretching peak at 1618 cm-I is indicative of an unsaturated carbon stretch, 
typically a C = C stretch. The crystallographic data discussed later in the chapter, agrees 
with the infrared data, all showing the ligand is in its anionic form. 
The KBr-IR absorption spectrum of compound 24, Figure 3.19, shows a N-H 
stretch at 3379cm- l . Stretching frequency peaks at 2972 cm-I, 2936 cm-Iand 2880 cm-I 
correspond to the Csp2-H and Csp3-H stretching frequencies. 
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Figure 3.19: IR spectrum of compound 24. 
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The absence of an absorption at 2200 cm-I suggests the absence of Csp-H functional 
group. The carbonyl peak appears at 1704 cm -I. The presence of both the carbonyl and 
amine stretching frequencies are indicative of a monodentately bound ligand, (N-pyridin-
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2-yl)-2,2-dimethylpropanarnide. This is also supported by the X-ray crystal structure 
data. 
D: UV -vis Analysis of Complexes 
Figure 3.21 show the UV-vis spectra typical for these complexes. Figure 3.20 
displays weak d-d transitions for compounds 16 and 17. The spectrum of the free ligand 
for both compounds 16 and 17, compound 4, is displayed in Figure 3.21. 
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Figure 3.20: UV-vis absorption trace of compounds 16 and 17 in 3 rnL CH2CI2. 
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Figure 3.21: UV-vis absorption trace of compound 4, Hmbchca, in 3 mL CH2Ch. 
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Figure 3.21 shows the ultraviolet spectrum of compound 4, N-(N'-1-methyl 
benzimidazol-2-yl)cyclohexanecarboxamide, with concentrations in the 11M range. These 
complexes obey Beer's law. At 11M concentrations, the spectra for these complexes are 
predominantly ligand absorptions. The weak d-d transitions for compounds 16 and 17 
appear at mM concentrations with ""max at 533 nm and 542 nm respectively. This is 
consistent with previous complexes synthesized in our lab [32] and results of similar 
Ni(I1) complexes with trans N202 donor set reported by Knoch and colleagues [139]. 
Additionally, a square planar Ni(I1) complex with a N20 2 donor set reported by Nejo and 
co-workers had ""max at 482 nm and 387 nm with molar absorptivities 173 and 402 
respectively [140), Table 3.3 shows the ""max of selected compounds with their respective 
molar absorptivity. 
.- . ax Table 3 3' ~ of selected cOffil2ounds 
Compound Complex ""max(nm),[E (M- I cm- I )] 
4 Hmbchca 249[17]; 300[26]; 310[34] 
16 Ni(mbchca)z 310[82]; 533[56] 
17 Co(mbchca)z 305[15]; 542[ 145] 
18 Zn(bba)z(Hbba) 302[63] 
19 VO(dmmbp)z 309[31] 
20 Ni(mbda)z 300[293]; 310[313] 
21 Ni(mbhda)z 309[76] 
24 CU2(OAc)4(Pap)z 235[18]; 277[8] 
It is worth noting that all three nickel complexes show a ligand ""max around 310 nm. 
E: Mass Spectrometric Analysis of Coordination Metal Complexes 
Mass spectrometry provides enormous information about the molecular mass and 
structure of a given sample. This information stems from the fragmentation pattern of the 
spectrum. However, a minor draw back of this technique is the appearance of additional 
peaks in the spectra that are due to sample ionization reactions, K+ and Na+ salts. The K+ 
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and Na+ ions are common contaminants introduced into the sample by matrix. It is worth 
noting that the number of additional peaks is proportional to the laser intensity. 
Consequently, samples contained in this work were collected at various laser intensities 











Figure 3.22: Mass spectrometric trace of compound 15 
The mass spectrometric trace of compound 15 (Figure 3.22) shows a molecular peak at 
663 .20 mJz with an intensity of 40%. This peak is due to the molecular ion fragment 
[Cu(mbdaht. Two daughter peaks appear at 150.40 mJz and 302.42 mJz. The peak at 
150.40 mJz represents the protonated fragment of I-methylbenzimidazole with a relative 
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Figure 3.23: Mass spectrometric trace of compound 16 
Figure 3.23 displays the mass spectrometric trace of compound 16 showing an ion peak 
at 576.87 rnJz with an intensity of 100 %. This peak is due to the molecular fragment 
[(mbchcahNit. The molecular ion peak at 892.30 rnJz has a relative intensity of 50 % 















Figure 3.24: Mass spectrometric trace of compound 17 
The mass spectrometric spectrum of compound 17 (Figure 3.24) shows an ion peak at 
258.45 rnJz with an intensity of 100% and represents the ligand, [Hmbchcat. The peak at 
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281.43 rnIz with an intensity of 20% is due to the molecular fragment [(Hmbchca)Nat, a 
sodium ion peak. Molecular ion peaks at 471.21 rnIz and 573.89 rnIz have relative 
intensities of 62 % and 95%. These peaks correspond to the fragments [(mbchca)(DBA-
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Figure 3.25 : Mass spectrometric trace of compound 18 
Figure 3.25 displays the mass spectrometric trace of compound 18. The ion peak at 
240.04 rnIz has an intensity of 100%. This peak is due to the molecular fragment [Hbbat, 
a protonated ligand ion. Molecular ion peaks at 263.35 rnIz , 542.10 rnIz and 842.31 rnIz 
have relative intensities of 14 %, 47 % and 9.75 %; corresponding to the fragments 
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Figure 3,26 : Mass spectormetric trace of compound 19 
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The mass spectromeric trace of compound 19 (Figure 3.26) shows an ion peak at 511.31 
rnIz with an intensity of 85%. This peak is due to the molecular fragment 
[(VO(Hdmrnbph)-CH4)t. Molecular ion peaks at 528.27 rnIz and 824.02 rnIz have 
relative intensities of 100 % and 70 %. These peaks correspond to the fragments 
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Figure 3.27: Mass spectrometric trace of compound 20 
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The mass spectrometric trace of compound 20 (Figure 3.27) shows a base peak at 659.24 
rnIz that corresponds to the fragment [(mbdah Nit. Daughter peaks appear at 116.4 rnIz, 
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150.4 rnIz and 302.42 rnIz . The peak at 302.42 rnIz represents the ligand fragment 
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Figure 3.28: Mass spectrometric trace of compound 21 
The mass spectrometric trace of compound 21 (Figure 3.28) shows an ion peak at 386.57 
rnIz with an intensity of 28%. This peak is due to the molecular fragment, [Hmbhdat. 
The ion peak at 827.40 rnIz has a relative intensity of 100 % and corresponds to the 
molecular ion fragment [Ni(mbhdaht. 
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Figure 3.29: Mass spectrometric trace of compound 22 
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The mass spectrometric spectrum of compound 22, Figure 3.29, shows an ion peak at 
150.44 miz with an intensity of 64%. This peak is due to the molecular fragment of a 
protonated benzimidazole ion [Hambt. Molecular ion peaks at 257.74 miz, 578.21 miz 
and 726.24 miz have relative intensities of 66 %, 100 % and 14 %. These peaks 
correspond to the fragments [mbchcat, [Zn(mbchcaht and [Zn(mbchcah(C6Hll)Cot 
respecti vel y. 
The mass spectrometric trace of compound 24 (Figure 3.30) shows an ion peak at 
583 .73 miz with an intensity of 15 %. This peak is due to the molecular fragment 
[Cu20Ac(Paph K] + and is inconsistent with the crystal structure, discussed later in the 
chapter. Daughter peaks appear at 242.76 miz and 179.47 miz with relative intensities of 
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Figure 3.30: Mass spectrometric trace of compound 24 
These peaks correspond to the fragments [CuPapt and the protonated ligand 2-
pivaloylamino pyridine ion [HPapt respectively. Table 3.4 shows a compilation of the 
theoretical and experimental masses of metal complexes. 
78 
Table 3 4· Selected Mass sQectrometric data of metal comolexes · . 
Compound Metal complex Theoretical mass(Rel. Ab' dance %) Experimental mass 
15 Cu(mbdah 663.34 (45) 659.24, 663.20 
16 Ni(mbchca)2 570.23 (48) 576.87,892.30 
17 Co(mbchca)2 571.22 (70) 573.89 
18 Zn(bbaMHbba) 773.18 (29) 542.10,842.31 
19 VO(dmmbph 527.20 (72) 528.27 
20 Ni(mbdah 658.35 (44) 659.24 
21 Ni(mbhchca)2 826.54 (39) 827.40 
22 Zn(mbchcah 576.22 (34) 578.21 
24 CU2(OAc MPap h 718.13 (34) 583.73 
With the exception of compounds 18 and 24, theoretical and experimental masses for the 
metal complexes are in agreement. The molecular ion peak, M+, of compound 18 is 
[Zn2(bbah(Hbba)t. This ion fragment varies from the x-ray crystal structure by a Zn2+ 
ion and is attributable to ionization reactions. The molecular ion fragment for compound 
24 however shows a fragment [Cu2(OAc)(Paph 0] + less in mass compared to the 
structure elucidated by x-ray. Additionally, the ion peak (892.30 rnIz) for compound 16, 
[(mbchca)3Nht, also results from ionization-complexation reactions. 
F: IH NMR Characterization and Analysis of Complexes 
Four coordinate Nickel (II) compounds form either square planar or tetrahedral 
complexes. It is diamagnetic when planar and paramagnetic in the later. Similar chemical 
shifts result in the 1 H NMR spectrum of the chelate and free ligand, when the structure of 
the complex in solution is planar. In contrast, peak broadening and very different 
chemical shifts for the chelate are observed in the case of tetrahedral. Figures 3.31-3.34, 
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show 1 H NMR of bis- chelated nickel (II) complexes. The 1 H NMR of the bis-chelate of 
compound 9, Ni(dmmbph, displayed in Figure 3.34 has been included for comparison. 
This compound is planar and trans in the solid state. With the exception of compound 20, 
the color of the solid powder is purple for all the Ni (II) complexes under discussion for 
this series. This purple color is maintained in CDCh suggesting that all four compounds 
stay four coordinate in solution. Table 3.5 shows the lH NMR chemical shifts for these 
compounds. Another d8 ion and Pt- analog of compound 20, compound 30 discussed later 
in Chapter IV, has also been added for comparison. The aromatic region of compound 30 
appears as four peaks with the splitting pattern doublet,triplet, triplet and doublet. X-ray 
crystal structure data show that this splitting pattern is associated with square planar cis-
bischelates of this series. 
Table 3.5: IH NMR Chemical Shifts 
Compd Metal complex Chemical Shifts, & (ppm) in CDCh 
16 Ni(mbchcah 13.6, 10.8,9.24,5.01,2.23, 1.72, 1.54, 1.33 
20 Ni(mbda)2 8.58,5.76,3.48,2.77,2.15, 1.56, 1.30, 1.21,0.839 
21 Ni(mbhchca)2 8.66, 5.72, 2.88, 2.20, 1.55, 1.29,0.886 
Ni(dmmbp)z 12.79,10.13,7.28,4.17,3.66,2.51,1.73,1.58,1.319,0.855 
30 Pt(mbda)2 7.15,7.03,6.67,6.37,3.77,2.53,1.82,1.61,1.44,1.36,1.29,0.881 
The lack of similar splitting patterns in the lH NMR spectra (Figure 3.31-3.34) of these 
Ni(lI) complexes suggests that they are paramagnetic. 
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Figure 3.3 ! : 'H NMR spectrum of compound 16 in CDC!3 
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Figure 3.33: 'H NMR spectrum of compound 21 
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Figure 3.34: 'H NMR spectrum of Ni(dmmbp)z. Hydrogen atoms of the ortep have been omitted for clarity. 
The peak at 7.28 ppm is the solvent peak (CDCI3) . 
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Figure 3.35: IH NMR spectrum of compound 30 
Roquette and co-workers have assigned paramagnetic chemical shifts of 
bisguanidine Ni (II) complexes by using paramagnetic shifts with the aid of diamagnetic 
NMR spectra of analogous Zn complexes and DFT ca1culations[34]. However, the goal 
here is to use the spectra to predict structure and isomerism. The spectra for compounds 
20 and 21 are identical and differ from Ni( dmmbp h and compound 16. Furthermore, they 
both show no peaks beyond 9.00 ppm for the given spectral window. This is not 
surprising since these two compounds have aliphatic hydrocarbons "tails" that differ only 
by a few hydrocarbons (C6H d. However, the peak at 3.48 ppm for compound 20 does 
not appear prominently in any of the other Ni (II) complexes. This is significant because 
this is usually the chemical shift of the methyl substituents (N-CH3) of the benzimidazole, 
seen in both the spectra of the free ligands and that of their diamagnetic Pt(lI) analogues 
(Figure 3.35 discussed in the next chapter). This suggests distortion for compounds 20 
and 21 are different and might be due to the difference in "tail" length. Another 
83 
possibility will be a combination of a chelate and monodentate ligation of the ligand with 
a nitrate ion attached at the fourth coordination point. In this mode, the shielding effect of 
the metal will be different for the respective mono dentate and chelate ligands since their 
chemical environments are different. However, both the IR and mass spectrometric data 
support a bis-chelated four coordinate Ni (II) complex. It is therefore likely that 
compounds 20 and 21 have different geometries / configurations in the solid phase. 
Consequently, the geometry in solution might be limited by sterics in two different ways. 
Thus, the difference in spectra. 
Crystal structures of both compound 16 and Ni( dmmbp h reveal that both 
complexes are square planar and trans. Crystals of compound 20 were obtained only in 
diethyl ether. However, the crystalline property was lost upon exposure to air, possibly 
due to solvent evaporation. Thus, its geometry in the solid phase could not be elucidated. 
Nevertheless, the UV -vis spectrum of compound 16 is consistent with similar 
tetrahedral Ni (II) complexes with trans N20 2 donor sets [139]. In solution Ni (II) 
complexes of type NiN20 2 are in equilibra between either a planar and tetrahedral 
geometry [139] on one hand and an octahedral, planar and tetrahedral interconversion 
[141] on the other. The configurational isomerism observed in these complexes is very 
rapid and the dominant geometry is determined by the nature of ligand and the type of 
solvent. For instance, steric bulk of the ligands and some organic solvents favor 
tetrahedral geometry. Conversely, lewis bases such as pyridine and methanol favor 
octahedral geometry and coordinate to the metal center at the axial positions [142]. It can 
therefore be concluded, based on the 'H NMR chemical shifts of the peaks, UV data, and 
the steric bulk of ligands that all the Ni (II) complexes of this series assume tetrahedral 
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geometry in solution and are consistent with trans NiN20 2 complexes found in literature 
[139-144]. Furthermore, this does not preclude factors such as additional shielding or 
deshielding effects felt by these protons brought about by ring currents as a result of their 
proximity to the center of a neighboring ring. This phenomenon is common to ring 
systems of this nature largely due to their chelation mode. Based on the IH NMR spectra, 
it can be concluded that compounds 20 and 21 are in the syn/cis and anti/trans 
coordination modes respectively. 
Unlike nickel (II) complexes, Zinc (II) complexes, with N20 2 1-
methylbenzimidazole donor sets, show little or no change in chemical shifts of their IH 
NMR spectra. Figure 3.36 shows the IH NMR spectrum for compound 23. The spectrum 
is similar to Zn(dmmbph [32]. The aromatic region shows three peaks with chemical 






Figure 3.36: IH NMR spectrum of compound 23 in CDCl) 
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The peak at 3.79 ppm corresponds to the methyl substituents of the nitrogen at position 
one of the benzimidazole and integrates to six protons. The peak at 2.30 ppm represents 
six protons corresponding to the two sets of methyl protons of the acetyl pendant. The 
peak at 1.59 ppm is a water peak, an impurity often found in deuterated chloroform. It is 
worth noting that the aromatic protons peaks are no longer aggregated compared to the 
free ligand. This suggests the ligands are bound to the metal, but not as monodentates. 
Figure 3.37 shows the lH NMR of compound 18. 
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Figure 3.37: 'H NMR spectrum of compound 18 in CDCI3 
The peaks at 7.98 ppm and 7.16 ppm correspond to the phenyl protons whilst the peaks at 
7.55 ppm, 7.38 ppm and 7.20 ppm represent the aromatic protons of the benzimidazole. 
The amide and N 1 protons do not show up in the spectrum and might be due to rapid 
solvent exchange. Again, the aromatic protons of the benzimidazole do not aggregate like 
in the free ligand. 
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G: X-ray Crystallographic Analysis of Coordination Metal Complexes 
Previous studies of X-ray crystal structure analysis of compound 9 bis-chelated 
complexes of Co2+. Ni2+. Cu2+ and Zn2+ performed in our laboratory, revealed that these 
complexes formed neutral four coordinated species ranging from tetrahedral to square 
planar from 2: 1 ligand to metal ratio reactions. The interactions in the lattices of these 
complexes are predominantly pi-stacking. Six new crystal structures of these complexes 
together with a dinuc1ear Cu2+ compound have been elucidated. This section examines 
the interactions within these new complexes and compares them to previous works. Table 
3.6 contains selected crystallographic data of the metal complexes in this series. With the 
exception of compounds 18 and 19, complexes crystallize as monoc1inics. 
Table 3 6' Selected Crystallograohic data for comQounds _ ..
Compd 15 Compd16 Compd 17 Compd 18 Compd 19 Compd 23 Compd24 
Crystal Monoclinic Monoclinic Monoclinic Triclinic Orthorhombic Monoclinic Monoclinic 
System 
Space 
Group P2t/c P2)/c P2t/c Pi Pbca P2t/c P2t/c 
a 18.505(3) A 14.1057(8) A 13.0866(4) A 9.7627(5) A 12.9214(13) A 8.2544(14) A 13. 8508(8) A 
b 5.1189(7) A 15.1769(8) A 23.0690(5) A 10.0352(5) A 17.1388(17) A 22.984(4) A 11.0612(5) A 
c 17.344(3) A 6.4460(4) A 19.5697(5) A 19.3560(11) A 23.445(2) A 10.3376(18) 11.0301 (6) A 
A 
u 90° 90° 90° 98.663(4)" 90° 90° 90° 
P 93.823 ° 102.9570 ° 106.002 ° 95.786(4) ° 90° 100.364(3)" 104.508(6)" 
Y 90° 90° 90° 100.010° 90° 90° 90° 
Volume 1639.3 A3 1344.83 A3 5679.0 A3 1830.38 A3 5192.1 A3 1929.2.x.3 1635.98 A3 
z 2 4 4 2 8 4 4 
Density 1.346 Mglm3 1.411 Mglm3 1.310 Mglm3 1.406 Mglm3 1.350 Mglm3 1.521 1.461 
Mg/m3 Mglm3 
GOF 1.061 1.086 1.089 1.027 1.061 1.087 1.058 
R1 0.0556 0.0450 0.0741 0.0353 0.0537 0.0753 0.0335 
wR2 0.0952 0.1063 0.1706 0.0539 0.1088 0.1508 0.0951 
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The crystal structure of compound 15, shown below, forms monoclinic crystals in the 
space group P2 1/c . The coordination sphere around the Cu (II) ion, a d
9 ion, can be 
described as square planar (Figure 3.38). 
Figure 3.38: ORTEP diagram of compound 15. Ellipsoids are shown at 30% probability. 
The ligand, N-(1-methylbenzimidazol-2-yl)decanamide, is in its anionic form and 
chelates to the Cu (II) ion through the nitrogen of the benzimidazole and the oxygen of 
the carbonyl. The chelated ligand assumes a trans configuration around the central atom 
with an average Cu-N bond length of 1.994(3)A. The average Cu-O and c-o bond 
lengths are 1.916(2) A and 1.280(4) A respectively. Compound 15 has bond angles of 
180.00(17) A, 88.92(10) A, 91.08(10) A and 180.00(15) A corresponding to N(1) - Cu-
N(1 ') , N(1) - Cu - 0(1), N(1) - Cu - 0(1 ') and 0(1) - Cu - 0(1 ') respectively (Table 
3.4). 
The crystal lattice can be described as alternating parallel cylindrical sheets of 
molecules engaged in cooperative H -1t stacking interactions, along the b axis of the unit 
cell. These sheets are intercalated obliquely by similar parallel sheets (Figure 3.39). This 
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results in an occasional edge to face hydrogen- n interactions between adjacent sheets, 
helping to further stabilize the long aliphatic chains of the ligand. 
Figure 3.39: Crystal lattice of compound 15. Alternating parallel sheets and Intercalating molecules 
displaying a point to face interaction. 
The hydrogens of Ca are engaged in weak C-H-··n interactions (Figure 3.40). 
HlOB is engaged in an interaction with the n-bond of C2-N 1 of the adjacent molecule 
whilst H10A is engaged in an interaction with the ami do oxygen (HlOA-O distance = 
2.83(4)A). These interactions help stabilize the aliphatic "tails" of adjacent molecules and 
places HlOB 2.62(7) A and 2.74(8)A from C2 and N1 respectively making a C2-HlOB-
N1 angle of 30.05°. The cooperative C-H·· ·n stacking, places adjacent Cu centers an 
average distance of 5.11 (4) A apart. It is worth noting that the Cu-Cu distance is greater 
than the typical 3.3-3.8 A separation typically seen for perfect alignment of aromatic 
rings of these types of heterocyclic systems and comfums a slipped, parallel displaced n-
stacking arrangement [145]. As a result, aliphatic hydrogens of the stacked molecules 
become separated by an average distance of 3.27 A. 
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Figure 3.40: Crystal lattice of compound 15 displaying (a) C-H-··1[ stacking interactions(top diagram). 
(b) Hydrogens have been omitted for the bottom figure for clarity. 
The stacking arrangement differs from that of trans bis-chelate Cu (II) and Ni (II) arnido 
complexes of compound 9. In the Cu (II) ami do complex, the twist of one chelate with 
respect to the other results in a torsional angle of 103.08° along the c-axis of the unit cell, 
whereas a torsional angle of 128.32° is seen in the lattice of the Ni (II) complex. 
Additionally, the pi-stacking between adjacent benzirnidazoles, in both cases, are almost 
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orthogonal to each other. That is, compound 15 does not show the distortion from square 
planar geometry as seen in the previous copper(II) and nickel(II) amido complexes in this 
series of ligands. This might be due to the need to stabilize the long aliphatic hydrocarbon 
chain in order to attain optimal overall packing. 
Figure 3.41 shows the crystal structure of compound 16 which crystallizes as a 
monoclinic in the space group P2dc . The molecular geometry is square planar. 
Figure 3.4l: ORTEP diagram of compound 16. Ellipsoids are shown at 30% probability. Hydrogen atoms 
on the complex were removed for clarity. 
Examination of the coordination sphere shows that the nickel (II) ion is coordinated to 
two ligands in a trans configuration with a N20 2 donor set (the nitrogen of the 
benzimidazole and the oxygen of the carbonyl) . Compound 16 has bond angles of 180.00, 
91. 12(7t, 88.88(7t and 179.998(1)0 corresponding to N(1) - Ni- N(1') , N(l) - Ni-
0(1), N(1) - Ni - 0 (1 ') and 0(1) - Ni - 0(1 ') respectively. The average Ni-N, Ni- 0 
and C- 0 bond distances are 1.9174(18) A, 1.8386(16) A and 1.291(3) A respectively. 
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The crystal lattice of compound 16 is similar to that of compound 4, its free 
ligand. In both lattices, the cyclohexyl group is in the chair configuration and is at an 
oblique angle to the benzimidazole plane. The average Ni .... Ni distance is 6.4SA. Unlike 
Ni(dmmbph, there are no visible pi-stacking in the crystal lattice. Instead, a 
Figure 3.42: Crystal lattice of compound 16. Intercalating molecules displaying an point to face interaction. 
All adjacent pi-stacking molecules have been omitted for clarity. 
network of edge to face C-H-··n; interactions, (H8 . . . Cl , Figure 3.42), hold the lattice 
together. These interactions have distances ranging from 2.72(6) A to 3.33(S)A. As a 
result, adjacent Ni (II) metal centers are diagonaJ to each other and each cyclohexyl 
group interacts with a benzimidazole of the adjacent molecule. 
Compound 17 (Figure 3.43), forms a monoclinic crystal in the space group P21/C. 
Compound 17 can be described as having a slightly distorted tetrahedral geometry. 
Examination of the coordination sphere shows that the cobalt (II) ion, a d7 ion, is 
coordinated to two anionic bidentate ligands with a N20 2 donor set. 
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Figure 3.43: ORTEP diagram of compound 17. Ellipsoids are shown at 50% probability. Hydrogen atoms 
on the complex were removed for clarity. Additionally , one of the cyclohexyl pendant is positionally 
disordered and has been modeled. 
The ligand, (N-l-methyl benzimidazol-2-yl)cyc1ohexylcarboxamido, chelates in a trans 
configuration around the central cobalt(U) atom. The Co-N bond length is 1.96A which is 
shorted than an amb monodentate reported by Antsyshkina which measured 2.108(9)A 
[146]. Compound 17 has angles of 130.05(16)0, 91.58(14) 0, 113.71(15) 0,112.55(15) 0, 
92.22(16) 0, and 119.40(14) ° corresponding to NI-Co-N4, NI-Co-Ol , NI-Co-02, 
N4-Co-Ol, N4 -Co- 02 and 01 - Co - 02 respectively. One cyc10hexyl group is 
positionally disordered and has been refined accordingly. Also, a co- crystal of compound 
17 shows slightly different bond angles but similar bond lengths and is labeled 17b in 
Table 3.7. Table 3.7 summarizes the bond lengths and angles of compounds 15-17. 
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Table 3.7: Selected bond lengths and angles for compounds 15,16 and 17. 
Bond Lengths (A) 
Compd 15 Compd 16 Compd 17 Compd 17b 
M-N1 1.994(3) 1.9175(18) 1.953(4) 1.956(4) 
M-N4 1.994(3) 1.9174(18) 1.957(4) 1.964(4) 
M-01 1.916(2) 1.8387(16) 1.942(3) 1.938(3) 
M-02 1.916(2) 1.8386(16) 1.949(3) 1.956(3) 
C-01 1.280(4) 1.291(3) 1.291 (5) 1.293(6) 
C-02 1.287(7) 1.286(5) 
Bond Angles (0) 
Compd 15 Compd 16 Compd 17 Compd 17b 
N1-M-N4 180.00(17) 180.0 130.05(16) 123.48(17) 
NI-M-01 88.92(10) 91.12(7) 91.58(14) 91.65(15) 
NI-M-02 91.08(10) 88.88(7) 113.71(15) 120.94(15) 
N4-M-01 91.08(10) 88.88(7) 112.55(15) 114.94(15) 
N4-M- 02* 88.92(10) 91.12(7) 92.22(16) 92.01(16) 
01-M-02 180.00(15) 179.998(1) 119.40(14) 115.99(15) 
* N4 = N01'and 02 = 01' 
Both NI-Co-02 and NI-Co-N4 angles of the co-crystals differ by seven degrees. The 
crystal lattice of compound 17 reveals an alternating 1t-stacking of benzimidazole and 
cyclohexyl pendants. Similarly, the cyclohexyl pendant is in the chair configuration with 
its hydrogen atoms engaged in hydrogen- 1t interactions. 
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Figure 3.44: Crystal lattice of compound 17. Hydrogens have been omitted for clarity. 
As a result of these interactions, the benzimidazole and cyclohexyl carbons are separated 
by an average distance of 4.04 A. Consequently, the cobalt centers become separated an 
average of 8.32A from each other. 
Compound 23 (Figure 3.45), crystallizes as a monoclinic in the space group P2,/c. 
Examination of the coordination sphere shows that the Zn 2+ ion, ad' 0 ion, is coordinated 
to two anionic bidentate ligands with a N20 2 donor set. The ligands, N-(benzimidazol-2-




Figure 3.45: ORTEP diagram of compound 23. Ellipsoids are shown at 30% probability. Hydrogen atoms 
have been omitted for clarity. 
Compound 23 can therefore be described as having a slightly distorted tetrahedral 
geometry. The compound has angles of 122.45(16)°,92.04(15)°, 124.72(15)°, 
123.94(16)°,92.40(15)°, and 102.48(15t corresponding to Nl -Zn-N4, NI-Zn -01, 
N1- Zn -02, N4 - Zn-01, N4 - Zn - 02 and 01 - Zn- 02 respectively (table 3.8). The 
average Zn - 0, Zn - Nand C - 0 bond lengths are 1.963(3)A, 1.943(9) A and 1.277(6) 
A. The unit cell is displayed below (Figure 3.46). 
Figure 3.46: ORTEP diagram of compound 23 showing packing in a unit cell. Ellipsoids are shown at 30% 
probability and hydrogens have been omitted for clarity. 
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The lattice of compound 23 can be described as having alternating parallel 
cooperative 1t -stacking interactions intercalated by orthogonal1t -stacking between 
ligands of adjacent molecules. As a result of these packing arrangements, channels are 
created in the lattice. 
Figure 3.47 shows the ortep diagram of compound 19. Compound 19 crystallizes 
as orthorhombic and belongs to the space group Pbca. Its geometry can be described as 
distorted square pyramidal. The central vanadium atom, a d I ion, is coordinated to two 
bidentate chelates in a trans configuration through a N20 2 donor set and an oxygen atom. 
Figure 3.47: ORTEP diagram of compound 19. Ellipsoids are shown at 30% probability 
The oxygen atom located at the apex of the molecule is double bonded to the central 
vanadium atom. The other bonds to the central vanadium atom are the nitrogen of the 
benzimidazole and the oxygen of the carbonyl. The distortion seen in the crystal lattice 
can be attributed to the repulsion between the V -0 double bond and the other V -0 and V-
N single bonds. Average C - 0 and V -N bond lengths are 1.294(8) A and 2.060(2) A. The 
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V- 0 bond lengths 1.9703(17) A, 1.9560(17) A, and 1.5850(19) A correspond to the 
single and double bonds respectively. The following bond angles 92.04(15t, 124.72(15t, 
123.94(16t, 92.40(15t and 102.48(15t represent N1-V-01, N1-V-02, N4-V-Ol, N4-V-
02 and 01-V - 02. The separation between adjacent heterocyclic rings is 3.49(4)A(Figure 
3.48). 
Figure 3.48: Crystal lattice of compound 19 showing the orientation of V=O bonds along c-axis. 
Additionally, the v=o bonds are oriented diagonally in pairs in an antiparallel manner. 
This allows for n-stacking interactions between the benzirnidazoles of some adjacent 
molecular pairs, a feature common amongst its Cu2+, Ni2+, Co2+ and Zn2+ analogs. 
Structures considered thus far, are consistent with the neutral bis-chelates of Cu2+, 
Ni2+, Co2+ and Zn2+ derivatives of compound 9, previously synthesized. However, with 
the exception of compounds 17 and 19, they differ in the types of interactions found in 
their respective lattices. That is, they do not display n-stacking interactions, but rather 
engage in C-H···n interactions; suggesting a correlation between the types of interactions 
in a lattice and the size and nature of the pendants. 
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We report a new five coordinated complex from these 1:2 metal-ligand reactions, 
compound 18 (Figure 3.49). It crystallizes into the space group PI and can be described as 
having a distorted trigonal bipyramidal geometry with the oxygens occupying the axial 
positions and T index of 30% (~=135 . 8 °, a=117.6°) or 50% (~=135.8°, a=105.9°) [147]. 
Examination of the coordination sphere shows that the zinc atom, a d I 0 ion, is coordinated 
to three ligands; two of which are bidentate chelates (NzOz donor set) and the third 
bonded through the nitrogen of the benzimidazole as a monodentate ligand. 
Figure 3.49: ORTEP diagram of compound 18. Ellipsoids are shown at 30% probability. 
The chelates adopt a trans configuration around the zinc (II) ion and are located in 
different planes. The resulting tilt of the individual ligands could be due to space 
maximization and most importantly, the minimization of electron repulsion of the 
aromatic rings. Consequently, the electron cloud of the rings are almost orthogonal to 
each other resulting in a point to face C-H· ··n interaction. The average Zn - 0 bond 
length is 2.0871(63) A, whilst the average Zn- N bond length of the chelates is 
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2.0026(66) A. Similarly, the C = 0 is 1.2257 A whilst that for C-O measures 1.27 A. The 
Zn- N bond length of the monodentate is slightly elongated and is 0.0867 A longer than 
the bis - chelate. Table 3.8 summarizes the bond lengths and angle for compounds 18, 19 
and 23. 
.. , Table 38· Selected bond lengths and angles of cOffiQounds 18 19 and 23 
Compound 18 Compound 19 Compound 23 
M-Nl 1.9885(15) 2.067(2) 1.945(4) 
M-N4 2.0168(16) 2.053(2) 1.942(4) 
M-Ol 2.1103(13) 1.9703(17) 1.966(3) 
M-02 2.0640(13) 1.9560(17) 1.960(3) 
M-03 1.5850(19) 
M-N7 2.1038(16) 
C-O(1) 1.278(2) 1.291 (3) 1.280(6) 
C-0(2) 1.268(2) 1.298(3) 1.274(6) 
C-0(3) 1.226(2) 
Compound 18 Compound 19 Compound 23 
NI-M-N4 135.80(6) 152.08(8) 122.45(16) 
NI-M-Ol 86.66(6) 83.98(8) 92.04(15) 
NI-M-02 101.76(6) 86.83(8) 124.72(15) 
NI-M-03 103.92(9) 
NI-M-N7 105.91(6) 
N4-M-Ol 88.31(6) 85.70(8) 123.94(16) 
N4-M- 02 86.90(6) 83.96(8) 92.40(15) 
N4-M-03 103.99(9) 
N4-M-N7 117.61(6) 





Bond angles of 171.38(5)°, 86.66(6)°, 88.31(6t, 86.90(5)°, 101.76(6)°,86.90(6)°, 
88.99(6)°, 135.80(6)°,105.91(6)° and 117.61(6)° correspond to 01 - Zn -02,01 - Zn-
N1, 01- Zn -N4, 01- Zn - N7, 02 - Zn -N1, 02 - Zn -N4, 02 - Zn - N7, N1- Zn-
N4, N1 - Zn -N7 and N4 - Zn -N7 respectively. 
The interactions observed in compound 18 include side to side intermolecular 
hydrogen bonding between the imide nitrogen (N6) and the hydrogen of the 
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benzimidazole of adjacent chelating ligands along the a-c plane of the unit cell (Figure 
3.50). 
Figure 3.50: ORTEP diagram of compound 18's crystal lattice. Sites of hydrogen bonding between 
molecules are shown in red dotted lines. 
Orthogonal to this (b-c plane), are point to face intramolecular interaction of the phenyl 
groups, coupled with an intermolecular 1t-stacking interaction between phenyl and 
adjacent benzimidazole. This orientation not only minimizes the electron cloud repulsion 
of the 1t- electrons, but also adds to the overall stability of the lattice. The parameters of 
the hydrogen bonding interactions observed in the lattice are shown in table 3.9. 
Table 3.9: Hydrogen bonds for Compound 18 [A and 0]. 
D-H d(D-H) d(H .. A) <DHA d(D .. A) A 
N2-H2N 0.91 L L.940 172.96 2.846 N6[x+l , y,z] 
N5-H5N 0.900 1.987 171.01 2.880 N3[x-l,y, z] 
N8-H8N 0.840 2.085 124.99 2.657 03 
N9-H9N 0.823 2.133 145.75 2.852 01 
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The expanded five coordination environment of the zinc (II) ion is similar to a bis-
chelated amido Ni complex of compound 9, (amb )Ni( dmmbp h , reported by Philip Bauer 
[32] and is only the second in this series of functionalized benzimidazole ligands 
produced in our laboratory (Figure 3.50). Unlike compound 18, (amb)Ni(dmmbph was 
generated from the titration of amb and Ni(dmmbp)2. 
Figure 3.51 : A tail - tail Hydrogen - 1[ interactions of (amb)Ni(dmmbp)2 along the c-axis of the unit cell. 
2-amino- l -methylbenzimidazole (amb) pointed in opposite directions of the bis-chelate plane 
The bis-chelated ligands in both compounds show a convex bend, allowing for hydrogen-
1t interactions of the apex ligand of the adjacent molecule in the lattice. However, the 
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Ni(II) complex does not posses the hydrogen bonding between the N1 hydrogen of the 
benzimidazole and the imido nitrogen of the adjacent chelate. This is because the N1 
position of the benzimidazole in the Ni (II) complex is occupied by a methyl group 
instead of a hydrogen. Consequently, the Ni (II) complex opts for a slipped 7t-stacking 
interaction with an adjacent benzimidazole ring (Figure 3.51). This interaction has an 
average distance of 2.83(5) A. Also, one of the hydrogens of the 2-amino group is 
involved in a hydrogen bonding interaction perpendicular to the bis-chelates (b-c plane) 
with an average distance of 2.09 A. 
A dinuclear copper complex, compound 24 (Figure 3.52), was obtained, in an 
attempt to generate a metal pyridine analog of compound 9. 
Figure 3.52: ORTEP diagram of Compound 24. Ellipsoids are shown at 30% probability. 
Compound 24 crystallizes into the space group P2 1/c. Both metal centers could be said to 
have distorted octahedral geometry. The Cu centers are bridged by four acetato ligands 
and a Cu- Cu bond. The sixth positions for each Cu center is occupied by the nitrogen of 
the ligand N(-pyridin-2-yl)-2,2-dimethylpropanamide. The monodentate ligands are trans 
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with respect to each other. Table 3.10 summarizes the various bond lengths and angles of 
the compound. 
Table 3 10' Selected bond lengths and angles of com~ound 24 
Bond Lengths (A) 
Compound 24 
Cu( I )-0(1) 1.9752(19) 
Cu(1)-N(1) 2.200(2) 
Cu(l)-Cu(l ') 2.6162(6) 
0(3)-C(3') 1.265(3) 
0(5)-C(10) 1.214(3) 
Bond Angles CO) 
Compound 24 
0(3 )-Cu( 1 )-0(1) 89.41(8) 
0(2 )-Cu( I )-O( 1) 169.04(8) 
0(3)-Cu(1)-N(1) 94.59(8) 
0(2 )-Cu(1 )-N (1 ) 99.30(8) 
0(3 )-Cu( 1 )-Cu( 1 ') 83.90(6) 
0(4 )-Cu(1 )-Cu(1 ') 85.15(6) 
0(2)-Cu(1 )-Cu( 1') 86.97(6) 
O( 1 )-Cu( 1 )-Cu( 1 ') 82.15(6) 
N(1 )-Cu(1 )-Cu(1') 173.58(6) 
C(1 ')-O(I)-Cu( 1) 125.53(17) 
C(3' )-0(3 )-Cu( 1) 123.86(17) 
C( 1 )-0(2)-Cu(1) 119.81(18) 
The crystal lattice is stabilized by a network of intra- and intermolecular hydrogen bond 
interactions. The intramolecular hydrogen bonding, Figure 3.53, is between an amide 
proton and an oxygen of the acetate with an average bond distance of 2.70 A. 
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Figure 3.53: ORTEP diagram of Compound 24 showing the intramolecular hydrogen bonding within 
crystal lattice. 
Figure 3.54: ORTEP diagram of Compound 24 showing intermolecular hydrogen bonding within crystal 
lattice. 
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Intermolecular hydrogen bonding interactions, Figure 3.54, with average bond 
distances of 2.67(3) A, at acute angles to the a-b plane of the unit cell, are observed 
between a meta pyridinyl proton and the oxygen of the carbonyl of an adjacent 
molecule's pyridinylligand. Other pyridinyl protons interact with either the oxygen of an 
acetate or carbonyl of an adjacent molecule with average distances of 2.69(5) A. The 
methyl protons of the acetyl group are also involved in occasional hydrogen bonding with 
the oxygen of the acetate of adjacent molecules and have average distances of 2.65(3) A. 
Table 3.11 contains the parameters associated with some of these hydrogen bonding 
interactions. 
Table 3.11: Hydrogen bonds for Compound 24 [A and 0]. 
D-H d(D-H) d(H .. A) <DHA d(D .. A) A 
N2-H20 0.768 2.420 152.24 3.121 04 
C8-H8 0.933 2.253 119.20 2.822 05 
These interactions are very identical to the secondary coordination environment of 
a bis (2-aminopyridine )copper(II) diaceto complex, reported by Garnovskii et al. The 
complex shows hydrogen bonding interactions between the hydrogens of the 2-amino 
group and the oxygens of the acetyl chelates [148]. Another structure, a bis (2-amino-1-
methylbenzimidazole)copper(II) diacetate complex, has been reported by Antsyshkina et 
al.[149]. However, unlike the previous compound, the primary environment of this 
complex reveals that both acetate ions are bound to a mononuclear copper(II) ion center 
through both oxygens. The secondary interactions in this complex comes from the 
protons of the 2-amino group and the oxygen of the acetate carbonyl (2.86A). 
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After a study of copper(II) acetate complexes of 2-amino substituted imidazole, 
thiazole, pyrimidines, benzimidazoles and pyridine derivatives with the general formula 
Cu(OAch L2, Garnovskii et al. came to the conclusion that the IR spectra for these 
complexes usually display less intense N-H stretching frequencies. This can be 
attributable to their hydrogen bonding interactions [138]. However, compound 24 
displays a very intense N-H stretching frequency around 3379cm-1 even though it exhibits 
similar hydrogen bonding interactions. 
H: Conclusions 
The IR, mass spectrometric data, and in some cases IH NMR and X-ray 
crystallographic data, all show that the benzimidazole ligands discussed in this series 
bond to the metal ions as chelates forming mostly four coordinate compounds. The 
chelation of these ligands is always through the nitrogen .of the benzimidazole and the 
oxygen of the carbonyl. 
Only V, Zn and Ni exhibited coordination environments greater than four. In these 
five coordinate compounds, the benzimidazoles were distorted from the ideal in an effort 
to minimize electron cloud repulsion. The crystal lattice of these compounds exhibited 1t 
-stacking interactions with occasional point to face C-H···1t interactions that help to 
stabilize the overall lattice. Both intermolecular and intramolecular interactions worked 
in tandem in a cooperative sense with 1t-stacking interactions influenced by the length of 
the attached pendant of the ligand. These interactions are a result of the distortions and 
deviations from ideal geometry in an effort to achieve maximum stability. 
As a group, the interactions found in the lattices of these complexes to a large extent 
are governed by the appendants of the benzimidazole ligands. That is, one would expect 
107 
pi-stacking to be a predominant interaction given the benzimidazole repeat motif of these 
complexes. However, interactions arise as a result of steric bulk of appendants, efficiency 
of packing molecules, and repulsion minimization. Repulsion minimization is evident in 
the five coordinates, where a tilt of the benzimidazole chelates occur. Pi-stacking 
dominates only the small pendant tetrahedral complexes in this series and is consistent 
with our previous findings. 
Table 3.12 shows the average bond lengths of metal-nitrogen and metal-oxygen bond 
distances of selected M2+ ion benzimidazole derivatives synthesized in our laboratory. 
Table 3.12: Average bond lengths of selected first row transition M2+ ions benzimidazole complex 
derivatives 
Bond type V4+ CoH NiH CU~H ZnL+ ZnL+ 
M-N (A) 2.060(2) 1.955(6) 1.895(9) 1.963(9) 2.060(2) 1.942(4) 
M-O (A) 1.963(1) 1.945(1) 1.848(9) 1.916(9) 1.963(2) 1.966(3) 
Shape Sq .Pyramidal tetrahedral Sq. planar Sq.planar Trig.hipyramidal tetrahedral 
The Ni- N bond measures 1.895(9) A and is shorter than the Co - N bond length, a 
phenomenon consistent with the periodic trend, periodicity of the p-block (i.e effective 
nuclear charge effect). However, this phenomenon is not seen in similar four - coordinate 
compounds of Cu or Zn ions for this series. A comparison of the four-coordinate 
compounds of the Cu and Zn reveals a longer and intermediate bond length respectively. 
This might be due to several factors among which are the nature of the binding ligand, 
subsequent alignment (presence or absence of intra/intermolecular interactions), resultant 
molecular strain, or torque of the moiety attached to the carbonyl. That is, the long chain 
carbon pendant of compound 15, for example, results in a longer Cu- N bond compared 
to the methyl group of compound 23. Much more stabilization is attained from the 1[-
stacking of the benzimidazole in the case of compound 15 in the planar configuration 
108 
than tetrahedral because of the long carbon chain. It is worth noting that for the same 
ligand, N -(1-methylbenzirnidazol-2-yl)cyclohexanecarboxamido, cobalt (II) prefers 
tetrahedral ( e4, t23) geometry whilst nickel (II) prefers square planar. 
The next chapter deals with the reactions of these ligands with platinum. 
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CHAPTER IV 
ISOMERIC CONFORMERS OF PLATINUM (II) COMPLEXES OF 2-
PIV ALOYL PYRIDINE AND BENZIMIDAZOLE LIGANDS 
A: Background Discussion 
Cisplatin, cis-diamminedichloroplatinum(II) (Figure 4.1), to date is one of the 
most successful anti-cancer drugs on the market [150]. It is highly effective in the 
treatment of ovarian and testicular cancers and is also utilized in the treatment of bladder, 
cervical, head and neck, esophageal and small cell lung cancers [151-152]. However, its' 
cytotoxicity leaves patients with numerous side effects including organ failure [73, 153]. 
Also, like most drugs on the market, efficacy diminishes due to the activity of the 
multidrug resistance protein (MRP) and acquired resistance [79, 150, 154]. It is in this 
regard that the constant need for new, less toxic and more effective compounds cannot be 
overemphasized. 
The mode of action of cisplatin on DNA has been extensively investigated and 
documented. Lippard et al. in a 1999 review, discussed and compared the efficacy of 
various platinum (II) and (IV) complexes including cisplatin. Cisplatin is believed to 
enter the cell through passive diffusion. The dichlorides are substituted by two molecules 
of water within the cell. This substitution does not happen outside the cell due to the high 
levels of chlorides within the intercellular space. Once activated, the diaquo platinum 
complex can bind to several targets among which are genomic DNA (gDNA), 
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mitochondrial DNA (mtDNA), cytoskeletal microfilaments, thiol containing 
proteins, and RNA. It should be noted that cisplatin has a high affinity for the N 7 of 
guanine and adenosine bases. Binding to these bases result in a 1, 2- intrastrand cross-
link. It is this bifunctional cross-link that prevents transcription of important proteins, 
resulting in induced apoptosis. Necrosis or apoptosis is induced by cisplatin via binding 
to the afore-mentioned targets in the cell, resulting in interference of metabolic pathways 
thereby compromising energy production and/or immune defense system deactivation. 
The other targets of cisplatin are phospholipids and phosphotidylserine of the cell 
membrane. Scheme 4.1 shows the various adducts of cisplatin. 
::x ..... ---<00\ b)~ 
Scheme 4.1 [153]: mode of action of cisplatin 
However, non small cell lung cancers and colorectal cancers have intrinsic 
resistance to cisplatin, while ovarian and small cell lung cancers develop resistance. It is 
believed in most academic circles that acquired resistance to cisplatin is conferred mainly 
through the deactivating actions of thiol metal-binding proteins such as glutathione 
(GSH) and metallothionein (MT) [57, 151]. After nearly four decades of intense research 
only a handful of compounds have showed some promise (Figure 4.1) . The latest 
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compounds are satraplatin and picoplatin. Satraplatin is under consideration for approval 
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Figure 4.1: Active platinum compounds. 
It is still not clear why large tumors are resistant to cisplatin. Membrane transport 
proteins ATP-binding cassette (ABC) family and solute carrier (SLC) transporters to a 
large extent control the efflux of drugs in cells [150]. Any modifications to these proteins 
will greatly determine intracellular drug concentration and efficacy. However, since 
cisplatin enters the cells through passive diffusion, modifications to these transport 
proteins do not directly affect cellular intake. A possible explanation for the diminished 
efficacy could be a combination of cell membrane disruption and increased MRP activity. 
Evidence of membrane modification in some cancer cells has been reported by Ying 
Huang [155]. It is not clear whether these modifications disrupt membrane fluidity. What 
is clear however, is that the intracellular concentration is lowered through the action of 
copper pumping protein ATPase A and B [45, 150]. 
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Another consideration with regards to a decrease in drug efficacy will be the role 
of hydrolytic enzymatic action. However, most drugs are designed with the actions of 
these enzymes in mind and an inspection of the compounds under discussion (Figure 4. 
1) reveals no enzymatic actions are required for these small compounds. Therefore 
enzymatic action can be ruled out. 
Platinum (II), a d8, typically forms square planar compounds. Due to its geometry, 
it is susceptible to nucleophilic attack, among others, from the top or bottom face. It is 
known that only 5-10% of covalently bound cell-associated cisplatin is found in the DNA 
fraction, whereas 75-85% of the drug binds to proteins [151, 153, 156-158]. A large 
amount of the cisplatin-protein interactions involves interactions with thiol containing 
proteins such as glutathione (GSH) and metallothionein (MT) which result in the 
deactivation of cisplatin and an increase in resistance acquisition. Accordingly, Heffeter 
et. al in a 2008 review cited elevated GSH levels and the thioredoxin system as playing a 
major role in chemotherapy resistance [45]. 
It is currently understood that factors that lead to drug resistance, including 
cisplatin, can be broadly catergorized into four parts; 
(i) reduced intracellular accumulation due to reduced drug uptake and! or enhanced efflux. 
(ii) conjugation with intracellular thiols like metallothionein (MT) and/ or glutathione (GSH). 
(iii) enhanced repair of platinum DNA adducts or enhanced tolerance of these adducts. 
(iv) changes in molecular pathways involved in regulation of cell survival and! or cell death [45, 
151] 
In an effort to overcome or circumvent these factors, combination therapy 
regiments including non-platinated complexes such as ruthenium, arsenic and gallium, 
have had to be employed. However, not much progress has been made [159]. Also, a 
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bifunctional DNA- binding trinuclear platinum complex BBR-3464 was suspended after 
phase II trials [45]. 
It is in light of the above four resistance acquisition factors that we propose a new 
series of platinated species that contain a 2-amino-l-methylbenzimidazole moiety that 
makes the platinum less accessible to thiol containing proteins as evident in Figure 4.2- i. 
That is, unlike previous drugs, the benzimidazole ligand, for example, assumes a 
conformation that makes access to the platinum core more difficult, thereby minimizing 
deactivation of the complex from reactions with thiols. 
R] 





(i) Compound 35 (ii) free ligand 
Figure 4.2: ORTEP diagram of compound 35 and a generic free ligand. 
The proposed framework also offers enormous flexibility including variation of 
attached pendants that can help probe alterations in sterics of the benzimidazole and its 
effect on reactivity towards targets such as DNA. Preliminary testing of the dichloride 
analogue of the compound in Figure 4.2-(i) compound 37, a type 1 complex, done by Dr. 
Fan using non-small lung cancer cells (A549) shows four-fold toxicity as compared to 
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cisplatin (i.e. LDso < l!-\-M compared to cisplatin's LDso value). Also the antitumor 
activity is enhanced when used in conjunction with a selenide reagent (MSA). The four-
fold toxicity of compound 37 has led to an examination of its pyridine analogue, 2-
pivaloylamino pyridine. This ligand was purchased from Sigma-Aldrich and was 
chararcterized using I H NMR. 
B: Synthesis and Characterization of Platinum (II) Complexes 
(i) 2-Pivaloyl Pyridine complexes; 
Synthesis of complexes: The platinum complexes were synthesized as shown in Scheme 
4.2, a methodology developed for 2-amino-l-methylbenzimidazole platinum(II) 
derivatives that selectively isolates cis-isomers[32]. Unlike the 2-amino-l-
methylbenzimidazole system, the pyridine ligand system gives a mixture of products. 
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Scheme 4.2: Generation-of dichloroplatinum(II) compounds 
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Compound 25 precipitates out of solution as a yellow solid at room temperature with a 
yield of 21 % in a 6 mL acetonitrile / 5 mL methanol / 10 mL water solution upon 
addition of stoichiometric amount of potassium hydroxide (ligand: base). The yield 
increases to 65.7% when the reaction is carried out in a methanol/water solution (l: 1 
v/v) at 50°C for 1.25 h. Compound 26 can be isolated via filtration, from a acetonitrile / 
water solution (6:5 v/v) and the addition of equimolar amount of potassium hydroxide 
(yield: 25.4%). Compound 27 precipitates with its cis conformer in a 4: 1 (Scheme 4.2) 
ratio over a four- hour period (yield 64.7%), when the reaction is carried out in an 
acetonitrile / water solution (4: 1 v/v) upon addition of stoichiometric amount of potassium 
hydroxide (ligand:base). However, a 3: 1 ratio is obtained when the solution ratio is 
changed to 12:5. Furthermore, a 1: 1 isomeric ratio was obtained for the solvent system 
2: 1. This phenomenon is different from what is observed in the 2-amino-l-
methylbenzimidazole system discussed later in the chapter, which gives exclusively one 
isomer over the other, most often favoring the cis isomer over the trans. 
Characterization of Pyridine complexes 
The IH NMR spectrum of compound 25 in CDCh, Figure 4.3, displays a singlet 
at 10.64 ppm that corresponds to two amide protons. The aromatic protons of both 
pyridines show up as a doublet (J = 4.25 Hz), doublet of doublets (J = 2.50 Hz, 1.00 Hz) 
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Figure 4.3: 'H NMR spectrum of compound 25 in CDCI3. 
at 8.41 ppm, 8.16 ppm, 7.74 ppm and 6.95 ppm respectively. However, these peaks 
appear as singlets in the ratio 2: 1: 1 in acetone-d6 with chemical shifts of 8.38 ppm, 7.98 
ppm and 7.09 ppm. The peak at 1.62 ppm represents the 18 protons of the tert-butyl 
group. The mass spectrum of compound 25 displays ion peaks at 180.38 mlz, 289.76 mlz, 
318.02 mlz, 553.32 mlz, and 680.77 mlz. The molecular ion peak at 680.77 represents the 
ion [H2(Pap)z Ptlt and has an intensity of 70%. The ion peak at 180.38 mlz is due to the 
fragment [HPapt and has a relative intensity of 100%. The peak at 289.76 mlz 
represents a [Pt(Pap-pivaloyl)t with a relative intensity of 70%, whilst the peak at 
318.02 mlz is due to a [Pt(pivaloyl)Kt ion with an intensity of 35%. The peak at 553.32 
mlz is due to a [Pt(Pap)2t with an intensity of 18%. 
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Figure 4.4: 'H NMR spectrum of compound 26 in CDC13 
Figure 4.4 shows the 'H NMR spectrum of compound 26 in CDCh. The singlet at 
10.19 ppm corresponds to the two amide protons. The aromatic protons of the pyridine 
moiety show up as a doublet of doublets (J = 24.0 Hz; Ja, Jb= 5.0,8.5 Hz), and two 
triplets (J = 7.5 Hz) at 8.54 ppm, 7.75 ppm and 7.03 ppm respectively. The peak at 1.60 
ppm represents the eighteen methyl protons. Examination of the mass spectrum shows 
ion peaks at 179.40 mlz, 288.59 mlz, 550.45 mlz and 678.33m1z with relative intensities 
of 100 %, 22 %, 15 % and 65 % respectively. These peaks correspond to the ion 
fragments [HPapt, [Pt(Pap-pivaloyl)t, [(Paph Pt t and [(Paph Pt I t. The spectral 
traces of the cis and trans iodo complexes show similar fragmentation pattern and is 
consistent with Haake et al. results [160]. 
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Figure 4.5 : IH NMR spectrum of compound 27 in CDC)3. 
The IH NMR spectrum of compound 27 in CDCh, Figure 4.5, shows two doublets and 
two triplets in the aromatic region. The doublets are centered at 8.82 ppm and 7.11 ppm 
with coupling constants of 5.50 Hz and 9.00 Hz respectively. Both doublets integrate to 
four protons. The triplets appear at 7.67 ppm and 6.87 ppm with coupling constants, J , 
7.50 Hz and 6.00 Hz. The peak at 1.26 ppm represents the eighteen protons of the two 
tert- butyl groups whilst the peak at 1.56 ppm is a water peak, a common solvent 
contaminant [127]. The mass spectrum of compound 27 shows a molecular peak 
[(Pt(Pap)z)H2t at 551.49 mJz. 
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Figure 4.6: 'H NMR spectrum of compound 28 in CDCI3. 
Figure 4.6 displays the IH NMR of compound 28 in CDCh. The spectrum shows an 
amide peak at 10.66 ppm that integrates to two protons. The aromatic region displays a 
doublet, singlet and two triplets all centered at 8.33 ppm (J = 4.00 Hz), 8.09 ppm, 7.76 
ppm (J = 7.00 Hz) and 6.89 ppm (J = 6.00 Hz) respectively. These peaks integrate to a 
total of eight protons. The mass spectrum of compound 28 displays peaks at 180.24 rn/z, 
289.87 rn/z , 553.44 rn/z, and 588.76 rn/z with relative intensities of 100 %, 18 %,20 % 
and 95 %, respectively. These peaks correspond to the ion fragments [H2Papt, [Pt(Pap-
pivaloyl)t, [(Pap)2Ptt and [(Pap)2PtClt. 
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Figure 4.7: 'H NMR spectrum of compound 29 in CDC)3' 
The IH NMR of compound 29 in CDCh is displayed in Figure 4.7. The spectrum shows 
an amide peak at 10.43 ppm. The aromatic region displays a singlet, doublet and two 
triplets centered at 8.60 ppm, 8.43 ppm, 7.82 ppm and 7.08 ppm respectively. These 
peaks integrate to eight pyridine protons. The peak for the eighteen protons of the two 
tert-butyl groups, appear at 1.56 ppm. The mass spectrum of compound 29 displays peaks 
at 179.53 m/z, 288.80 m/z, 485.61 m/z, 551.84 m/z and 587.83 m/z with relative 
intensities of 100%, 9.92%, 20%, 15.73% and 60% respectively. 
The aromatic region of the IH NMR spectrum of compound 27 shows a similar 
splitting pattern to its cis-conformer (Figure 4.8). However, the aromatic protons are 
relatively shifted downfield. These proton appear as a doublet (J = 3.00 Hz), triplet (J = 
7.50 Hz), doublet (J = 4.00 Hz) and a triplet (J = 4.00 Hz), with chemical shifts in 
deuterated chloroform of 8.85 ppm,7.71 ppm, 7.15 ppm and 6.88 ppm respectively. 
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(ii) ' H NMR of trans and cis amido complexes in a ratio of 4:1 in CDCI3 
Figure 4.8 : The aromatic region of the IH NMR of compound 27 and its cis-isomer. 
In an effort to optimize the yield for the cis- isomer, Method C of compound 27 
was employed. However even at relatively high temperatures, the trans-form seems to be 
dominant or the preferred state. A IH NMR experiment, (Figure 4.9), was performed to 
understand why this system differed from the system of benzimidazole platinum 
derivatives, (discussed later in the chapter), which gave cis- isomers exclusively. 
Figure 4.14 shows the IH NMR stacked plot spectrum of the reaction of 
Compound 25 (0.0023g, 4.1 f,lM) , dissolved in 0.5 mL d-acetonitrile / 200f,lL D20 
solution with 4f,lL 3.93M KOH. The reaction was monitored over 10 h. 
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Figure 4.9: Compound 25 dissolved in 0.5 mL d-acetonitrile / 200~L D20 solution with 4~L 3.93M KOH 
The amide peak appears at approximately 9.4 ppm and its intensity diminishes 
with time due to the conversion of compound 25 to compound 27. It should be noted that 
the amount of base used was 2.7 times more than the required amount. A repeat of the 
above experiment with 1.3 times base yielded similar results. The free rotation of the 
pyridine ring around the Pt-N bond axis coupled with the less steric bulk and ring strain 
could be why the trans state is preferred. 
C: FT -IR of Pyridine Complexes 
Figure 4.10 displays a KBr-IR absorption spectrum of compound 25 that is representative 
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Figure 4.10: IR spectrum of compound 25 
The Csp2-H absorption stretch appears at 3113 cm-
I
. Peaks at 2969 cm-I and 2871 cm- I are 
indicative ofCsp3-H stretches. The carbonyl stretch appears at 1713 cm-
I
• Selected IR data 
for compound 25-29 have been compiled in the table below (Table 4.1). 
Table 4 1· Selected IR data for comoound 25-29 ..
Compound uN-H (em-I) uCsprH (em-I) uCsprH (em-I) uC = 0 (em-I) 
25 3306 3113(w) 2969,2871 1713 
26 3300 3113 (w) 2963,2871 1713 
27 3128,3097 2963,2871 
28 3294 3106 2951 1700 
29 3336 3140 2969 1700 
The presence of the N-H and carbonyl stretching frequencies for compounds 25, 26, 28 
and 29 suggest that the respective ligands are ligated to the metal as monodentates. The 
3000 cm- I to 4000 cm- I region of compound 27 is identical to compound 36, its 1-
methylbenzimidazole analogue. A stretching frequency at 1621 cm- I , indicative of a C = 
C functionality can be seen in the spectrum of compound 27. The absence of a carbonyl 
stretch indicates that the ligand is chelated to the platinum metal. 
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The amide protons of compound 25, the cis isomer, is more deshielded than the 
trans isomer, compound 26. Accordingly, their IR spectra show that the amide peak for 
compound 25 has a higher stretching frequency. However, such is not the case for the 
dichloro- isomers, compounds 28 and 29. Eventhough their amide peaks follow the same 
order in terms of deshielding, their IR stretching frequencies are reversed. Since IR to 
some extent is an indication of bond strength, this finding suggests different reactivity for 
the various compounds and might be significant in an acid-base reaction. The observed 
phenomenon might be due to different s-character contributions towards the N-H bond. 
Additionally, the conversion of compound 25 to compound 27 can be carried out at room 
temperature, whereas compound 28 requires higher temperatures. 
D: X-ray Crystallography of Pyridine Complexes 
X-ray crystal analysis was performed on four of the six isomers. Tables 4.2 and 4.3 
contain selected x-ray crystallographic parameters that include bond angles and lengths 
for these complexes. 
Table 42' Selected CrystallograQhic data of comoounds 25-28 
25 26 27 28 
Crystal System Triclinic Orthorhombic Monoclinic Triclinic 
Space Group PI Pbca P 21/c PI 
a 9.502(2) A 12.78166(14) A 6.0476(2) A 8.5986(3) A 
b 10.692(3) A 9.19192(9) A 13.5698(5) A 11.1609(4) A 
c 14.141(4) A 20.5324(2) A 11.8620(4) A 13.2153(4) A 
IX 102.244(4)° 90° 90° 77.623(2)° 
~ 98.049(4)° 90° 95.157(3)° 85.944(2)° 
Y 113.604(3t 90° 90° 72.662(3)° 
Volume 1245.3(5) A3 2412.30(4) A3 969.52(6) A3 1182.45(7) A3 
z 2 4 4 2 
Density 2.142 Mg/m3 2.218 Mg/m3 1.882 Mg/m3 1.748 Mg/m3 
GOF 1.050 1.022 1.038 1.086 
RI 0.0281 0.0222 0.0193 0.0160 
wR2 0.0719 0.0628 0.0477 0.0390 
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Table 4 3· Selected bond lengths and angles of com~ounds 25-28 · . 
Bond lengths (A) 
25 26 27 28 
Pt(1)-N(I) 2.060(4) 2.037(2) 2.024(3) 2.0441(19) 
Pt(1)-N(3) 2.071(4) 2.037(2) 2.024(3) 2.0354(18) 
Pt(1)-X(2) 2.5846(7) 2.59749(18) 2.2889(5) 
Pt(1)-X(1) 2.5890(7) 2.59750(18) 2.2907(6) 
pte 1 )-O(avg) 1.986(2) 
C - O(avg) 1.213(1) 1.217(4) 1.292(3) 1.208(3) 
Bond angles CO) 
25 26 27 28 
N(3)-Pt(1)-N(1) 88.42(15) 180.0 180.0 88.85(7) 
N(3)-Pt(1)-X(I) 175.53(10) 91.17(7) 179.12(5) 
N(1)-Pt(1)-X(1) 87.11(10) 88.83(7) 91.09(5) 
N(1 ')-Pt(1 )-X( 1 ') 88.83(7) 
N(3)-Pt( 1 )-X(2) 91.08(10) 89.02(6) 
N(1 )-Pt(1 )-X(2) 179.41(10) 177.06(5) 
N( 1)-Pt(1)-X(1 ') 91.17(7) 
X(I)-Pt(1)-X(2) 93.395(13) 180.0 91.07(2) 
N (1 )-Pt(1 )-0(1 ) 90.74(7) 
N (1 )-Pt(1 )-0(1 3) 89.26(7) 
N (1_3)-Pt(1 )-0(1) 89.26(7) 
N (1 3)-Pt(1 )-0(1 3) 90.74(7) 
O(1)-Ptl -0(1 3) 180.00(2) 
Compound 25 forms triclinic crystals in the space group PI and has two molecules 
per unit cell (table 4.2). The coordination sphere around the Pt (II) ion, a d8 ion, can be 
described as square planar (Figure 4.11).The ligands bind to the metal as monodentates 
through the nitrogen of the pyridine derivative. One of the Pt-N bond lengths is elongated 
and longer than the shorter (2.060(4) A) by 0.011 A. The Pt-I bonds measure 2.5846(7) A 
and 2.5890(7)A respectively. The average COO bond length is 1.213(1) A. Figure 4.15 
shows an ortep diagram of compound 25. 
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Figure 4.11 : ORTEP diagram of compound 25. Ellipsoids are shown at 30% probability. Hydrogen atoms 
on the complex were removed for clarity. 
Compound 25 has bond angles of 88.42(15t, 175.53(lOt, 87.l1(10t, 91.08(lOt and 
l79.4l(lOt corresponding to N(3)-Pt(1)-N(1), N(3)-Pt(1)-I(1), N(1)-Pt(1)-I(1), N(3)-
Pt(1)-I(2) and N(1)-Pt(1)-I(2) respectively (table 4.3). The crystal lattice of compound 25, 
displays a network of slipped 1t-stacking (C1-C2, 3.68(7)A.) and interactions between 
pyridine hydrogens (H12) and the oxygen (01) of the carbonyl with an average distance 
of 2.50(5) A. «< Cl2-H12-01 angle of 133.13° and torsional angle of 98.06°). A third 
interaction of the pyridine rings is with the tert-butyl hydrogens with an average distance 
of 2.75 A. Figure 4.12 displays some of these interactions of the lattice. 
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Figure 4.12: Crystal lattice packing diagram of compound 25. 
These interactions are similar to those of its 2-amino-l-methylbenzimidazole analogue, 
compound 35. However, unlike its analogue there are no methylene chloride molecules 
involved in the network of interactions. The iodides are engaged in a C- H .. . 1t interaction 
with the tert-butyl group and have an average distance of 3.14 A (not shown in Figure 
4.12). Also visible are interactions with pyridine hydrogens. Compound 26 forms 
orthorhombic crystals in the space group Pbca. The coordination sphere around the Pt (II) 






Figure 4.13: ORTEP diagram of compound 26. Ellipsoids are shown at 50% probability. Except amide 
protons, hydrogen atoms on the complex were removed for clarity. 
The ligands bind to the metal as monodentates through the nitrogen of the pyridine 
derivative. Both Pt-N bond lengths are equidistant (2.04 A) and differ from the results of 
Wimmer et. al. by 0.05 A [161]. However, the Pt-I bond lengths are identical and 
measure 2.60 A (table 4.2). The average c-o bond length is 1.22 A. Compound 26 has 
bond angles of 180.0°, 91.17(7) 0, 88.83(7t, 88.83(7)°, and 91.17(7)° corresponding to 
Nl'-Ptl-Nl ,Nl'-Ptl-Il,NI-Ptl-Il,Nl'-Ptl-Il' andNI-Ptl-Il' respectively 
(table 4.3). The crystal lattice of compound 26, displays a network of interactions 
between pyridine hydrogens and the oxygen of the carbonyl (2.51A). A second set of 
interactions involves the tert-butyl hydrogens and the pyridine rings in an edge/point to 
face 1t-hydrogen interaction similar to its cis isomer, with an average distance of 2.75A. 
However, unlike its cis isomer, the pyridine rings are oriented parallel to each other and 
show no sign of cooperative 1t-stacking. The I-Pt-I bonds have an alternating diagonal 
orientation along the a-axis of the unit cell. The iodides are engaged in C- H ... 1t 
129 
interactions with the tert-butyl group with average distances of 3.14 A and 4.09 A (Figure 
4.14). 
Figure 4.14: Crystal lattice packing diagram of compound 26, view along the b-axis. 
Compound 27 forms monoclinic crytals in the space group P 21fc . The coordination 
sphere around the Pt (II) ion is square planar with a N20 2 donor set (Figure 4.15). 
Figure 4.15: ORTEP diagram of compound 27. Ellipsoids are shown at 50% probability. Hydrogen atoms 
have been omitted for clarity. 
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The ligands are in their anionic form and are chelated to the central Pt (II) ion as 
bidentates in a trans configuration. The Pt-N bond lengths are shorter than compounds 
25, 26 and 28. However, the C-O bond is longer (1.29 A). Compound 27 has bond angles 
of90.74(7t, 89.26(7) 0,89.26(7) 0 90.74(7) 0 and 180.00(2) 0 corresponding to N(l)-
Pt(1)-O(1) ,N(1)-Pt(1)-0(1_3), N(1_3)-Pt(1)-O(l), N(L3)-Pt(1)-O(l_3) and O(1)-Pt(1)-
0(1_3) respectively (table 4.3). The average Pt-O bond distance is 1.99 A and is shorter 
than the mono dentate nitrato reported by Tessier et at. [162] . The crystal lattice of 
compound 26, Figure 4.16, displays a network of interactions between pyridine rings and 
the hydrogens of the tert-butyl group of adjacent molecules with an average distance of 
3.36 A. 
Figure 4.16: Crystal lattice packing diagram of compound 27, showing C-H- ··n interactions 
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The lattice also shows cooperative pi- stacking between molecules (Figure 4.17). The 
average distance between adjacent molecules is 3.36A. This cooperative interaction is not 
seen in the 2-arnino-1-methylbenzirnidazole analogue. Also, unlike the analogue the 
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Figure 4.17: Cooperative slipped 1t-stacking in compound 27, view along the a-axis. 
Compound 28 forms triclinic crystals in the space group P-1 . The coordination sphere 
around the Pt (II) ion is also square planar with a N2Clz donor set (Figure 4.18 ). The 
ligands binds to the metal as monodentates. One of the Pt-N bond lengths is elongated 
and therefore longer than the shorter (2.04A) by 0.0087 A. The Pt-CI bonds are 
equidistance and measure 2.29 A (comparable to Kato et al. [163]). The average C-O 
bond length is 1.21 A. Compound 28 has bond angles of 88.85(7t, 179.12(5) 0, 91.09(5) 
0,89.02(6) 0 and 177.06(5) 0 corresponding to N(3)-Pt(1)-N(1) , N(3)-Pt(1)-CI(1), N(l)-





Figure 4.18: ORTEP diagram of compound 28. Ellipsoids are shown at 40% probability. Hydrogen atoms 
(except amide protons) have been removed for clarity. 
The crystal lattice of compound 28, displays a network of interactions similar to 
compound 25 with an average distance of 2.51 A. 
Figure 4.19: Crystal lattice packing diagram of compound 28, view along the b-axis. 
These interactions are similar to its 2-amino-I-methylbenzimidazole analogue. 
The tabe below contains the parameters of hydrogen bonding found in the lattice. 
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Table 4.4 : Hydrogen bonds for compound 28 [A and 0]. 
D-H d(D-H) d(H .. A) <DHA d(D .. A) A 
N2-H2N 0.708 2.599 145.17 3.206 CII 
N4-H4N 0.827 2.756 131.42 3.361 CI2 
The H donor -acceptor separation is significantly less than that of its diiodo analogue, 
compound 25. Thus, from a structural view point one would expect a relatively higher 
melting point(assuming equal number of total interactions) . 
E: UV -vis of Pyridine Complexes 
Figure 4.20 shows a typical UV spectrum of these pyridine platinum complexes in 
dichloromethane. The cis diiodo isomer, compound 25, shows a third A max at 437 nm not 
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Figure 4.20: UV -vis spectrum of compound 25 in 3 mL dichloromethane at various concentrations (Stock 
conc. 4.5 mM, 1 ilL in 3 mL == 1.5 11M) 
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The molar absorptivity and Amax for these pyridine complexes have been compiled in the 
table below. 
Table 45· UV-vis absorl2tion data (200 nm-1100 nm) for comolexes 25-29 obtained using CH?hh .. , , 
~ 
Compd Amax (nm) E (M-1 cm -I) Concentration range (M) 
25 293,380,437 2.41 x lOb, 3.58 X 1O:J, 3.35 X 1O:J 6.23 xlO-1U - 1.25 x 10- ~ 
26 236,298 1.49 x 104 , 5.86 x lO j 5.81 xlO-b - 1.74 xlO 4 
27 273,355 3.91 x 101, 0.90 X 101 8.46 xlO-:J - 1.69xlO-j 
28 242,295 5.30 x 1O:J, 3.38 X 1O:J 3.22 xlO-b - 6.44 x 10- :J 
29 237,295 3.28 x lO j , 2.38 x lO j 1.72 xlO-:J - 4.29 x 10- 4 
(ii) Synthesis, characterization, and analysis of platinum- benzimidazole derivatives 
Schemes 4.3 and 4.4 show two pathways of obtaining cis dichloro- analogues of platinum 
(II). Scheme 4.3 provides a pathway that converts tetrachloroplatinate(II) to 
tetraiodoplatinate(II). Addition of two equivalents of ligands affords a diiodo complex. 
The diiodo complex is then converted into an amido form with treatment of two 
equivalents of base. Treatment of the amido complex with HCI (g) yields the desired 
dichloro- isomer. 
2lCC~ ~~NH j 
# N r R 
o 
Scheme 4.3: Reaction protocol of benzimidazole-platinum complexes; R = alkyl or aryl 
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This pathway increases the overall yield of the reaction by taking advantage of ligand 
substitution chemistry involving platinum (II) compounds. Additionally, this synthetic 
route utilizes the greater trans effect of iodine compared to chlorine, hence the 
conversion of tetrachloroplatinate to tetraiodoplatinate. Furthermore, the retention of 
stereochemistry of the intermediate to generate the desired cis-isomer. However, 
controlling the stoichiometry of the gas in solution is difficult and excess HClleads to the 
decomposition of the product. A more direct synthetic approach, Scheme 4.4, utilizes two 
equivalents of ligand and potassium tetrachloroplatinate dissolved in an organic solvent 
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Scheme 4.4: Generation of cis -isomers (R= alkyl, aryl) 
This approach gives the desired cis- isomer in lower yields comparatively but is safer. 
However, in some cases, minute traces of the trans- isomer precipitates with the cis 
product when this synthetic route is used. This can be remedied by washing the 
precipitate with cold methanol or acetone followed by a water wash. 
The organic solvents usually employed in this synthetic approach include ethanol, 
methanol, acetonitrile, and tetrahydrofuran. It is worth noting that the yield is 
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significantly affected when this reaction is carried out in tetrahydrofuran and water. 
Therefore, the THF/water combination should be limited to ligand solubility 
considerations. 
Characterization of Complexes 
The 1 H NMR of these Pt(II) complexes are similar to that of their respective free 
ligands with the only exception being when they are bis-chelated to the metal (amido 
form). In this form, the aromatic protons of the benzimidazole are no longer aggregated. 
They appear as a doublet, triplet, triplet and doublet (Figure 4.28). Consequently, the 
respective 1 H NMR spectra have been moved to the appendix. The chemical shifts of the 
peaks are listed in this section. 
The mass spectrometric trace of compound 30 displayed in Figure 4.21 shows an 
ion peak at 150.74 m/z with an intensity of 100 %. This peak is due to a protonated 2-
amino-1-methylbenzimidazole ion fragment, [Hambt. Daughter ion peaks at 302.57 m/z 
and 340.46 m/z have relative intensities of 20 % and 10 %. These peaks correspond to the 
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Figure 4.21 : Mass spectrometric trace of compound 30 
The peak at 795.55 mJz corresponds to the molecular ion fragment [(mbda)2Pt] + and 
agrees with the calculated theoretical mass of 797.40 g/mo!. The I H NMR spectrum of 
compound 30 shows benzimidazole proton peaks that appear as a doublet, triplet, triplet, 
and doublet in the aromatic region with chemical shifts of7.15 ppm,7.03 ppm, 6.67 ppm 
and 6.37 ppm. The methyl protons on the nitrogen of the benzimidazole, designated N 1, 
appear as a singlet at 3.77 ppm. Peaks at 2.53 ppm, 1.82ppm, 1.61 ppm, 1.44 ppm, and 
0.88 ppm appear as a triplet, doublet of a doublet, singlet, multiplet, and triplet 
respectively. These peaks integrate in the ratio 4H:4H:8H:4H:6H. A broad peak at 1.29 
ppm represents twelve protons of the pendant. 
The mass spectrometric trace of compound 31 (Figure 4.22) shows a molecular 
ion peak, [((HmbchcahPtI2)H2] +, at 965 mJz with an intensity of 13 %. This peak is 
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Figure 4.22: Mass spectrometric trace of compound 31 
Daughter ion peaks appear at 258.46 rnIz, 708.36rn1z and 855.31 rnIz with intensities of 
100%, 35% and 30%. These peaks correspond to the ion fragments [Hmbchcat, 
[(Hmbchca)zPtt, and [(Hmbchca)zPtINat respectively. The IH NMR spectrum displays 
a singlet at 9.73 ppm corresponding to the two amide peaks. The multiplet and singlet at 
7.55 pm and 7.15 ppm represents the eight aromatic protons (6H:2H). The six methyl 
protons of the benzimidazole appear as a singlet at 3.67 ppm. Peaks corresponding to the 
twenty-two cyclohexyl protons appear at 2.80 ppm, 2.45 ppm, 2.29 ppm, 1.96 ppm, 1.50 
ppm and 1.40 ppm. The l3C NMR spectrum displays peaks at 174.84 ppm, 144.82 ppm, 
136.83 ppm, 132.76 ppm, 124.06 ppm, 123.74 ppm, 122.79 ppm, 117.00 ppm, 111.38 
ppm, 110.02 ppm, 108.87 ppm, 48.41 ppm, 45.70 ppm, 32.27 ppm, 29.22 ppm, 28.28 
ppm, and 25.973 ppm. The peak at 174.84 ppm corresponds to the carbonyl carbon. 
Figure 4.23 displays the mass spectrometric trace of compound 32. The molecular 
ion peak, [((mbchca)zPt)Ht, appears at 708.13 rnIz with an intensity of 100 %. This peak 
is in agreement with the calculated theoretical mass 707.25 g/mol for compound 32. The 
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Figure 4.23: Mass spectrometric trace of compound 32 
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The ion peaks at 148.40 mJz corresponds to the fragment [(amb)Ht. The IH NMR 
spectrum of compound 32 shows a proton splitting pattern in the aromatic region similar 
to compound 30. The peaks appear as a doublet, triplet, triplet and doublet with chemical 
shifts of 7.14 ppm, 7.02 ppm, 6.66 ppm, and 6.38 ppm that correspond to the 
benzimidazole protons. The methyl protons on the nitrogen of the benzimidazole, 
designated N1, appear as a singlet at 3.65 ppm. Protons of the cyclohexyl pendant appear 
at 2.54 ppm, 2.11 ppm, 1.83 ppm, 1.70 ppm, 1.63 ppm, 1.57 ppm and 1.36 ppm as five 
triplets, a singlet and multiplet respectively. Its IR spectrum is similar to that of 
compound 36 with stretching freqencies at 3059 cm-1, 2925 cm-1, and 2852 cm-1 
corresponding to Csp2-Hand Csp2-H stretches. A C = C stretch appears at 1615 cm-1. 
The mass spectrometric trace of compound 33 (Figure 4.24) shows an ion peak at 
258.48 mJz with an intensity of 100% and represents the ligand, [(Hmbchca)Ht. 
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Figure 4.24: Mass spectrometric trace of compound 33 
The peaks at 280.46 rnJz and 709.42 rnJz with relative intensities of 12% and 30% 
represent the molecular fragments of [(Hmbchca)Nat, a sodium ion peak, and 
[(Pt(mbchcah)Ht respectively. The molecular ion peak appears at 745.37 rnJz with a 
peak intensity of 35% and represents the fragment [(Hmbchca)2PtClt. This peak differs 
from the calculated theoretical molecular mass, 779.21 g/mol, by a chloride ion. The IH 
NMR spectrum of compound 33 displays an amide peak at 10.14 ppm and a multiplet at 
7.14 ppm corresponding to the benzimidazole protons. The six methyl protons appear as 
a singlet at 3.71 ppm. The twenty-two cyclohexyl proton peaks appear at 2.77 ppm, 2.41 
ppm, 2.25 ppm, 1.96 ppm, 1.80 ppm, 1.50 and 1.37 ppm. The cyclohexyl protons 
splitting pattern is similar to the diiodo isomer compound 31 and the free ligand. 
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Figure 4.25: Mass spectrometric trace of compound 34 
The mass spectrometric trace of compound 34 (Figure 4.25) shows an ion peak: at 386.45 
rn/z with an intensity of 100%. This peak is due to the ion fragment of the protonated 
ligand ion [(Hmbhda)Ht. The peak at 735.43 rn/z with peak intensity of 88% 
corresponds the fragment [Pt(mbhda)(matrix-DBA)t. The molecular ion peak:, 
[Pt(mbhdaht, appears at 964.18 rn/z and has a relative peak: intensity of 30 %. The 
theoretical and experimental masses of compound 34 are in agreement. 
Compounds 35 - 37 have been characterized by IH NMR in our laboratory [32]. The 
respective IR and mass spectrometric traces of compounds 36 and 37 are displayed in 
Figures 4.26- 4.30 for comparison to compounds in Chapter ill. Figure 4.28 shows the 
aromatic region of the IH NMR spectrum of compound 36. This is a characteristic 
splitting pattern of the amido form and is also used as a diagnostic tool for syn isomeric 
intermediates for the 2-arnino-1-methylbenzirnidazole derivatives. 
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Figure 4.26: Infrared trace of compound 36 
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Figure 4.27 : Mass spectrometric trace of compound 36 
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Figure 4.28: Aromatic region of the IH NMR spectrum of compound 36. The singlet is a solvent peak 
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Figure 4.29: Mass spectrometric trace of compound 37 
Figure 4.30: Infrared trace of compound 37 
The mass spectrometric trace of compound 38 (Figure 4.31) shows daughter ion 
peaks at 218.86 rnIz, 240.82 rnIz, 460.64 rnIz, 544.41rn1z, 629.26 rnIz, 671.99 rnIz, 677.13 
rnIz, 755.90 rnIz, and 888.49 rnIz with peak intensities of 100 %, 15.56 %, 10.04 %,47.36 
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Figure 4.31: Mass spectrometric trace of compound 38 
These correspond to the ion fragments [Hdmbpt, [HdmbpNat, [(HdmbphNat, 
[Pt(Hdmbp )(benzimidazole) t, [Pt(Hdmbp h t , [Pt(Hdmbp h Kt , [Pt(Hdmbp h N a2t , 
[Pt(Hdmbph lt, [Pt(Hdmbp)2lzt. The theoretical mass 883 .02 g/mol is less than the 
experimental by five and might be due to isotopic effects. 
The mass spectrometric trace of compound 39 (Figure 4.32) shows an ion peak at 
219.04 rnIz with an intensity of 100%. This peak is due to the ligand ion fragment 
[(Hdmbp)H2t . Daughter ion peaks at 241.06 rnIz and 627.55 rnIz have relative intensities 
of 18 % and 20 %. 
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Figure 4.32: Mass spectrometric trace of compound 39 
These peaks correspond to the fragments [HdmbpNat and [Pt(Hdmbpht respectively, 
The molecular peak, [Pt(HdmbphClt, at 665,58 m/z has a peak intensity of 40% and 
differs from the theoretical mass, 699,15 g/mol, by the mass of a chloride ion, The peak 
at 739,32 m/z corresponds to the fragment [(Pt(Hdmbp)2Ch)Kt, The 'H NMR shows a 
clean sample with an amide peak at 11.33 ppm. The peak at 10.436 ppm represents the 
proton of the Nl nitrogen of the benzimidazole. Aromatic protons appear as singlets with 
chemical shifts of 8.20 ppm and 7,39 ppm. The tert-butyl group appears as a singlet at 
1.56 ppm. Both physical methods confirm the synthesis of the desired product. 
The mass spectrometric trace of compound 40 (Figure 4.33) shows an ion peak, 
[(Hbchca)3Ptt at 924.19 m/z with an intensity of 37 %. Daughter ion peaks appear at 
244.88 m/z, 266.96 m/z, 282.73 m/z, 681.42 m/z and 808.12 m/z, with intensities of 
100%, 24%, 8 %, 20 % and 44 %. 
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Figure 4.33: Mass spectrometric trace of compound 40 
These peaks correspond to the ion fragments [Hbchcat, [Hbchca Nat, 
[HbchcaKt, [(bchcahPtt, and [(HbchcahPtlt respectively. The 13C NMR spectrum 
displays peaks at 123.15 ppm, 122.45 ppm, 118.86 ppm, 132.76 ppm, 124.06 ppm, 
123.74 ppm, 122.79 ppm, 117.00 ppm, 111.38 ppm, 111.94 ppm, 44.77 ppm, 35.23 ppm, 
26.53 ppm, 26.53 ppm, 25.44 ppm, and 25. 19 ppm. The IR spectrum shows stretching 
frequencies at 3312 cm-I , 3058 cm-I , 2929 cm-I , 2853 cm-I and 1708 cm-I corresponding 
to the N-H, Csp2-H, Csp3-H and carbonyl stretches respectively. 
The mass spectrometric trace of compound 41 (Figure 4.34) shows a ion peak at 
637 .23 mlz with an intensity of 17.91 %. This peak is due to the ion fragment 
[Pt(Hmbph Clt. Daughter ion peaks at 600.33 mlz and 204.82 mlz have relative 
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Figure 4.34: Mass spectrometric trace of compound 41 
These peaks correspond to the fragments [Hmbpt and [Pt(Hmbpht respectively. 
The IH NMR spectrum shows an amide peak at 10.20 ppm, integrating to two protons. 
The peak at 3.74 ppm represents the six protons of the methyl groups attached to the N 1 
nitrogen of the benzimidazole. The eight aromatic protons appear as a multiplet centered 
at 7.17 ppm. Peaks at 1.21ppm and 0.815 ppm correspond to the five protons of the 
propyl chain. The IR reveals stretches a 3251 em-I, 3145 em-I, 2978 em-I, 2941 em-I and 





Figure 4.35: Mass spectrometric trace of compound 46 
The mass spectrometric trace of compound 46 (Figure 4.35), a second generation 
compound, shows a molecular ion peak, [Pt(HLbochCht, at 933.02 rn/z with an intensity 
of23%. Daughter ion peaks at 233.81 rn/z, 255 rn/z, 271.71 rn/z, 333.59 rn/z, 355.59 rn/z, 
371.49 rn/z, 580.87 rn/z, and 968.24 rn/z have relative intensities of 53%,81 %,52%,28 
%,53%,100% ,28 % and 22 %. These peaks correspond to the fragments [(HLboc _ 
boc)t, [(HLboc - boc)Nat, [(HLboc_ boc)Kt, [(HLboc)t, [(HLboc) Nat, [(HLboc)Kt, 
[Pt(HLboc -boc)(amb)t, [(Pt(HLboChCh)Kt respectively. The IH NMR shows an amide 
peak at 10.59 ppm. A peak at 3.90 ppm represents the six protons of the Nl nitrogen of 
the benzimidazole. The aromatic protons appear as a multiplet with chemical shifts 7.17 
ppm. Singlets at 2.00 ppm and 1.76 ppm correspond to the twelve protons of the four 
methyl groups of the pendant. The tert-butyl group of the boc protecting group appears as 
a singlet at 1.45 ppm. 
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Overall, both the IH NMR and mass spectrometric spectra confirm the synthesis 
of the respective desired products. The IH NMR spectra of these complexes show clean 
products. Furthermore, complex spectra are similar to their respective free ligand 
differing only in the aromatic region. That is, the aromatic protons of the monodentates of 
the 2-amino- I-methylbenzimidazole derivatives show less aggregation than their 
respective free ligands whilst aromatic protons of the bis-chelates appears as doublets and 
triplets. Additionally, IR data confirm the presence or absence of amide protons in the 
respective complexes. 
F: X-ray Crystallographic Analysis of Complexes 
X-ray structure analysis on six Pt(lI), Pt(IV) complexes and a ligand are presented in this 
section. Tables 4.6 and 4.7 show selected crystallographic data including bond angles and 
bond lengths for these compounds. 
Table 4.6: Crystallogra12hic data for coffi12ounds 4, 30, 41, 42a, 41b, 41c and 46 
4 30 41 42a 42b 42c 46 
Crystal Monoclinic Orthorhombic Triclinic Monoclinic Monoclinic Monoclinic Monoclinic 
System 
Space P2dn P2,2,2, PI 12/a 12/a P2dc P2dn 
Group 
a 
14.1720(3) A 4.7998(5) A 10.2102(5) A 16.7763(13) A 16.7763(13) A 10.4180(9) A 17.7393(5) A 
b 
6.04320(8) A 18.2520(17) A 10.6491(6) A 18.6042(13) A 18.6042(13) A 17.0912(14) A 11.4632(3) A 
c 15.7484(3) A 41.322(4) A 12.0364(6) A 18.2199(13) A 18.2199(13) A 8.0463(7) A 19.3959(5) A 
(l 90° 90° 70.699(5)° 90°. 90°. 90° 90° 
P 107.3724(19)" 90° 76.753(4)" 102.526(2)° 102.526(2)" 97.0640(10)° 99.794(3)° 
Y 90° 90° 79.119(4)° 90° 90° 90° 90° 
Volume 1287.24(4) A3 3620.1(6) A3 1193.16(11) A3 5551.3(7) A3 5551.3(7) A3 1421.8(2) A3 3886.66(17) A3 
z 4 4 2 4 4 2 4 
Density 1.328 Mglm3 1.460 Mglm3 1.872 Mglm3 1.837 Mglm3 1.837 Mglm3 1.795 Mglm3 1.591 Mglm3 
GOF 1.017 1.313 1.072 1.074 1.074 1.043 1.068 
RI 
0.0355 0.0522 0.0279 0.0279 0.0147 0.0338 
0.0691 
wR2 0.0812 0.1638 0.0984 0.0688 0.0688 0.0338 0.0716 
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Table 4.7: Bond lengths and angles of cOffil2ounds 4, 30, 41, 42a,42b, 42c and 46 
Bond Lengths (A) 
4 30 41 423 42b 42c 46 
Pt-NI 1.996(10) 2.029(5) 2.005(3) 2.016(3) 2.0144(16) 2.026(3) 
Pt-N4 1.981(10) 2.023(5) 2.005(3) 2.016(3) 2.0143(16) 2.028(3) 
Pt-OJ 2.002(9) 2.006(2) 
Pt-02 2.005(9) 2.006(2) 
Pt-CII 2.2977(17) 2.3210(14) 2.3092(8) 2.3035(5) 2.2991(9) 
Pt-CI2 2.2975(15) 2.3196(13) 2.3091(8) 2.3035(5) 2.3022(9) 
C-OI 1.2186(12) 1.268(16) 1.219(8) 1.315(4) 1.210(4) 1.209(2) 1.207(4) 
C-02 1.289(14) 1.213(4) 
C-03 1.348(4) 
Bond Angles CO) 
NI- Pt-N4 101.7(4) 91.37(19) 178.22(16) 89.84(16) 179.999(1) 90.28(11) 
NI- Pt-OJ 86.6(4) 88.40(11) 
NI- Pt-02 165.8(4) 91.68(11) 
NI-Pt-CII 90.66(15) 90.89(8) 176.50(8) 90.20(4) 90.69(8) 
NI-Pt-CI2 176.79(15) 89.11(8) 90.15(8) 89.80(4) 177.39(9) 
N4- Pt-OJ 169.9(4) 91.69(11) 
N4-Pt- 02 90.1(4) 88.40(11) 
OI-Pt-02 82.6(3) 174.82(15) 
02-Pt-Cll 87.41(7) 
02-Pt-CI2 92.59(7) 
N4-Pt-CII 177.84(13) 90.89(8) 90.14(8) 89.80(4) 178.44(9) 
N4-Pt-CI2 88.32(14) 89.11(8) 176.49(8) 90.20(4) 89.40(8) 






Compound 4 has been included in this section because crystals were obtained from a 
acetonitrile/ water solution of K2PtCh and methylene chloride. Compound 4 forms 
monoclinic crystals in the space group P2dn. The C-O bond length measures 1.2186(12) 
A (Table 4.6) and is consistent with a carbonyl carbon-oxygen bond length. 
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Figure 4.36: ORTEP diagram of compound 4. Ellipsoids are shown at 50% probability. 
The cyclohexyl group is in a chair configuration (Figure 4.36) with the hydrogens in the 
axial and equatorial positions. These hydrogens are engaged in either C-H .. . n 
interactions with the n- system of the benzimidazole or hydrogen bonding with the 
oxygen of the carbonyl (Figure 4.37). 
Figure 4.37: Some interactions and contacts in the crystal lattice of compound 4 along the a-axis . 
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C-H ... 1t interactions are further facilitated by the twist of the cyclohexyl group with 
respect to the plane of the benzimidazole resulting in« CI-N1-C2 angle of 120.95° and a 
torsion angle of 60.12°. The amide proton is oriented such that, it interacts with the lone 
pair electron of the benzimidazole nitrogen (N3) of an adjacent molecule with an average 
distance of 2.97 A. 
Compound 30 forms orthorhombic crystals in the space group P212121• The 
coordination sphere around the Pt (II) ion, a dB ion, can be described as distorted square 
planar (Figure 4.38). The ligand, N-(N' -1-methylbenzimidazol-2-yl)decanamide, is in its 
anionic form and chelates to the Pt (II) ion through the nitrogen of the benzimidazole and 
the oxygen of the carbonyl. 
Figure 4.38 : ORTEP diagram of compound 30. Capped sticks are shown at 40% probability. 
The chelated ligand assumes a cis configuration around the central atom with an 
average Pt-N bond length of 1.988(6)A. The average Pt-O bond length is 2.004(4) A 
whilst the C-O bond distance is 1.2786(5) A. Compound 30 has bond angles of 101.7(4) 
A, 86.6(4) A, 165.8(4) A and 82.6(3) A corresponding to N(1) - Pt - N(l ' ) , N(l) - Pt -
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0(1), N(1) - Pt - 0(1 ') and 0(1 ) - Pt - 0(1 ') respectively (Table 4.6). The crystal lattice 
shows four molecules per asymmetric unit (Figure 4.39). 
Figure 4.39: Unit cell of compound 30 with hydrogens omitted for clarity. 
Unlike its Cu2+ analogue, compound 15, the chelated benzimidazole ligands are syn and 
out of the plane of the central pe+ ion. The ligands form a combinational network of 
cooperative slipped / parallel displaced 1t- 1t stacking and C-H ... 1t interactions. C-H ... 1t 
interactions are also visible between the aliphatic hydrogens (Cu) and adjacent oxygen 
atoms with a torsional angle, « Ptl -02-CH26A of 87.5° and « C26-H26A-02 of 113.1 ° 
(Figure 4.40). This interaction differs from that of the Cu2+ analogue. That is, only one 
Cu-hydrogen is engaged in a C-H ... 1t interaction, whereas both hydrogens are engaged in 




Figure 4.40: ORTEP diagram of compound 30 showing packing and hydrogen bonding interactions 
between stacks. Hydrogens have been omitted in (a) for clarity. 
Compound 41 forms triclinic crystals in the space group Pi. The coordination 
sphere around the Pt (II) ion can be described as square planar (Figure 4. 41). The ligand, 
N-(N' -1-methylbenzimidazol-2-yl)propanamide, binds to the Pt (II) ion as a monodentate 
through the nitrogen (N3) of the benzimidazole and assumes a cis configuration around 
the central atom with an average Pt-N bond length of 2.026(5)A. The average Pt-Cl and 
C-O bond distances are 2.2976 A and 1.219(8) A respectively. Compound 41 has bond 
angles of 91.37(19) A, 90.66(15) A and 176.79(15) A corresponding to N(1) - Pt - N(1 ') 




Figure 4.4 1: ORTEP diagram of compound 41 . Ellipsoids are shown at 50% probability. Hydrogen atoms 
have been omitted for clarity. 
The crystal lattice of compound 41 is similar to that of dihalide compounds with 
short pendants of this system. The chlorides are engaged in C-H .. . n(Cl) interactions with 
amide protons of adjacent molecules and are an average distance of 2.57 A apart. There 
are also C-H···n interactions involving methyl hydrogens and the benzimidazole ligands 
of adjacent molecules with an average distance of 2.93A separating them. There is no 
evidence of cooperative n-stacking in the lattice. However, T-shapedlpoint - face C-H- ··n 





Figure 4.42: "Capped-sticks" ORTEP diagram of compound 41 showing packing and hydrogen bonding 
interactions in the crystal lattice. 
Table 4.8 displays selected bond lengths and angles of hydrogen bonds found in the 
lattice of compound 41. 
Table 4.8: Hydrogen bonds for compound 41 [A and 0]. 
D-H d(D-H) d(H .. A) <DHA d(D .. A) A 
N3-H3N 0.762 2.565 156.55 3.278 Cl2 [ -x+ I, -y+ 1, -z+ 1 ] 
N6-H6N 0.663 2.612 160.80 3.245 CI2 [-x+I , -y+l , -z+l] 
The angle between the H-donor (d) and acceptor (CI2) for both N3-H3N and N6-H6N are 
156.6° and 160.8° respectively. Furthermore, both hydrogens are 2.6 A from their 
respective acceptor atom (CI2). 
Figure 4.43 displays the packing arrangement seen in the lattice of compounds 
42(a,b).The crystal lattice reveals an octahedral Pt(IV) bis-chelated complex, compound 
42a, with two chlorides occupying the axial position (Figure 4.44). 
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Figure 4.43: Packing of compounds 42a and 42b. "Capped-sticks" represent the Pt(IV) complex. The 
wireframe represents the Pt (II) complex. Hydrogens have been removed for clarity. 
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Figure 4.44: ORTEP diagram of compounds 42b with a co-crystal of a Pt(IV) trans complex, 42a( left). 
Ellipsoids are shown at 40% probability. Hydrogen atoms have been omitted for clarity. 
The twist in the bis-chelated benzimidazoles of compound 42a is similar to compound 
30. Compound 42a shows slipped 1t-stacking with adjacent Pt(IV) molecules with an 
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average distance of 3.3SA (Figure 4.45). The axial chlorides are engaged in C-H ... 1t(Cl) 
interactions with the hydrogens (H7, HSC) of adjacent benzimidazoles (2.95A). Figures 
4.45-4.47 display some interactions found in the lattice of compound 42. 
Figure 4.45: ORTEP diagram of compound 42a showing axial chlorides and bis-chelated twisted out of the 
N-Pt-N plane and showing slipped 1t-stacking interactions in the crystal lattice. 
Figure 4.46: "Capped-sticks" ORTEP diagram of compound 42a showing C-H,,·1t interactions in the crystal 
lattice. 
The Pt(ll) complex, compound 42b, also shows 'slipped' 1t".1t interactions (3.39A) 
amongst the phenyl groups of adjacent molecules. However. it has more overlap 
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compared to compound 42a. Additonally, its chlorides are also engaged in C-H .. ·1t (CI) 
interactions with average distances of 2.81A. 
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Figure 4.47: "Capped-sticks" ORTEP diagram of compounds 42a and 42b showing packing and some 
interactions in the crystal lattice. 
The lattice also displays occasional point to face C-H ... 1t interactions between 
benzimidazole protons and phenyl groups of both the Pt(ll) and Pt(IV) moieties (Figure 
4.47). The trans Pt(II) isomer of compound 42b, compound 42c, is displayed in Figure 
4.48. It forms monoclinic crystals in the space group P2 1/c. Its molecular geometry is 
square planar. Examination of the coordination sphere shows the Pt (II) ion coordinated 
to two monodentate benzimidazole ligands and two chlorides in a trans configuration. 
The ligands, N-(N' -1-methylbenzimidaz-2-yl)benzamide, are coordinated through the 
nitrogen (N3) of the benzimidazole. 
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Figure 4.48: ORTEP diagram of compound 42c showing packing and hydrogen bonding interactions 
between stacks. Hydrogens have been omitted for clarity. 
Compound 42c has bond angles of 179.999 A., 90.20(4) A., 89.80(4) A. and 180.0A. 
corresponding to N(l) - Pt- N(l '), N(l) - Pt - CI (1), N(l) - Pt - CI (1 ') and CI(l) - Pt-
CI(l ') respectively. The average Pt - Nand Pt - CI bond lengths are 2.014 A. and 2.304 
A. respectively. 
The crystal lattice shows a H-donor / acceptor (2.48A.) relationship between the 
chlorides and the amide hydrogen (Figure 4.49). The phenyl groups are diagonal and out 
of the benzimidazole-Pt plane, an orientation previously seen in compound 4, a 
cyclohexyl pendant. Another type of interaction visible in this lattice is a slipped 1t ... 1t 
interactions (C1-C7), Figure 4.51. 
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Figure 4.49: "Capped-sticks" ORTEP diagram of compound 42c showing hydrogen bonding between 
chlorides and amide hydrogens in the crystal lattice. 
Figure 4.50: "Capped-sticks" ORTEP diagram of compounds 42c showing packing and some interactions 
in the crystal lattice. 
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Compound 46 forms monoclinic crystals in the space group P2dn. The ligand, (N' -1-
methylbenzimidazol-2-yl) - N-boc-2-amino-2,2-dimethylacetamide, binds to the Pt (II) 
ion through the nitrogen of the benzimidazole as a monodentate (Figure 4.51). 
C16 
Figure 4.51: ORTEP diagram of compound 46. Ellipsoids are shown at 50% probability. Hydrogen atoms 
have been omitted for clarity. 
The ligand assumes a cis configuration around the central atom with an average Pt-N 
bond length of 2.027(3)A. The average Pt- Cl and c-o bond lengths are 2.30 A and 1.256 
A respectively. Compound 46 has bond angles of 90.28(1l)A, 90.69(8) A and 177.39(9) 
A corresponding to N(l) - Pt - N(l ') , N(1) - Pt - Cl(1) and N(l) - Pt - Cl (1 ') 
respectively. Its crystal lattice shows hydrogen bonding between the chlorides, amide 
protons and carbonyl oxygens. The parameters of these hydrogen bond interactions have 
been compiled in table 4.9. 
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Table 4.9: Hydrogen bonds for compound 46 [A and 0]. 
D-H d(D-H) d(H .. A) <DHA d(D .. A) A 
N3-H3N 0.793 2.392 144.38 3.071 Cll 
N4-H4N 0.701 2.440 163.01 3.117 04 [ x, y-1 , z ] 
N7-H7N 0.694 2.300 116.03 2.678 N8 
N7-H7N 0.694 2.535 140.04 3.099 CI2 
N8-H8N 0.879 2.602 169.49 3.469 CI2 [ -x+2, -y+2, -z+2 ] 
Additionally, the tert-butyl of both boc-groups are oriented in opposite directions. Figure 
4.52 shows some of the interactions seen in the lattice. 
Figure 4.52: "Capped-sticks" ORTEP diagram of compound 46 showing hydrogen bonding interactions in 
the crystal lattice. T-butyl groups oriented in opposite direction. 
The orientation of the benzimidazoles are similar to other dichlorides in this series. The 
dichlorides are also engaged in C-H ... nCCl) interactions with benzimidazole protons. 
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There is no evidence of cooperative n -stacking in the crystal lattice. However, unlike 
previous compounds of this series, the platinum core appears to be more shielded by both 
the pendants and the benzimidazoles. This would likely prevent or slow down 
deactivating reactions with thiols such as glutathione (Figure 4.53). 
Figure 4.53: "Capped-sticks" ORTEP diagram of compound 46 showing a semi- encapsulation of the 
metal , preventing possible interactions with thiol s such as glutathione. 
Overall, the crystal structures are in agreement with the other physical methods. None of 
the lattices examined showed a full face to face n-stacking overlap. However, the 
interactions of the benzimidzole repeat motifs were usually slipped n-stacking with 
varying degrees of overlap. Furthermore, eventhough hydrogen bond interactions are the 
strongest of all non-covalent interactions, not all the lattices displayed it. Instead, lattices 
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favored interactions that brought about the most stability regardless of the hydrogen 
donor and acceptor capability of the respective complexes. 
G: UV -vis Studies of Complexes 
Table 4.9 shows Amax values of selected Pt(II) complexes performed in 3mL 
dichloromethane. The "Amb" refers to 2-amino-l-methylbenzimidazole whilst AB 
represents 2-amino-lH -benzimidazole. 
Table 4 10· ~ values of selected PHIl) comolexes ax 
Compound Ligand Complex Amax(nm), [8 (M-I em-I)] 
4 Hmbchca L 249 [17]; 300 [26]; 310 [34] 
30 Amb-(CH2)gCH3 PtL2 288 [28],322[28] 
31 Amb-C6Hll PtL2I2 248 [10],299 [9],310 [5] 
32 Amb-C6H 11 PtL2 288 [7], 324 [6] 
33 Amb-C6Hll PtL2Cl2 279 [13] 
34 Amb-(CH2)14CH3 PtL2 280 [39], 364 [3] 
40 AB-C~ll PtL2I2 286 [11],294 
41 Amb-CH2CH3 PtL2Cl2 279 [10] 
Compared to the diiodo- and amido forms of the 2amino-l-methylbenzimidazole 
derivatives, the dichlorides have only one Amax(279 nm). The amido derivatives of this 
series have characteristic two Amax. The Amax of compound 31 is similar to that of its free 
ligand compound 4. 
Solvent Effects on Compound 37: Compound 37 showed comparable cytotoxity 
(discussed later in the chapter) to cisplatin against prostrate cancer cell lines (DUI45). It 
showed better inhibitory activity in the concentration range O.4!lM- 8.0!lM. Based on this 
information, UV studies were carried out to investigate the reactivity of compound 37 
with glutathione, a known deactivating agent of platinated species in the cell. Scheme 4.5 





Scheme 4.5: Possible interactions of glutathione with compound 37. Carboxylic and amine hydrogens in 
the product have been omitted for clarity. 
The first pathway (i), shows compound 37 ligated to the tripeptide, as a monodentate, 
through the sulfur [164]. The second possibility will be a chelation of one molecule of 
glutathione through a nitrogen and a sulfur (ii). Another possibility is a chelation to the 
monomer through a nitrogen and an oxygen. 
The study was carried out in three different solvent systems. The first of which 
was a 7 mLwaterl 3 mL methanol mixture. The second and third were 10 mL anhydrous 
dichloromethane (DCM) and 8 mL dimethylsulfoxide (DMSO) I 2 mL water. All three 
systems had a 1:2 ratio (compound 37: GSH). The concentrations of compound 37 were 
8.39 X 1O-6 /lM, 14.86 x 1O-4 /lM and 15.82 x 10-4 /lM respectively. Figures 4.54 shows a 
combined UV-vis spectra for all three solvent systems obtained after 14 days. The spectra 
for the individual reactants is displayed in Figure 4.55 for comparison. 
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Figure 4.54: UV-vis spectrum ofGSH and compound 37 in 100% DCM, 70% MeOHl30% water, and 
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Figure 4.55 : UV-vis spectrum of GSH, compound 37 and an aliquot of DMSO/water reaction solution 
system. 
An absorption band with "'max at 310 nm increases in intensity with time in all 
three solvent systems. However, the absorption is more intense in the DMSO solvent 
system. The various combinations of solvents were reached based on the solubility of the 
reactants . It should be noted that other tests have been designed to monitor the binding of 
platinated species to GSH including assays that have phosphate buffers and NADPH 
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coupled reactions [64, 165]. Additionally, this study is aimed at finding the effects of 
solvent on the reactivity of thiols and the platinated complexes of this series. 
The absorption band with "max at 310 nm increases in intensity with time 
appreciably in the DMSO system compared to both the methanol/water and DCM 
systems. Unlike the two solvent systems, no precipitate was observed in the reaction 
vessel as time elapsed. The precipitate was confirmed as Pt-dmso adducts by mass 
spectrometry. The absorption band with "max at 310 nm is due to free ligand. From the 
data, it can be concluded that decomposition of compound 37 is accelerated in the dmso 
solvent system. No evidence of a Pt-GSH adduct formation was observed. 
H: Bioassay of Complexes 
Selected compounds were tested to ascertain their cytotoxicity profile against prostrate 
cancer cell lines, (DUI45, PC3 and LNCaP), using the MTT assay method in Dr Bates 
Laboratory. This method measures the metabolism of MTT, (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide), at 570 nm. Figures 4.56 - 4.63 display the profiles 
of these compounds. 
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Figure 4.56: MIT Assay of Cell line: DU14S; cytotoxicity of cisplatin (CP) and compound 37 (RB I) 
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Figure 4.56 shows the treatment of DU145 cancer cell lines with cisplatin and 
compound 37 designated CP and RB 1 respectively. Compound 37 appears to have a 
higher dose response for the concentration ranges 0 - 0.5 f.lM and 4.0-8.0 f.lM. The 
responses are comparable for the ranges 8.0 f.lM - 16.0 f.lM. The pyridine analogue of 
compound 37, compound 28, shows a similar inhibition profile (Figure 4.57). However, 
compound 28 shows a slightly better dose response between 0 - 1.56 f.lM. Compound 36, 
a cis bis-chelate with a t-butyl pendant, has a similar profile to compound 28. Both 
compounds show a better dose response compared to compound 42b, a dichloride 
cisplatin analogue with phenyl pendants. Additionally, the ICso values (discussed later in 
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Figure 4.57: MIT Assay of Cell line: DU145. Cytotoxic profiles of compounds 28 (B), 42b (C) and 36 (D) 
However, all three compounds show the same cytotoxic profile against immortalized 
epithelial prostate cells, RWPE-I (Figure 4.58). Against PC3 and LNCaP cell lines, both 
compounds 28 and 36 show identical cytotoxic activity with PC3 cells displaying 
acquired resistance to all three compounds after a treatment concentration of 6.25 f.lM. 
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Figure 4.59: MIT Assay of Cell line: PC3. Cytotoxic profiles of compds 28 (B), 42b (C) and 36 (D) 
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Figure 4.60: MIT Assay of the LNCaP Cell line: Cytotoxic profiles of compds 28 (B), 42b (C) and 36 (D) 
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Figures 4.61- 4.63 displays cytotoxic profiles of compounds 27, 36, 42d and 32 
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Figure 4.63: LNCaP Cell line: Cytotoxic profiles of compds 27 (A), 36 (D), 42d (E) and 32 (F) 
Compound 27 is a trans pyridine analogue of the cis 2-amino-1-methylbenzimidazole, 
compound 36. It shows the least cytotoxicity against all three cancer cell lines. For the 
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concentration range 1.31lM- 5.0 IlM, compounds 32 and 36 display higher dose responses 
against all three cell lines. Compound 42d, however, requires slightly higher 
concentrations to attain comparable dose responses to both compounds 32 and 36. The 
IC50 values for all the selected compounds is displayed in the table below. 
Table 4 11' ICio values (uM) of selected Pt(lD comDlexes 
IC50 values (11M) 
Expt 1 
Cisplatin Compd28 Compd36 Compd37 Compd42b 
DU 145 2.00 2.81 2.73 5.00 7.65 
PC3 N/A N/A 
LNCaP N/A 2.57 2.73 N/A 7.23 
RWPE-l N/A 0.78 0.78 N/A 0.78 
Expt2 
Compd27 Compd32 Compd36 old-Compd 36 Compd42d 
DU 145 35.25 2.20 0.88 3.12 32.10 
PC3 35.00 2.08 0.98 0.75 2.21 
LNCaP N/A 8.75 2.26 4.00 28.00 
From the table, based on the IC 50 values, compounds 28, 32 and 36 show 
comparable cytotoxicity to cisplatin. Old-compound 36, which is just an old stock of 
compound 36 that was stored in distilled! sterile DMSO, shows reduced cytotoxicity for 
both DU145 and LNCaP cell lines. This might be due to the decomposition in solution as 
seen earlier in the GSH experiment. However, against PC3 cell lines its cytotoxicity 
appears to be enhanced (IC50 = 0.75 IlM). The enhanced activity could be attributed to the 
additional cytotoxic effects of the free ligand [166-167] and the metal. 
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I: Conclusions 
All physical methods are in agreement and confirm the successful synthesis of the 
desired compounds. The three ligand systems, 2-amino-l-methylbenzimidazole, 2-amino-
IH benzimidazole, and the pyridine, show unique characteristics and some similarities. A 
comparison of the benzimidazole systems reveals subtle differences. For example, the 
diiodo analogues of the cyclohexyl pendants show differences in solubility. That is, the 1-
methyl derivative dissolves in chloroform but does not dissolve in acetone. Its I-H-
benzimidazole analogue, however dissolves in.acetone. 
The pyridine system is affected by the composition and type of solvent during 
platinum complexation. Unlike the 2-amino-l-methylbenzimidazole system, a mixture of 
cis and trans isomers are obtained for the amido form. Ironically, separation of these 
isomers using column chromatography was unsuccessful. Although thin layer 
chromatography, using diethyl ether, showed selectivity for one isomer over the other, 
replication on a large scale was also not successful. Additional methods including solvent 
polarity variation and solvent mixture combinations were also not succesful. 
The packing arrangements in the pyridine dichloride and amido complexes are 
similar to that of the 2- amino-I-methyl benzimidazole analogues. A complete face- to-
face overlap of the n-systems was not observed for the complexes discussed in this 
chapter. However, lattices displayed varying degrees of overlap and interactions ranging 
from strong hydrogen bonding to weak Van der waal. 
Finally, the cytotoxicity of the complexes so far tested are comparable to 
cisplatin. The successful synthesis of the second generation type of complexes, 
compound 46, provides promise for a targeted approach toward tumor cells. Furthermore, 
174 
prelimianary bioassay results show a direct correlation between dose response and the 
type of heterocycle in the binding domain of type 1 complexes. Consequently, derivatives 




From a synthetic view point, the amidation of the 2-amino-lH-benzimidazole 
with acyl chlorides are not as straight forward as their I-methylbenzimidazole 
counterparts. The Nl proton presents an additional site of amide bond formation and as a 
result, amide formation at the 2-amino position requires synthesis at higher temperatures. 
Ligands of both benzimidazole systems show evidence of tautomerization. As a result, 
their IH NMR spectra show broad or no amide peaks in solvents such as chloroform. 
However, amide protons are visible when solvents such as DMSO-d6 are used. The 
collapse or aggregation of the aromatic protons is only seen in the 2-amino-l-
methylbenzimidazole derivatives. 
Attempts to obtain cis dichloro- or diiodo- analogues for some ligands of IH-
benzimidazole have failed. This might be due to solubility of ligands or the extra metal 
binding site provided by Nl which might be competing with N3. Additionally, the lack of 
solubility of these ligands also does not make it possible to use protocols developed for 
their 2-amino-l-methylbenzimidazole counterparts. 
The diiodo- and dichloro- analogues of compound 11 could not be synthesized 
using the developed protocols. This might be due to a series of factors among which are 
the inductive electron-withdrawing effect of the trichloride pendant. This might reduce 
the availability of the lone pair of electrons of N3 of the benzimidazole to coordinate to 
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the platinum. Also, unlike its tert-butyl or methyl analogues which are electron donating, 
the chlorides provide lone pairs of their own and these might be competing with lone 
pairs of the N3 nitrogen of the benzimidazole. Nevertheless, the coordination of 
compound 11 to platinum needs another look because unlike its three analogues, its 
solubility in methanol and water is appreciably higher due to the additional hydrogen 
bonding ability through the chlorides. Successful synthesis of its cisplatin analogue will 
have the advantage of enhance water solubility. Additionally unlike its analogs, it would 
be possible to calculate its Log P value for comparison to known drugs in the market 
(both metal and non-metal based). Another potential advantage that can be drawn from a 
successful cisplatin analogue of compound 11 would be the ability to tune the reactivity 
of the metal, through variation of the degree of electron withdrawing Idonating 
substituents, thereby making it slightly less reactive to deactivating moieties like 
glutathione. 
The cis-isomer of the compound 27 could not be isolated via column 
chromatography even though thin layer paper chromatography showed separation of the 
isomers in ethyl ether, methanol, and chloroform, with ethyl ether giving the most 
separation. Based on our findings, all the isomeric conformers are affected by both the 
composition of the solvent system and temperature. 
The cis dichloro- analogues of the pyridine and 2-amino-l-methylbenzimidazole 
systems have similar cytotoxic profiles. This suggests that changing the binding domain 
moieties does not significantly affect the cytotoxic properties of the compounds under 
discussion. Furthermore, this adds to the flexibility of the overall framework and could 
potentially be an answer to native drug resistance among populations, and acquired 
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resistance via cellular tolerance or effective combat or neutralization of these compounds/ 
drugs. To this end, combinational theurapeutics could greatly benefit from such effective 
compounds. 
Although the Pt(1I) dichloro complexes of compound 9 and 2-pivaloylamino 
pyridine have similar cytotoxic profiles, their reactivity with first row transition metal 
show great differences. Whereas, compound 9 forms bis-chelates with V(IV), Co(ll), 
Ni(lI), Cu(1I) and Zn(II), no such complex formation have been reported or synthesized 
for the pyridine ligand. The inability to obtain similar bis-chelate analogs with the 
pyridine system could be partly due to the relatively limited number of atoms (compared 
to the I-methylbenzimidazole system) that can participate in resonance or tautomerism 
and the stabilization of resultant charges of the intermediates. Additionally, the 
involvement of the metal binding nitrogen in such a process, directly destroys the 
aromaticity of only the pyridine system. While first row transition complexes were not 
tested for suitability as models for active sites of enzymes, some insight was gained in 
terms of the fundamental properties including reactivity of the metals, pyridine and 1-
methyl benzimidazole systems. Our findings suggests that these amide functionalized 
benzimidazole moieties prefer to coordinate to first row transition metals as bis-chelates, 
binding through the nitrogen of the benzimidazole and the oxygen of the carbonyl. Based 
on the reaction conditions, these benzimidazole ligands tend to coordinate to first row 
transition metal, resulting in either tetrahedral or trans square planar geometries. Only Ni 
(II) and Zn (II) appear to have the ability to expand coordination number to five. The 
expansion of coordination spheres of both Ni (II) and Zn(1I) I-methylbenzimidazole 
complexes make them good candidates for catalytic studies. The distortions in solution 
178 
and the expansion of coordination of the Ni (II) complexes could also be potentially 
harnessed in enzyme modeling. It should be noted that additional properties of these 
complexes could find utility in other disciplines. 
The crystal structure of compound 46 reveals a semi - protected metal core. This 
arrangement can disrupt or prevent the binding of glutathione or metallothionein, 
minimizing deactivation [108-110]. A similar ligand to compound 46, compound 8 has 
been synthesized. The phthalimide can be removed via hydrolysis ( acid or based 
catalyzed). The removal of the phthalimide group can be accomplished using the Ing-
Manske procedure [168]. Similarly, using Na2S in aqueous THF or acetone gives the 
desired primary amine [169]. Also, treatment with NaBH4-2-propanol followed by acetic 
acid [170] or 40% aqueous methylamine generates the primary amine [171]. It should be 
noted that these reactions are relatively slow and might hydrolyze the benzimidazole-
glycyl peptidic linkage as well. 
The successful synthesis of compound 46 suggests that this framework's 
recognition domain can be expanded to include binding to specific antibodies that are 
tailored toward specific targets on cancer cell membrane including transmembrane 
proteins. This would allow for localized drug delivery and minimize interactions with 
normal cells, thereby reducing potential side effects. The boc group of compound 46 can 
easily be removed by treatment with trifluoroacetic acid which will allow another 
peptidic coupling to nucleic acids for example. Subsequently, such a compound would 
have the advantage of two portions that can bind to DNA; the specific sequence of 
nucleic acids binding to a promoter region and the platinum to N7 of guanine during the 
S-phase of mitosis resulting in the interruption of transcription and translation. Also, the 
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peptidic linkages of compound 46 and similar compounds can serve as hydrogen bonding 
sites. These sites can interest with DNA through hydrogen bonding and facilitate the 
binding of the platinum to relatively guanine rich regions outside the telomeric regions. 
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Crystallographic Data 



















Completeness to theta = 29. 10° 
Completeness to theta = 26.32° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff peak and hole 
rmb320lt 





PI 211n 1 
a= 14.1720(3) A 
b = 6.04320(8) A 






0.22 x 0.18 x 0.13 mm3 
3.40 to 29.10° 
13= 107.3724(19)°. 
-19<=h<=19, -8<=k<=8, -21<=1<=21 
27003 
3264 [R(int) = 0.0267] 
94.4% 
99.7% 
Semi-empirical from equivalents 
1.00000 and 0.95004 
Full-matrix least-squares on F2 
3264 / 0/ 248 
1.017 
Rl = 0.0355, wR2 = 0.0812 
Rl = 0.0452, wR2 = 0.0840 
0.512 and -0.21 I e.A-3 
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Table A2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 
103) for nnb3201t. U(eq) is defmed as one third of the trace of the orthogonalized uij tensor. 
x y z U(eq) 
0(1) 9322(1) 7416(1) 2044(1) 22(1) 
N(1) 9440(1) 6970(2) 645(1) 14(1) 
N(2) 11156(1) 6468(1) 763(1) 15(1) 
N(3) 10693(1) 9721(1) 1215(1) 14(1) 
C(l) 8936(1) 6882(2) 1272(1) 15(1) 
C(2) 10424(1) 7660(2) 877(1) 14(1) 
C(3) 11982(1) 7843(2) 1065(1) 14(1) 
C(4) 12979(1) 7454(2) 1142(1) 16(1) 
C(5) 13649(1) 9136(2) 1488(1) 18(1) 
C(6) 13353(1) 11165(2) 1759(1) 18(1) 
C(7) 12371(1) 11571(2) 1700(1) 16(1) 
C(8) 11704(1) 9872(2) 1351(1) 14(1) 
C(9) 10064(1) 11443(2) 1400(1) 18(1) 
C(10) 7864(1) 6208(2) 912(1) 15(1) 
C(ll) 7228(1) 8307(2) 835(1) 20(1) 
C(12) 6125(1) 7758(2) 533(1) 24(1) 
C(13) 5870(1) 6038(2) 1135(1) 22(1) 
C(14) 6487(1) 3950(2) 1193(1) 20(1) 
C(15) 7592(1) 4500(2) 1516(1) 19(1) 
Table A3. Anisotropic displacement parameters (A2x 103) for nnb320lt. The anisotropic 
displacement factor exponent takes the fonn: -202[ h2 a*2Ull + ... + 2 h k a* b* U12] 
Ull {)22 U33 {)23 UJ3 U12 
0(1) 17(1) 34(1) 15(1) -3(1) 5(1) -5(1) 
N(1) 12(1) 17(1) 15(1) -3(1) 5(1) -1(1) 
N(2) 13(1) 16(1) 15(1) -1(1) 5(1) 0(1) 
N(3) 12(1) 14(1) 15(1) -1(1) 4(1) 0(1) 
C(1) 14(1) 16(1) 16(1) 0(1) 5(1) 1(1) 
C(2) 14(1) 15(1) 12(1) 0(1) 4(1) 0(1) 
C(3) 14(1) 16(1) 12(1) 0(1) 4(1) -1(1) 
C(4) 15(1) 19(1) 16(1) 0(1) 5(1) 2(1) 
C(5) 13(1) 24(1) 17(1) 1(1) 4(1) 0(1) 
C(6) 16(1) 19(1) 17(1) 1(1) 2(1) -4(1) 
C(7) 17(1) 15(1) 16(1) 0(1) 3(1) 0(1) 
C(8) 13(1) 16(1) 12(1) 2(1) 4(1) 1(1) 
C(9) 16(1) 16(1) 22(1) -2(1) 6(1) 2(1) 
C(1O) 13(1) 18(1) 15(1) -2(1) 5(1) -1(1) 
C(ll) 15(1) 17(1) 25(1) 2(1) 3(1) -1(1) 
C(12) 14(1) 20(1) 34(1) 1{l) 1(1) 2(1) 
C(13) 13(1) 26(1) 28(1) -6(1) 8(1) -2(1) 
C(14) 18(1) 20(1) 23(1) 2(1) 8(1) -3(1) 
C{l5) 16(1) 19(1) 23(1) 4(1) 6(1) 1(1) 
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Table A4. Hydrogen coordinates (x 104) and isotropic displacement parameters CA2x 10 3) 
for rmb3201t. 
x y z U(eq) 
H(1N) 9230(10) 6130(20) 153(9) 25(3) 
H(4) 13196(9) 6020(20) 976(8) 20(3) 
H(5) 14343(10) 8910(20) 1545(8) 22(3) 
H(6) 13850(9) 12280(20) 2002(9) 23(3) 
H(7) 12156(9) 12950(20) 1885(8) 18(3) 
H(9A) 9413(10) 11360(20) 958(9) 23(3) 
H(9B) 9991(9) 11240(20) 1989(9) 22(3) 
H(9C) 10376(9) 12870(20) 1364(8) 22(3) 
H(1O) 7738(9) 5590(20) 315(8) 16(3) 
H(IIA) 7386(10) 9360(20) 420(9) 28(3) 
H(lIB) 7414(9) 9030(20) 1433(9) 21(3) 
H(12A) 5742(11) 9130(30) 529(10) 35(4) 
H(12B) 5936(9) 7180(20) -90(9) 23(3) 
H(13A) 5176(10) 5660(20) 925(9) 28(3) 
H(13B) 5994(10) 6650(20) 1747(9) 28(3) 
H(14A) 6332(10) 2870(20) 1599(9) 26(3) 
H(14B) 6335(9) 3230(20) 583(9) 22(3) 
H(15A) 8002(11) 3120(20) 1534(9) 32(4) 
H(15B) 7772(9) 5120(20) 2127(9) 24(3) 
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Crystal color, habit 




Completeness to theta = 25.07° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb268p21c 






a = 18.505(3) A 
b = 5.1189(7) A 






0.413x 0.109 x 0.026 mm3 
green needle 
2.21 to 25.07° 
13= 93.823(2)°. 
-22<=h<=21, -6<=k<=6, -20<=1<=20 
10932 
2885 [R(int) = 0.0562] 
99.4% 
SADABS 
0.895 and 0.712 
Full-matrix least-squares on F2 
2885/0/207 
1.061 
Rl = 0.0556, wR2 = 0.0952 
Rl = 0.0713, wR2 = 0.0999 
0.539 and -0.494 e.A-3 
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Table A6. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 
103) for rmb268P21c. U(eq) is defined as one third of the trace of the orthogonalized uij tensor. 
x y z U(eq) 
Cu(1) 10000 5000 0 11(1) 
0(1) 9195(1) 2956(5) 293(1) 16(1) 
N(1) 10621(1) 3219(5) 824(2) 10(1) 
N(2) 10859(1) 407(5) 1787(2) 12(1) 
N(3) 9734(1) -155(6) 1123(2) 15(1) 
C(1) 10365(2) 1177(6) 1215(2) 11(1) 
C(2) 11315(2) 3715(7) 1158(2) 11(1) 
C(3) 11838(2) 5565(6) 998(2) 14(1) 
C(4) 12487(2) 5564(7) 1449(2) 16(1) 
C(5) 12621(2) 3766(7) 2047(2) 16(1) 
C(6) 12111(2) 1927(7) 2216(2) 16(1) 
C(7) 11463(2) 1942(7) 1764(2) 12(1) 
C(8) 10750(2) -1595(7) 2370(2) 16(1) 
C(9) 9200(2) 820(6) 676(2) 11(1) 
C(10) 8503(2) -698(6) 616(2) 14(1) 
C(11) 7880(2) 681(7) 981(2) 17(1) 
C(12) 7172(2) -811(7) 826(2) 17(1) 
C(13) 6806(2) -393(7) 20(2) 19(1) 
C(14) 6128(2) -1987(7) -132(2) 19(1) 
C(15) 5704(2) -1354(7) -894(2) 19(1) 
C(16) 5037(2) -3025(7) -1057(2) 22(1) 
C(17) 4580(2) -2310(7) -1784(2) 20(1) 
C(18) 3925(2) -4051(8) -1934(2) 25(1) 
Table A7. Anisotropic displacement parameters (A2x 103) for rmb268P21c. The anisotropic 
displacement factor exponent takes the form: -202[ h2 a*2Ull + ... + 2 h k a* b* U12 ] 
UIJ T.F2 U33 T.F3 UI3 Ul2 
Cu(l) 11(1) 11(1) 10(1) 5(1) -1(1) -1(1) 
0(1) 13(1) 18(1) 17(1) 7(1) 0(1) -2(1) 
N(1) 9(1) 10(2) 10(1) 2(1) -1(1) 0(1) 
N(2) 15(1) 8(2) 13(1) 2(1) 1(1) -1(1) 
N(3) 13(1) 14(2) 17(1) 0(1) 1(1) 2(1) 
C(1) 16(2) 10(2) 7(2) -1(1) 1(1) 2(1) 
C(2) 11(2) 12(2) 8(2) -2(1) 2(1) 5(1) 
C(3) 18(2) 13(2) 10(2) 1(1) 0(1) -1(1) 
C(4) 18(2) 13(2) 18(2) 1(1) 2(1) -3(1) 
C(5) 15(2) 21(2) 12(2) -3(2) -2(1) 0(2) 
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C(6) 22(2) 16(2) 8(2) 0(1) -2(1) 3(2) 
C(7) 14(2) 11(2) 12(2) -2(1) 4(1) 1(1) 
C(8) 19(2) 14(2) 15(2) 5(2) 1(2) -4(2) 
C(9) 15(2) 7(2) 10(2) -2(1) 4(1) 1(1) 
C(10) 17(2) 7(2) 16(2) 0(1) 0(1) 0(1) 
C(ll) 21(2) 16(2) 13(2) -1(1) 1(1) -2(1) 
C(12) 17(2) 17(2) 19(2) -1(2) 6(2) -2(1) 
C(13) 19(2) 17(2) 20(2) 0(2) -1(1) 0(2) 
C(14) 19(2) 17(2) 21(2) 1(2) 1(2) 0(2) 
C(15) 19(2) 18(2) 21(2) 1(2) -1(2) 1(2) 
C(16) 24(2) 19(2) 22(2) 1(2) -2(2) 0(2) 
C(17) 22(2) 17(2) 22(2) 0(2) 1(2) 1(2) 
C(18) 25(2) 24(2) 26(2) -3(2) -5(2) 1(2) 
Table A8. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb268P21c. 
x y z U(eq) 
H(3) 11753 6793 592 16 
H(4) 12848 6815 1349 19 
H(5) 13072 3811 2343 19 
H(6) 12199 704 2623 19 
H(8A) 10732 -767 2878 24 
H(8B) 11151 -2845 2383 24 
H(8C) 10293 -2512 2240 24 
H(IOA) 8584 -2414 870 16 
H(10B) 8362 -1025 64 16 
H(IlA) 7826 2469 767 20 
H(11B) 7991 830 1545 20 
H(12A) 6831 -277 1213 21 
H(12B) 7269 -2700 899 21 
H(13A) 6684 1481 -45 22 
H(13B) 7153 -849 -370 22 
H(14A) 5809 -1700 297 23 
H(14B) 6261 -3860 -130 23 
H(15A) 5555 503 -888 23 
H(15B) 6027 -1580 -1321 23 
H(16A) 4731 -2896 -611 26 
H(16B) 5191 -4870 -1098 26 
H(17A) 4416 -478 -1741 24 
H(17B) 4884 -2416 -2231 24 
H(18A) 4084 -5857 -2003 38 
H(18B) 3647 -3465 -2402 38 
H(18C) 3621 -3958 -1494 38 
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Completeness to theta = 27.54° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb316p21c 






a= 14.1057(8) A 
b = 15.1769(8) A 






0.45 x 0.16 x 0.07 mm3 
2.68 to 27.54° 
13= 102.9570(10)°. 
-18<=h<=18, -19<=k<=19, -8<=1<=8 
11331 
3017 [R(int) = 0.0249] 
97.1 % 
None 
0.9486 and 0.7257 
Full-matrix least-squares on p2 
3017/0/179 
1.086 
Rl = 0.0450, wR2 = 0.1063 
Rl = 0.0487, wR2 = 0.1083 
0.399 and -0.276 e.A-3 
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Table AIO. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 
103) for rmb316P21c. U(eq) is defined as one third of the trace of the orthogonalized uij tensor. 
x y z U(eq) 
Ni(l) 0 10000 0 13(1) 
0(1) 1238(1) 9727(1) 1473(3) 19(1) 
N(1) -552(1) 9310(1) 1925(3) 14(1) 
N(2) -541(1) 8632(1) 5020(3) 16(1) 
N(3) 979(1) 9055(1) 4545(3) 16(1) 
C(1) 6(2) 9030(1) 3787(3) 14(1) 
C(2) -1509(2) 9043(2) 1940(4) 15(1) 
C(3) -2387(2) 9092(2) 433(4) 19(1) 
C(4) -3212(2) 8744(2) 965(4) 21(1) 
C(5) -3184(2) 8340(2) 2920(4) 20(1) 
C(6) -2316(2) 8262(2) 4418(4) 18(1) 
C(7) -1495(2) 8622(2) 3886(3) 15(1) 
C(8) -155(2) 8177(2) 7024(4) 19(1) 
C(9) 1522(2) 9374(1) 3331(3) 15(1) 
C(1O) 2615(2) 9335(2) 4154(3) 15(1) 
C(ll) 2926(2) 8935(2) 6384(4) 23(1) 
C(12) 4032(2) 8964(2) 7162(4) 28(1) 
C(13) 4543(2) 8512(2) 5607(4) 31(1) 
C(14) 4215(2) 8892(2) 3372(4) 30(1) 
C(15) 3106(2) 8847(2) 2595(4) 23(1) 
Table All. Anisotropic displacement parameters (A2x 103) for rmb316P21c. The anisotropic 
displacement factor exponent takes the form: -202[ h2 a*2Ull + ... + 2 h k a* b* U12 ] 
Ull tJ22 tJ33 tJ23 UI3 U12 
Ni(l) 13(1) 14(1) 11(1) 3(1) 2(1) 0(1) 
0(1) 14(1) 25(1) 17(1) 8(1) 2(1) 1(1) 
N(I) 14(1) 12(1) 14(1) 2(1) 3(1) 0(1) 
N(2) 18(1) 16(1) 13(1) 1(1) 4(1) -2(1) 
N(3) 17(1) 17(1) 13(1) 1(1) 2(1) 0(1) 
C(1) 20(1) 12(1) 12(1) -2(1) 6(1) -1(1) 
C(2) 18(1) 13(1) 16(1) 0(1) 5(1) 0(1) 
C(3) 19(1) 16(1) 21(1) 4(1) 3(1) 0(1) 
C(4) 15(1) 20(1) 27(1) 2(1) 4(1) 2(1) 
C(5) 17(1) 18(1) 28(1) 0(1) 10(1) 0(1) 
C(6) 21(1) 16(1) 20(1) 0(1) 10(1) 0(1) 
C(7) 18(1) 14(1) 14(1) -3(1) 4(1) 1(1) 
C(8) 25(1) 19(1) 13(1) 3(1) 3(1) -2(1) 
C(9) 18(1) 13(1) 13(1) 0(1) 2(1) 0(1) 
C(10) 16(1) 15(1) 13(1) 2(1) 1(1) 0(1) 
C(ll) 19(1) 34(1) 16(1) 7(1) 2(1) 3(1) 
C(12) 20(1) 47(2) 14(1) 4(1) -1(1) 6(1) 
C(13) 22(1) 41(2) 27(1) 0(1) -1(1) 13(1) 
C(14) 20(1) 53(2) 19(1) -5(1) 3(1) 11(1) 
C(15) 20(1) 30(1) 16(1) -4(1) 0(1) 6(1) 
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Table A12. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb316P21c. 
x y z U(eq) 
H(3) -2419 9350 -890 23 
H(4) -3805 8783 -18 25 
H(5) -3754 8120 3221 24 
H(6) -2283 7983 5716 22 
H(8A) -116 7557 6764 29 
H(8B) -576 8276 7982 29 
H(8C) 483 8400 7647 29 
H(10) 2855 9943 4246 18 
H(lIA) 2627 9261 7363 28 
H(llB) 2705 8329 6355 28 
H(l2A) 4244 9573 7341 33 
H(12B) 4216 8676 8537 33 
H(13A) 4401 7886 5573 37 
H(13B) 5240 8586 6092 37 
H(14A) 4519 8565 2402 37 
H(l4B) 4426 9501 3372 37 
H(l5A) 2898 8237 2482 28 
H(15B) 2915 9113 1195 28 
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Completeness to theta = 27.98° 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on p2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb3121t 






a = 13.0866(4) A 
b = 23.0690(5) A 







2.92 to 27.98°. 
p= 106.002(3)°. 
'Y = 90°. 
-16<=h<=17, -29<=k<=30, -24<=1<=25 
75925 
12632 [R(int) = 0.0665] 
92.4% 
Full-matrix least-squares on F2 
12632/25 I 645 
1.089 
Rl = 0.0741, wR2 = 0.1706 
Rl = 0.1358, wR2 = 0.1816 
1.556 and -0.767 e.A-3 
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Table A14. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 
103) for rmb3121t. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x y z U(eq) 
Co(1) 888(1) 3607(1) 1241(1) 34(1) 
Co(2) 3612(1) 6210(1) 3444(1) 40(1) 
0(1) 672(2) 3935(1) 2104(2) 35(1) 
0(2) -293(3) 3224(2) 563(2) 44(1) 
0(3) 4701(3) 6724(1) 4022(2) 45(1) 
0(4) 3943(3) 5855(1) 2633(2) 45(1) 
N(1) 1237(3) 4366(2) 926(2) 32(1) 
N(2) 1305(3) 5330(2) 940(2) 36(1) 
N(3) 1113(3) 4903(2) 1985(2) 34(1) 
N(4) 1725(3) 2892(2) 1418(2) 41(1) 
N(5) 1958(4) 1933(2) 1387(3) 65(1) 
N(6) 366(4) 2274(2) 650(3) 62(1) 
N(7) 2529(3) 6815(2) 3315(2) 36(1) 
N(8) 1966(3) 7731(2) 3266(2) 38(1) 
N(9) 3776(3) 7603(2) 3806(2) 40(1) 
N(10) 3496(3) 5452(2) 3874(2) 41(1) 
N(ll) 3984(3) 4532(2) 4090(3) 47(1) 
N(12) 4011(3) 4880(2) 2970(3) 45(1) 
C(1) 1378(3) 4562(2) 282(2) 34(1) 
C(2) 1461(4) 4252(2) -301(3) 44(1) 
C(3) 1584(4) 4570(3) -886(3) 51(1) 
C(4) 1623(4) 5169(2) -872(3) 46(1) 
C(5) 1544(4) 5479(2) -287(3) 43(1) 
C(6) 1420(3) 5161(2) 286(2) 35(1) 
C(7) 1202(3) 4844(2) 1312(3) 32(1) 
C(8) 1292(5) 5924(2) 1185(3) 53(2) 
C(9) 871(3) 4460(2) 2331(2) 30(1) 
C(10) 775(4) 4583(2) 3066(2) 34(1) 
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C(ll) -362(4) 4777(2) 3018(2) 38(1) 
C(12) -478(5) 4916(2) 3759(3) 48(1) 
C(l3) -179(5) 4400(2) 4254(3) 48(1) 
C(14) 935(5) 4208(2) 4306(3) 53(2) 
C(15) 1080(4) 4065(2) 3573(3) 44(1) 
C(16) 2715(4) 2751(2) 1874(3) 49(1) 
C(17) 3473(4) 3094(3) 2306(3) 63(2) 
C(18) 4392(5) 2817(4) 2699(4) 88(2) 
C(19) 4541(6) 2229(4) 2657(4) 94(3) 
C(20) 3784(6) 1886(3) 2238(4) 87(2) 
C(21) 2864(5) 2155(3) 1851(3) 61(2) 
C(22) 1289(5) 2388(2) 1133(3) 50(1) 
C(23) 1719(7) 1320(3) 1223(4) 94(3) 
C(24) -332(4) 2684(3) 391(3) 54(2) 
C(25A) -1305(7) 2619(4) -279(5) 40(1) 
C(26A) -2064(7) 2184(4) -84(5) 40(1) 
C(27A) -3038(7) 2090(4) -756(5) 40(1) 
C(28A) -2732(8) 2399(4) -1546(5) 40(1) 
C(29A) -1755(8) 1994(4) -1412(5) 40(1) 
C(30A) -825(9) 2240(4) -810(6) 40(1) 
C(25B) -1249(8) 2369(5) -135(6) 49(1) 
C(26B) -2219(8) 2738(4) -268(5) 49(1) 
C(27B) -3130(8) 2477(5) -908(6) 49(1) 
C(28B) -2685(8) 1861(4) -1318(6) 49(1) 
C(29B) -1914(9) 2248(5) -1539(6) 49(1) 
C(30B) -968(10) 2409(5) -880(6) 49(1) 
C(32) 1432(4) 6828(2) 3004(2) 36(1) 
C(33) 725(4) 6380(2) 2753(3) 46(1) 
C(34) -325(5) 6527(2) 2458(3) 57(2) 
C(35) -669(5) 7102(2) 2406(3) 56(2) 
C(36) 31(4) 7548(2) 2658(3) 49(1) 
C(37) 1076(4) 7401(2) 2963(2) 38(1) 
C(38) 2829(4) 7372(2) 3477(2) 38(1) 
C(39) 2005(4) 8360(2) 3360(3) 43(1) 
C(40) 4620(4) 7280(2) 4074(3) 41(1) 
C(41) 5592(6) 7604(3) 4487(4) 87(1) 
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C(42) 5298(6) 7990(3) 5057(4) 87(1) 
C(43) 6264(6) 8325(4) 5502(4) 87(1) 
C(44) 7147(6) 7973(3) 5802(4) 87(1) 
C(45) 7461(6) 7582(3) 5266(4) 87(1) 
C(46) 6505(5) 7235(3) 4854(4) 87(1) 
C(47) 3418(4) 5306(2) 4548(3) 43(1) 
C(48) 3090(4) 5628(2) 5043(3) 52(1) 
C(49) 3132(4) 5365(3) 5684(3) 58(2) 
C(50) 3492(5) 4799(3) 5825(4) 65(2) 
C(51) 3791(4) 4468(3) 5335(3) 56(2) 
C(52) 3746(4) 4725(2) 4691(3) 46(1) 
C(53) 3834(4) 4976(2} 3605(3) 43(1) 
C(54) 4351(4) 3954(2) 3985(3) 59(2) 
C(55) 4035(4) 5309(2) 2533(3) 42(1) 
C(56A) 4191(15) 5169(6) 1789(10) 70(2) 
C(57A) 4196(11) 4528(5) 1643(7) 70(2) 
C(58A) 4455(10) 4396(6) 966(6) 70(2) 
C(59A) 5559(10) 4468(6) 1243(8) 70(2) 
C(60A) 5647(10) 5278(6) 1114(7) 70(2) 
C(61A) 5319(10) 5450(6) 1777(7) 70(2) 
C(56B) 4245(19) 5095(8) 1850(11) 96(2) 
C(57B) 5217(12) 4586(7) 1997(9) 96(2) 
C(58B) 6193(12) 4709(7) 1746(8) 96(2) 
C(59B) 5526(13) 4771(8) 886(8) 96(2) 
C(60B) 4371(13) 5312(7) 617(8) 96(2) 
C(6lB) 4307(13) 5566(7) 1344(8) 96(2) 
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Table AIS. Anisotropic displacement parameters (A2x 103) for rmb3121t. The anisotropic 
displacement factor exponent takes the form: -20 2[ h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
Ull l]22 {]33 l]23 UJ3 Ul2 
Co(1) 34(1) 35(1) 31(1) 0(1) 6(1) -1(1) 
Co(2) 46(1) 26(1) 47(1) 0(1) 12(1) 5(1) 
0(1) 43(2) 30(2) 32(2) -1(1) 11(2) -4(2) 
0(2) 38(2) 55(2) 35(2) -8(2) 3(2) -7(2) 
0(3) 47(2) 33(2) 49(2) 0(2) 4(2) 2(2) 
0(4) 54(2) 29(2) 56(2) -2(2) 20(2) 2(2) 
N(l) 28(2) 38(2) 29(2) 4(2) 7(2) 2(2) 
N(2) 39(2) 36(2) 35(2) 4(2) 15(2) -4(2) 
N(3) 37(2) 34(2) 31(2) 2(2) 13(2) -6(2) 
N(4) 45(3) 41(2) 35(2) -6(2) 7(2) 5(2) 
N(5) 90(4) 45(3) 54(3) -12(2) 10(3) 20(3) 
N(6) 64(3) 58(3) 58(3) -26(3) 5(3) 0(3) 
N(7) 46(3) 23(2) 36(2) -1(2) 8(2) 6(2) 
N(8) 57(3) 26(2) 28(2) -1(2) 11(2) 10(2) 
N(9) 50(3) 30(2) 36(2) -1(2) 7(2) 2(2) 
N(lO) 38(2) 31(2) 53(3) 5(2) 11(2) 1(2) 
N(ll) 37(2) 31(2) 72(3) 10(2) 13(2) 3(2) 
N(l2) 40(3) 32(2) 65(3) -3(2) 14(2) 1(2) 
C(1) 23(2) 50(3) 27(3) 2(2) 3(2) 1(2) 
C(2) 42(3) 49(3) 40(3) 2(3) 11(2) 1(2) 
C(3) 46(3) 75(4) 31(3) -3(3) 8(2) -4(3) 
C(4) 38(3) 64(4) 34(3) 13(3) 5(2) -2(3) 
C(5) 35(3) 52(3) 41(3) 9(3) 9(2) -3(2) 
C(6) 25(2) 48(3) 31(3) 6(2) 7(2) -1(2) 
C(7) 24(2) 34(3) 38(3) 7(2) 7(2) -2(2) 
C(8) 72(4) 41(3) 55(4) 8(3) 31(3) -10(3) 
C(9) 25(2) 30(3) 35(3) 0(2) 7(2) -4(2) 
C(10) 37(3) 34(3) 29(3) 1(2) 8(2) -7(2) 
C(ll) 48(3) 31(3) 36(3) 0(2) 15(2) -1(2) 
C(12) 64(4) 41(3) 45(3) -9(2) 27(3) -5(3) 
C(13) 74(4) 42(3) 38(3) -8(2) 30(3) -16(3) 
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C(14) 73(4) 53(3) 29(3) 10(2) 8(3) -12(3) 
C(I5) 45(3) 47(3) 37(3) 8(2) 9(2) 0(2) 
C(16) 46(3) 56(3) 40(3) -6(3) 3(3) 18(3) 
C(17) 48(4) 67(4) 63(4) -19(3) -3(3) 14(3) 
C(l8) 57(4) 109(6) 77(5) -25(4) -15(4) 20(4) 
C(19) 82(5) 109(6) 76(5) -16(5) -5(4) 62(5) 
C(20) 117(6) 75(5) 56(4) -10(4) 5(4) 58(5) 
C(21) 72(4) 60(4) 45(3) -13(3) 6(3) 33(3) 
C(22) 62(4) 45(3) 41(3) -12(3) 12(3) 9(3) 
C(23) 155(8) 40(4) 82(5) -20(3) 24(5) 21(4) 
C(24) 47(3) 78(4) 37(3) -26(3) 12(3) -17(3) 
C(32) 46(3) 30(3) 32(3) -2(2) 11(2) 7(2) 
C(33) 57(3) 29(3) 48(3) -8(2) 8(3) 6(3) 
C(34) 57(4) 43(3) 61(4) -16(3) 2(3) 3(3) 
C(35) 54(4) 53(4) 54(4) -13(3) 2(3) 14(3) 
C(36) 65(4) 43(3) 34(3) -4(2) 6(3) 18(3) 
C(37) 52(3) 33(3) 29(3) -5(2) 10(2) 4(2) 
C(38) 57(3) 32(3) 26(3) 1(2) 11(2) 5(3) 
C(39) 64(4) 29(3) 35(3) -4(2) 12(3) 9(2) 
C(40) 53(3) 36(3) 35(3) -2(2) 15(2) -9(3) 
C(41) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(42) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(43) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(44) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(45) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(46) 75(2) 99(2) 78(2) -20(2) 6(2) -27(2) 
C(47) 30(3) 40(3) 60(4) 5(3) 12(3) -4(2) 
C(48) 43(3) 50(3) 62(4) 11(3) 15(3) 1(3) 
C(49) 46(3) 73(4) 57(4) 9(3) 18(3) -7(3) 
C(50) 47(4) 77(5) 65(4) 27(4) 5(3) -18(3) 
C(51) 42(3) 52(4) 69(4) 17(3) 5(3) -6(3) 
C(52) 31(3) 41(3) 64(4) 12(3) 8(3) -3(2) 
C(53) 34(3) 26(3) 67(4) 3(3) 9(3) 0(2) 
C(54) 50(4) 31(3) 95(5) 12(3) 17(3) 6(3) 
C(55) 34(3) 35(3) 59(4) -2(3) 16(3) 0(2) 
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Table A16. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb312lt. 
x y z U(eq) 
H(2) 1437 3849 -308 53 
H(3) 1640 4374 -1289 61 
H(4) 1705 5367 -1268 55 
H(5) 1571 5882 -277 51 
H(8A) 863 5948 1510 80 
H(8B) 1002 6173 785 80 
H(8C) 2005 6044 1421 80 
H(1O) 1254 4904 3265 41 
H(11A) -535 5118 2718 46 
H(IIB) -856 4472 2802 46 
H(l2A) -24 5242 3957 57 
H(12B) -1207 5026 3720 57 
H(I3A) -235 4505 4723 58 
H(l3B) -669 4084 4078 58 
H(14A) 1100 3867 4608 63 
H(I4B) 1428 4512 4525 63 
H(15A) 640 3734 3373 52 
H(15B) 1816 3961 3623 52 
H(17) 3380 3492 2335 75 
H(l8) 4924 3037 3001 105 
H(I9) 5175 2063 2922 113 
H(20) 3880 1488 2212 104 
H(23 A) 2159 1176 941 141 
H(23B) 985 1278 964 141 
H(23C) 1857 1103 1658 141 
H(33) 948 5995 2782 55 
H(34) -818 6234 2288 68 
H(35) -1383 7185 2197 67 
232 
H(36) -193 7932 2623 59 
H(39A) 2570 8459 3773 65 
H(39B) 1340 8494 3421 65 
H(39C) 2130 8540 2949 65 
H(41) 5822 7859 4156 104 
H(42A) 4747 8263 4823 104 
H(42B) 5017 7748 5368 104 
H(43) 6264 8725 5567 104 
H(44A) 6991 7733 6168 104 
H(44B) 7747 8219 6028 104 
H(45A) 7727 7816 4941 104 
H(45B) 8022 7321 5513 104 
H(46A) 6710 6998 4505 104 
H(46B) 6285 6977 5179 104 
H(48) 2851 6007 4949 62 
H(49) 2916 5571 6029 70 
H(50) 3530 4640 6268 78 
H(51) 4014 4086 5431 67 
H(54A) 4818 3815 4422 89 
H(54B) 4725 3966 3626 89 
H(54C) 3751 3698 3835 89 
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Crystal color, habit 
Crystal size 




Completeness to theta = 27.99° 
Completeness to theta = 25.03° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb311lt 






a = 9.7627(5) A 
b = 10.0352(5) A 







0.32 x 0.25 x 0.16 mm3 
2.92 to 27.99° 
a= 98.663(4)°. 
p= 95.786(4t· 
Y = 100.010(4)°. 
-12<=h<=II, -12<=k<=13, -24<=1<=25 
22843 
7680 [R(int) = 0.0391] 
87.1 % 
99.8% 
Semi-empirical from equivalents 
1.00000 and 0.78143 
Full-matrix least-squares on F2 
7680/0/511 
1.027 
Rl = 0.0353, wR2 = 0.0539 
Rl = 0.0647, wR2 = 0.0560 
0.501 and -0.448 e.A-3 
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Table A1S. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for rmb3111t. U(eq) is defined as one third of the trace of the orthogonalized uij 
tensor. 
x y z U(eq) 
Zn(l) 5185(1) 5969(1) 7357(1) 13(1) 
0(1) 5836(1) 4368(1) 6712(1) 15(1) 
0(2) 4297(1) 7313(1) 8005(1) 16(1) 
0(3) 3798(2) 736(1) 8021(1) 27(1) 
N(1) 7074(2) 7081(2) 7341(1) 12(1) 
N(2) 9406(2) 7350(2) 7470(1) 15(1) 
N(3) 8256(2) 5145(2) 6960(1) 14(1) 
N(4) 3337(2) 5518(2) 6723(1) 12(1) 
N(5) 983(2) 5082(2) 6526(1) 14{l) 
N(6) 1939(2) 6323(2) 7635(1) 15(1) 
N(7) 5411(2) 4849(2) 8182(1) 15(1) 
N(8) 5301(2) 3072(2) 8758{l) 18(1) 
N(9) 4313(2) 2660(2) 7539(1) 18(1) 
C(1) 7657(2) 8438(2) 7666{l) 13(1) 
C(2) 7012(2) 9531(2) 7890{l) 17{l) 
C(3) 7866(2) 10760(2) 8204(1) 21(1) 
C(4) 9328(2) 10914(2) 8296(1) 20(1) 
C(5) 9977(2) 9834(2) 8076(1) 18(1) 
C(6) 9117(2) 8611(2) 7755(1) 14(1) 
C(7) 8172(2) 6463(2) 7240(1) 14(1) 
C(8) 7106(2) 4200(2) 6735(1) 13(1) 
C(9) 7310(2) 2759(2) 6491(1) 15(1) 
C(10) 8542(2) 2324(2) 6698(1) 17(1) 
C(ll) 8652(2) 953(2) 6510(1) 22{l) 
C(12) 7535(2) 24(2) 6126(1) 27(1) 
C(13) 6308(2) 445(2) 5911(1) 28(1) 
C(14) 6190(2) 1808(2) 6089(1) 21{l) 
C(15) 2882(2) 4806(2) 6029(1) 12(1) 
C(16) 3657(2) 4410(2) 5491(1) 16(1) 
C(17) 2904(2) 3750(2) 4845(1) 18(1) 
C(18) 1442(2) 3459(2) 4738(1) 19{1) 
C(19) 675(2) 3837(2) 5270(1) 16{l) 
C(20) 1429(2) 4525(2) 5910(1) 12(1) 
C(21) 2141(2) 5674(2) 6995(1) 14(1) 
C(22) 3010(2) 7086(2) 8086(1) 14(1) 
C(23) 2597(2) 7788(2) 8750(1) 15(1) 
C(24) 1311(2) 7337(2) 8974(1) 21{l) 
C(25) 945(2) 8038(2) 9581{l) 28(1) 
C(26) 1844(2) 9188(2) 9961(1) 30(1) 
C(27) 3135(2) 9626(2) 9747(1) 27(1) 
C(28) 3509(2) 8924(2) 9147(1) 19(1) 
C(29) 6070(2) 5320(2) 8885(1) 15(1) 
C(30) 6696(2) 6629(2) 9226{l) 20{l) 
C(31) 7260(2) 6772(2) 9927(1) 23(1) 
C(32) 7200(2) 5647(2) 10274(1) 25{l) 
C(33) 6568(2) 4336(2) 9939(1) 24(1) 
C(34) 6006(2) 4208(2) 9241(1) 18(1) 
C(35) 4990(2) 3515(2) 8145{l) 16(1) 
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C(36) 3740(2) 1293(2) 7500(1) 19(1) 
C(37) 3050(2) 559(2) 6796(1) 17(1) 
C(38) 2994(2) -846(2) 6638(1) 24(1) 
C(39) 2388(2) -1566(2) 5981(1) 30(1) 
C(40) 1829(2) -882(2) 5484(1) 28(1) 
C(41) 1853(2) 507(2) 5642(1) 26(1) 
C(42) 2471(2) 1237(2) 6298(1) 22(1) 
Table A19. Anisotropic displacement parameters (A2x 103) for nnb311lt. The anisotropic 
displacement factor exponent takes the fonn: -20 2( h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
UI1 tJ22 U33 tJ23 U13 U12 
Zn(l) 10(1) 16(1) 15(1) 2(1) 4(1) 4(1) 
0(1) 9(1) 18(1) 17(1) -2(1) 3(1) 3(1) 
0(2) 8(1) 19(1) 19(1) -1(1) 4(1) 4(1) 
0(3) 32(1) 21(1) 27(1) 8(1) 5(1) 2(1) 
N(1) 10(1) 14(1) 13(1) 2(1) 3(1) 4(1) 
N(2) 8(1) 17(1) 20(1) -1(1) 2(1) 5(1) 
N(3) 11(1) 16(1) 14(1) 0(1) 3(1) 3(1) 
N(4) 8(1) 17(1) 13(1) 3(1) 5(1) 4(1) 
N(5) 5(1) 22(1) 16(1) 1(1) 2(1) 4(1) 
N(6) 10(1) 22(1) 14(1) 0(1) 4(1) 4(1) 
N(7) 15(1) 15(1) 16(1) 2(1) 4(1) 6(1) 
N(8) 21(1) 16(1) 20(1) 5(1) 6(1) 6(1) 
N(9) 22(1) 17(1) 16(1) 8(1) 6(1) 2(1) 
C(1) 13(1) 14(1) 12(1) 2(1) 4(1) 2(1) 
C(2) 12(1) 21(1) 19(1) 5(1) 7(1) 5(1) 
C(3) 24(1) 19(1) 23(1) 1(1) 9(1) 9(1) 
C(4) 20(1) 15(1) 20(1) -1(1) 4(1) -3(1) 
C(5) 12(1) 21(1) 20(1) 2(1) 2(1) 0(1) 
C(6) 13(1) 16(1) 14(1) 3(1) 5(1) 4(1) 
C(7) 12(1) 20(1) 12(1) 4(1) 5(1) 4(1) 
C(8) 15(1) 20(1) 6(1) 3(1) 4(1) 6(1) 
C(9) 13(1) 16(1) 15(1) 3(1) 7(1) 2(1) 
C(10) 17(1) 20(1) 16(1) 4(1) 6(1) 3(1) 
C(ll) 23(1) 25(1) 22(1) 8(1) 12(1) 12(1) 
C(12) 36(2) 18(1) 28(1) -2(1) 14(1) 6(1) 
C(13) 24(1) 23(1) 32(2) -7(1) 9(1) 0(1) 
C(14) 17(1) 23(1) 23(1) -1(1) 7(1) 5(1) 
C(15) 11(1) 13(1) 14(1) 4(1) 1(1) 2(1) 
C(16) 12(1) 18(1) 19(1) 6(1) 5(1) 1(1) 
C(17) 21(1) 16(1) 18(1) 4(1) 7(1) 4(1) 
C(18) 22(1) 15(1) 17(1) 1(1) -3(1) 3(1) 
C(19) 13(1) 13(1) 23(1) 4(1) 1(1) 2(1) 
C(20) 14(1) 9(1) 16(1) 4(1) 5(1) 3(1) 
C(21) 10(1) 15(1) 17(1) 4(1) 2(1) 4(1) 
C(22) 17(1) 15(1) 15(1) 7(1) 5(1) 8(1) 
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C(23) 12(1) 21(1) 12(1) 5(1) 3(1) 6(1) 
C(24) 19(1) 32(1) 16(1) 7(1) 4(1) 9(1) 
C(25) 19(1) 50(2) 19(1) 8(1) 11(1) 12(1) 
C(26) 33(2) 50(2) 13(1) 2(1) 9(1) 19(1) 
C(27) 28(1) 33(2) 17(1) -2(1) 1(1) 10(1) 
C(28) 17(1) 27(1) 16(1) 6(1) 6(1) 8(1) 
C(29) 11(1) 20(1) 17(1) 5(1) 6(1) 7(1) 
C(30) 18(1) 24(1) 19(1) 6(1) 5(1) 6(1) 
C(31) 18(1) 28(1) 20(1) -2(1) 4(1) 5(1) 
C(32) 22(1) 40(2) 17(1) 5(1) 4(1) 11(1) 
C(33) 25(1) 31(2) 22(1) 12(1) 7(1) 14(1) 
C(34) 14(1) 21(1) 19(1) 3(1) 5(1) 6(1) 
C(35) 14(1) 20(1) 16(1) 4(1) 6(1) 8(1) 
C(36) 15(1) 17(1) 28(1) 6(1) 9(1) 4(1) 
C(37) 14(1) 15(1) 22(1) 5(1) 4(1) 1(1) 
C(38) 25(1) 20(1) 26(1) 9(1) -1(1) 3(1) 
C(39) 38(2) 15(1) 35(2) 7(1) 2(1) -1(1) 
C(40) 32(1) 24(1) 24(1) 4(1) -2(1) -5(1) 
C(41) 25(1) 23(1) 30(2) 11(1) 0(1) 2(1) 
C(42) 23(1) 15(1) 29(1) 5(1) 5(1) 3(1) 
Table A20. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb311lt 
x y z U(eq) 
H(2N) 10260(20) 7095(18) 7534(9) 18 
H(5N) 90(20) 5029(19) 6621(10) 20(6) 
H(8N) . 5050(20) 2250(20) 8798(11) 30(7) 
H(9N) 4438(18) 3007(18) 7186(9) 10(50) 
H(2) 6041 9434 7831 20 
H(3) 7460 11505 8358 26 
H(64) 9874 11759 8509 23 
H(5) 10948 9928 8141 22 
H(10) 9296 2950 6962 21 
H(l1) 9480 668 6645 26 
H(12) 7604 -893 6009 32 
H(13) 5559 -189 5647 33 
H(14) 5367 2089 5940 25 
H(16) 4632 4579 5562 19 
H(l7) 3392 3497 4473 22 
H(18) 977 3001 4302 23 
H(19) -301 3643 5204 20 
H(24) 699 6567 8718 26 
H(25) 90 7732 9732 34 
H(26) 1585 9668 10361 37 
H(27) 3747 10393 10006 32 
H(28) 4381 9214 9008 23 
H(30) 6738 7381 8995 24 
H(31) 7688 7639 10171 27 
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H(32) 7596 5782 10743 30 
H(33) 6524 3583 10170 29 
H(38) 3364 -1304 6974 28 
H(39) 2356 -2506 5873 36 
H(40) 1434 -1365 5040 34 
H(41) 1456 955 5309 31 
H(42) 2499 2177 6403 27 
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Crystal color, habit 




Completeness to theta = 28.070 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb260pbca 






a = 12.9214(13) A 
b = 17.1388(17) A 




0.421 mm- i 
2216 
0.46 x 0.18 x 0.08 mm3 
blue plate 
2.16 to 28.070 
-17<=h<= 16, -22<=k<=21, -30<=1<=29 
43202 
6183 [R(int) = 0.0328] 
97.9% 
SADABS 
0.912 and 0.785 
Full-matrix least-squares on F2 
6183/0/333 
1.061 
Rl = 0.0537, wR2 = 0.1088 
Rl = 0.0715, wR2 = 0.1257 
0.461 and -0.554 e.A-3 
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Table A22. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb260Pbca. U(eq) is defmed as one third of the trace of the orthogonalized uij 
tensor. 
x y z U(eq) 
V(I) 2827(1) 1036(1) 4103(1) 18(1) 
0(1) 3578(1) 1143(1) 4830(1) 22(1) 
0(2) 2737(1) 306(1) 3464(1) 24(1) 
0(3) 2061(1) 1749(1) 4014(1) 28(1) 
N(I) 4201(2) 1417(1) 3748(1) 20(1) 
N(2) 5850(2) 1800(1) 3696(1) 26(1) 
N(3) 5253(2) 1544(1) 4615(1) 21(1) 
N(4) 1945(2) 219(1) 4520(1) 21(1) 
N(5) 1237(2) -936(1) 4715(1) 25(1) 
N(6) 1826(2) -783(1) 3778(1) 24(1) 
C(1) 5063(2) 1574(1) 4046(1) 20(1) 
C(2) 4449(2) 1551(1) 3176(1) 21(1) 
C(3) 3852(2) 1498(2) 2685(1) 26(1) 
C(4) 4326(2) 1676(2) 2169(1) 30(1) 
C(5) 5359(2) 1906(2) 2137(1) 31(1) 
C(6) 5957(2) 1973(2) 2627(1) 31(1) 
C(7) 5483(2) 1792(2) 3142(1) 24(1) 
C(8) 6903(2) 1964(2) 3874(1) 38(1) 
C(9) 4514(2) 1331(1) 4964(1) 20(1) 
C(10) 4787(2) 1273(2) 5597(1) 23(1) 
C(11) 4651(3) 424(2) 5778(1) 45(1) 
C(12) 5892(2) 1544(2) 5706(1) 47(1) 
C(13) 4044(2) 1776(2) 5944(1) 31(1) 
C(14) 1701(2) -487(1) 4311(1) 22(1) 
C(15) 1570(2) 236(2) 5076(1) 22(1) 
C(16) 1531(2) 838(2) 5470(1) 27(1) 
C(17) 1067(2) 686(2) 5993(1) 31(1) 
C(18) 646(2) -45(2) 6120(1) 30(1) 
C(19) 662(2) -646(2) 5725(1) 30(1) 
C(20) 1132(2) -493(2) 5204(1) 24(1) 
C(21) 938(2) -1746(2) 4641(1) 33(1) 
C(22) 2299(2) -369(1) 3392(1) 22(1) 
C(23) 2382(2) -707(2) 2791(1) 28(1) 
C(24) 1899(3) -1521(2) 2761(1) 36(1) 
C(25) 1801(3) -160(2) 2381(1) 40(1) 
C(26) 3528(2) -746(2) 2628(1) 34(1) 
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Table A23. Anisotropic displacement parameters (A2x 103) for rmb260Pbca. The anisotropic 
displacement factor exponent takes the form: -202 ( h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
U ll lJ22 U33 lJ23 Ul3 Ul2 
V(1) 17(1) 19(1) 19(1) -1(1) -1(1) -1(1) 
0(1) 18(1) 29(1) 19(1) -2(1) -3(1) -3(1) 
0(2) 28(1) 23(1) 21(1) -6(1) 1(1) -6(1) 
0(3) 26(1) 29(1) 30(1) 1(1) -2(1) 3(l} 
N(l) 19(1) 21(1) 19(1) 1(1) 1(1) -3(1) 
N(2) 20(1) 30(1) 27(1) 1(1) 1(1) -5(1) 
N(3) 20(1) 22(1) 22(1) -1(1) -2(1) -2(1) 
N(4) 20(1) 23(1) 20(1) -2(1) 1(1) -4(1) 
N(5) 26(1) 24(1) 25(1) 3(1) 1(1) -4(1) 
N(6) 27(1) 23(1) 22(1) -2(1) -2(1) -3(1) 
C(1) 20(1) 17(1) 23(1) -1(1) -1(1) -1(1) 
C(2) 25(1) 18(1) 21(1) -1(1) 2(1) 2(1) 
C(3) 31(1) 26(1) 21(1) 2(1) -2(1) -2(1) 
C(4) 42(2) 27(1) 21(1) 1(1) -2(1) 4(1) 
C(5) 38(2) 30(1) 25(1) 5(1) 9(1) 4(1) 
C(6) 29(1) 32(1) 32(1) 5(1) 8(1) 1(1) 
C(7) 26(1) 21(1) 25(1) 1(1) 2(1) 0(1) 
C(8) 22(1) 55(2) 38(2) 5(1) -1(1) -10(1) 
C(9) 22(1) 17(1) 21(1) -3(1) -3(1) 2(1) 
C(10) 26(1) 24(1) 19(1) -3(1) -6(1) 1(1) 
C(ll) 82(3) 26(1) 25(1) 0(1) -10(2) 7(2) 
C(12) 28(2) 84(3) 27(2) -4(2) -8(1) -5(2) 
C(13) 38(2) 34(1) 23(1) -6(1) -3(1) 9(1) 
C(14) 22(1) 20(1) 23(1) 0(1) -1(1) -3(1) 
C(15) 17(1) 28(1) 21(1) -1(1) 0(1) -1(1) 
C(16) 24(1) 34(1) 24(1) -1(1) 1(1) -4(1) 
C(17) 28(1) 40(2) 24(1) -3(1) 1(1) 2(1) 
C(18) 27(1) 42(2) 22(1) 5(1) 3(1) 1(1) 
C(19) 27(1) 34(1) 28(1) 10(1) 0(1) -1(1) 
C(20) 22(1) 27(1) 23(1) 3(1) -2(1) -1(1) 
C(21) 41(2) 21(1) 36(2) 4(1) -1(1) -6(1) 
C(22) 21(1) 22(1) 23(1) -4(1) -4(1) -1(1) 
C(23) 35(1) 26(1) 23(1) -6(1) -2(1) 0(1) 
C(24) 48(2) 31(1) 30(1) -9(1) 1(1) -7(1) 
C(25) 54(2) 37(2) 30(2) -4(1) -15(1) 1(1) 




Table A24. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb260Pbca. 
x y z U(eq) 
H(3) 3146 l346 2701 31 
H(4) 3934 1640 1828 36 
H(5) 5658 2018 1776 38 
H(6) 6659 2136 2610 37 
H(8A) 6912 2081 4283 57 
H(8B) 7167 2414 3661 57 
H(8C) 7340 1508 3798 57 
H(llA) 4799 373 6186 67 
H(llB) 5130 94 5561 67 
H(llC) 3938 259 5703 67 
H(l2A) 5965 2089 5584 70 
H(l2B) 6373 1217 5489 70 
H(12C) 6047 1502 6114 70 
H(l3A) 4205 1723 6351 47 
H(l3B) 3332 1605 5874 47 
H(l3C) 4119 2323 5830 47 
H(16) 1811 l337 5386 32 
H(l7) 1034 1089 6270 37 
H(18) 344 -l31 6484 37 
H(19) 364 -1140 5806 35 
H(21A) 899 -1868 4233 49 
H(2lB) 260 -1833 4817 49 
H(21C) 1452 -2085 4823 49 
H(24A) 2252 -1868 3030 54 
H(24B) 1972 -1727 2373 54 
H(24C) 1163 -1489 2860 54 
H(25A) 1071 -l32 2492 60 
H(25B) 1855 -362 1991 60 
H(25C) 2108 362 2398 60 
H(26A) 3832 -223 2651 51 
H(26B) 3594 -943 2237 51 
H(26C) 3892 -1097 2890 51 
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Completeness to theta = 27.54° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb317p21c 






a = 8.2544(14) A 
b = 22.984(4) A 






0.22 x 0.16 x 0.14 mm3 
l.77 to 27.54° 
~= 100.364(3)°. 
-lO<=h<=lO, -29<=k<=29, -13<=1<=13 
16202 
4323 [R(int) = 0.0657] 
97.1 % 
SADABS 
0.8386 and 0.7625 
Full-matrix least-squares on F2 
4323/0/286 
1.087 
Rl = 0.0753, wR2 = 0.1508 
Rl = 0.0839, wR2 = 0.1549 
0.643 and -0.773 e.A-3 
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Table A26. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Alx 103) for nnb317P2lc. U(eq) is defmed as one third of the trace of the orthogonalized Uij 
tensor. 
x y z U(eq) 
Zn(l) 2902(1) 3789(1) -816(1) 16(1) 
0(1) 1220(4) 3369(2) -2056(3) 24(1) 
0(2) 4079(4) 4223(1) -1992(3) 20(1) 
N(1) 3689(5) 3075(2) 94(4) 16(1) 
N(2) 3852(5) 2120(2) 399(4) 17(1) 
N(3) 2054(5) 2413(2) -1500(4) 18(1) 
N(4) 2466(5) 4490(2) 114(4) 16(1) 
N(5) 2162(5) 5447(2) 320(4) 16(1) 
N(6) 3336(5) 5169(2) -1475(4) 18(1) 
C(1) 3139(6) 2556(2) -391(5) 16(1) 
C(2) 4901(6) 2363(2) 1455(5) 16(1) 
C(3) 5875(6) 2114(2) 2537(5) 20(1) 
C(4) 6761(6) 2492(2) 3439(5) 21(1) 
C(5) 6664(6) 3098(2) 3255(5) 22(1) 
C(6) 5681(6) 3344(2) 2168(4) 18(1) 
C(7) 4788(6) 2966(2) 1260(4) 16(1) 
C(8) 3572(7) 1499(2) 178(5) 23(1) 
C(9) 1218(6) 2818(2) -2232(5) 18(1) 
C(lO) 63(6) 2600(2) -3440(5) 21(1) 
C(ll) 2694(5) 5017(2) -404(5) 15(1) 
C(12) 1586(6) 5195(2) 1364(4) 16(1) 
C(13) 927(6) 5434(2) 2393(5) 20(1) 
C(14) 469(7) 5047(2) 3275(5) 25(1) 
C(15) 688(7) 4448(2) 3174(5) 26(1) 
C(16) 1356(6) 4211(2) 2147(5) 21(1) 
C(17) 1787(6) 4594(2) 1231(4) 16(1) 
C(18) 2165(6) 6067(2) 28(5) 20(1) 
C(19) 3937(6) 4770(2) -2179(4) 16(1) 
C(20) 4498(6) 4995(2) -3403(5) 21(1) 
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Table A27. Anisotropic displacement parameters (A2x 103) for nnb317P21 c. The anisotropic 
displacement factor exponent takes the fonn: -202l h2 a*2Ull + ... + 2 h k a* b* U12 ] 
Ull U22 lJ33 U23 Ul3 U12 
Zn(1) 23(1) 10(1) 15(1) 0(1) 3(1) 1(1) 
0(1) 28(2) 15(2) 25(2) -3(1) -2(2) 3(1) 
0(2) 29(2) 14(2) 20(2) 0(1) 10(1) 3(1) 
N(l) 22(2) 12(2) 14(2) 0(2) 5(2) 2(2) 
N(2) 21(2) 14(2) 14(2) 0(2) 2(2) -1(2) 
N(3) 24(2) 13(2) 16(2) -2(2) 4(2) -3(2) 
N(4) 22(2) 12(2) 14(2) -3(2) 2(2) 0(2) 
N(5) 23(2) 13(2) 13(2) -1(2) 3(2) 1(2) 
N(6) 23(2) 14(2) 17(2) 1(2) 6(2) 1(2) 
C(1) 17(2) 15(2) 17(2) 0(2) 9(2) 0(2) 
C(2) 18(2) 14(2) 17(2) -1(2) 7(2) 0(2) 
C(3) 24(3) 16(2) 19(2) 3(2) 3(2) 0(2) 
C(4) 25(3) 25(2) 14(2) 5(2) 4(2) 0(2) 
C(5) 26(3) 23(2) 16(2) -5(2) 1(2) -S(2) 
C(6) 24(2) 17(2) 14(2) 1(2) 7(2) -3(2) 
C(7) 21(2) 17(2) 12(2) 2(2) 8(2) 1(2) 
C(8) 35(3) 13(2) 19(2) -1(2) 3(2) -2(2) 
C(9) 19(2) 21(2) 16(2) -1(2) 5(2) -1(2) 
C(10) 26(3) 19(2) 18(2) -2(2) 3(2) -1(2) 
C(ll) 12(2) IS(2) 17(2) -3(2) 1(2) 1(2) 
C(12) 17(2) 16(2) IS(2) 0(2) 0(2) 2(2) 
C(13) 24(3) 21(2) 14(2) -S(2) 0(2) 6(2) 
C(14) 27(3) 34(3) 16(2) -2(2) 8(2) 7(2) 
C(IS) 31(3) 31(3) 18(2) 6(2) 6(2) 4(2) 
C(16) 23(3) 24(2) 17(2) 2(2) 2(2) 2(2) 
C(17) 19(2) IS(2) 12(2) -1(2) -1(2) 0(2) 
C(18) 29(3) 11(2) 21(2) 0(2) 6(2) 1(2) 
C(19) 17(2) 16(2) 13(2) -3(2) -1(2) 0(2) 
C(20) 29(3) 15(2) 19(2) -3(2) 7(2) 0(2) 
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Table A28. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb317P21 c. 
x y z U(eq) 
H(3) 5934 1713 2654 13(12) 
H(4) 7435 2342 4183 23(15) 
H(5) 7277 3339 3881 27(15) 
H(6) 5620 3745 2051 22(14) 
H(8A) 2868 1357 753 80(30) 
H(8B) 4607 1297 356 60(20) 
H(8C) 3058 1435 -719 44(19) 
H(lOA) -1054 2683 -3357 29(16) 
H(10B) 199 2188 -3523 80(30) 
H(10C) 311 2792 -4206 60(20) 
H(13) 803 5833 2479 16(13) 
H(14) -4 5190 3962 25(15) 
H(15) 382 4203 3804 50(20) 
H(16) 1507 3812 2079 33(16) 
H(18A) 3246 6223 332 23(14) 
H(18B) 1386 6262 464 27(15) 
H(18C) 1866 6125 -904 25(15) 
H(20A) 5518 4812 -3490 14(13) 
H(20B) 4653 5409 -3335 32(16) 
H(20C) 3678 4908 -4161 18(14) 
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Crystal color, habit 
Crystal size 




Completeness to theta = 28.88° 
Completeness to theta = 26.32° 
Refinement method 
Data 1 restraints 1 parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff peak and hole 
rmb329lt 






a = 13.8508(8) A 
b = 11.0612(5) A 




1.358 mm- i 
748 
blue-green cut block 
0.41 x 0.38 x 0.38 mm3 
3.55 to 28.88° 
0.= 90° 
13= 104.508(6)° 
-18<=h<=10, -9<=k<=14, -12<=1<=14 
6513 
3607 [R(int) = 0.0276] 
83.9% 
96.7% 
Full-matrix least-squares on F2 
3607/0/208 
1.058 
Rl = 0.0335, wR2 = 0.0951 
Rl = 0.0469, wR2 = 0.0972 
0.666 and -0.532 e.A-3 
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Table A30. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb329lt. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
x y z U(eq) 
Cu(1) 5713(1) -136(1) 1022(1) 11(1) 
0(1) 5250(2) -1831(2) 833(2) 16(1) 
0(3) 4658(1) 238(2) 1868(2) 18(1) 
0(2) 5996(2) 1602(2) 895(2) 18(1) 
0(4) 6575(1) -439(2) -123(2) 16(1) 
0(5) 9608(2) 1144(2) 3468(2) 23(1) 
N(I) 6839(2) -565(2) 2761(2) 13(1) 
N(2) 8138(2) 462(2) 2260(2) 18(1) 
C(1) 5480(2) 2219(2) -2(2) 14(1) 
C(5) 6465(2) -1254(2) 3544(2) 15(1) 
C(2) 5760(2) 3530(3) -73(3) 23(1) 
C(6) 7017(2) -1628(2) 4701(2) 16(1) 
C(3) 6242(2) -435(2) -1299(2) 13(1) 
C(7) 8008(2) -1299(3) 5062(3) 18(1) 
C(4) 6955(2) -691(3) -2093(3) 23(1) 
C(8) 8415(2) -600(3) 4276(3) 17(1) 
C(9) 7804(2) -245(2) 3133(2) 14(1) 
C(10) 8992(2) 1128(2) 2468(3) 15(1) 
C(ll) 9152(2) 1895(3) 1371(3) 18(1) 
C(12) 9147(3) 3213(3) 1782(4) 42(1) 
C(14) 10178(2) 1568(4) 1185(3) 32(1) 
C(13) 8377(3) 1697(4) 133(3) 35(1) 
Table A31. Anisotropic displacement parameters (A2x 103) for nnb3291t. The anisotropic 
displacement factor exponent takes the fonn: -202[ h2 a*2Ull + ... + 2 h k a* b* U12 ] 
Ull lJ22 U33 lJ23 UB U12 
Cu(l) 10(1) 12(1) 11(1) 0(1) 3(1) 1(1) 
0(1) 16(1) 13(1) 20(1) 1(1) 2(1) 0(1) 
0(3) 15(1) 24(1) 15(1) -1(1) 4(1) 7(1) 
0(2) 17(1) 12(1) 23(1) 0(1) -1(1) 0(1) 
0(4) 12(1) 20(1) 15(1) 1(1) 4(1) 2(1) 
0(5) 19(1) 28(1) 19(1) 6(1) 0(1) -8(1) 
N(I) 12(1) 15(1) 13(1) 1(1) 4(1) 0(1) 
N(2) 12(1) 27(1) 13(1) 7(1) 0(1) -5(1) 
C(1) 13(1) 14(1) 18(1) -2(1) 7(1) -1(1) 
C(5) 15(1) 16(1) 16(1) -1(1) 5(1) -4(1) 
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C(2) 23(2) 15(1) 29(2) 2(1) 2(1) -3(1) 
C(6) 21(2) 13(1) 13(1) 2(1) 7(1) -3(1) 
C(3) 15(1) 9(1) 17(1) 0(1) 7(1) 0(1) 
C(7) 20(2) 19(1) 13(1) 4(1) 0(1) -2(1) 
C(4) 20(2) 32(2) 19(2) -2(1) 10(1) 4(1) 
C(8) 13(1) 21(1) 16(1) 1(1) 1(1) -4(1) 
C(9) 13(1) 14(1) 14(1) 0(1) 4(1) -1(1) 
C(10) 14(1) 16(1) 17(1) 1(1) 5(1) 0(1) 
C(U) 15(1) 21(1) 18(1) 4(1) 6(1) -3(1) 
C(12) 71(3) 21(2) 43(2) 10(2) 29(2) 2(2) 
C(14) 22(2) 50(2) 27(2) 8(2) 12(1) -1(2) 
C(13) 24(2) 58(2) 23(2) 19(2) 2(1) -12(2) 
Table A32. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb3291t. 
x y z U(eq) 
H(5) 5801 -1490 3289 18 
H(2A) 5430 3850 -880 35 
H(2B) 6469 3595 47 35 
H(2C) 5560 3979 568 35 
H(6) 6729 -2088 5224 19 
H(7) 8403 -1548 5833 21 
H(4A) 7115 50 -2452 34 
H(4B) 6652 -1243 -2750 34 
H(4C) 7554 -1043 -1583 34 
H(8) 9083 -373 4508 20 
H(12A) 9281 3729 1143 63 
H(12B) 9651 3331 2547 63 
H(12C) 8505 3409 1913 63 
H(14A) 10198 721 1004 48 
H(14B) 10682 1752 1934 48 
H(14C) 10300 2028 499 48 
H(13A) 8550 2170 -511 53 
H(13B) 7732 1940 221 53 
H(13C) 8360 857 -89 53 
H(20) 7780(30) 480(30) 1600(30) 20(9) 
249 



















Completeness to theta = 27.66° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on p2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb317repr055 






a = 9.502(2) A 
b = 10.692(3) A 






0.24 x 0.16 x 0.15 mm3 
1.52 to 27.66° 
a,= 102. 244(4t. 
~= 98.049(4)°. 
y = 113.604(3)°. 
-12<=h<=12, -13<=k<=13, -18<=1<=18 
10877 
5546 [R(int) = 0.0194] 
95.2% 
SADABS 
0.3750 and 0.2456 
Full-matrix least-squares on F2 
5546/0/276 
1.050 
Rl = 0.0281, wR2 = 0.0719 
Rl = 0.0305, wR2 = 0.0734 
2.259 and -1.344 e.A-3 
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Table A34. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for rmb317repro55. U(eq) is defmed as one third of the trace of the orthogonalized 
Uij tensor. 
x y z U(eq) 
Pt(1) 5137(1) 7998(1) 7501(1) 17(1) 
1(1) 7848(1) 8829(1) 7050(1) 23(1) 
1(2) 5372(1) 10555(1) 8032(1) 28(1) 
0(1) 6874(4) 4997(4) 9531(3) 30(1) 
0(2) -726(4) 6132(4) 5337(3) 28(1) 
N(I) 4936(4) 5955(4) 7089(3) 19(1) 
N(2) 6486(4) 6455(4) 8668(3) 18(1) 
N(3) 2947(5) 7172(4) 7827(3) 20(1) 
N(4) 1786(5) 7385(4) 6368(3) 23(1) 
C(1) 4112(5) 5104(5) 6160(3) 23(1) 
C(2) 3992(6) 3752(5) 5810(4) 25(1) 
C(3) 4714(5) 3246(5) 6464(4) 24(1) 
C(4) 5555(5) 4106(5) 7419(4) 21(1) 
C(5) 5656(5) 5472(5) 7728(3) 18(1) 
C(6) 7066(5) 6182(5) 9512(4) 22(1) 
C(7) 8028(5) 7496(5) 10423(3) 22(1) 
C(8) 7969(6) 8869(5) 10306(4) 27(1) 
C(9) 7392(7) 7158(6) 11324(4) 31(1) 
C(10) 9757(6) 7704(6) 10587(4) 30(1) 
C(11) 2872(6) 6788(5) 8685(4) 24(1) 
C(12) 1470(6) 6111(6) 8917(4) 31(1) 
C(13) 76(6) 5827(5) 8266(4) 27(1) 
C(14) 116(6) 6228(5) 7405(4) 24(1) 
C(15) 1587(5) 6902(5) 7193(3) 21(1) 
C(16) 631(5) 7032(5) 5503(4) 21(1) 
C(17) 1264(6) 7928(5) 4809(4) 24(1) 
C(l8) 2703(7) 7784(8) 4542(4) 42(1) 
C(19) 1701(7) 9480(6) 5345(4) 37(1) 
C(20) -38(6) 7411(6) 3846(4) 28(1) 
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Table A35. Anisotropicdisplacementparameters (A2x 103)forrmb317repro55. The 
anisotropic displacement factor exponent takes the form: -20 2( h2 a*2U 11 + ... + 2 h k a* b* 
U12 ] 
UIJ {J22 U33 {J23 U13 Ul2 
Pt(l) 17(1) 14(1) 19(1) 6(1) 1(1) 6(1) 
1(1) 21(1) 19(1) 21(1) 4(1) S(l) 3(1) 
1(2) 29(1) 17(1) 37(1) 7(1) 3(1) 11(1) 
0(1) 34(2) 19(2) 31(2) 9(2) -3(2) 8(2) 
0(2) 22(2) 28(2) 28(2) 10(2) 2(1) 6(2) 
N(l) lS(2) 19(2) 18(2) 4(2) 3(1) 4(2) 
N(2) 18(2) 19(2) lS(2) 3(1) 0(1) 8(2) 
N(3) 21(2) 17(2) 2S(2) 8(2) 6(2) 10(2) 
N(4) 21(2) 2S(2) 23(2) 10(2) 2(2) 9(2) 
C(1) 20(2) 24(2) 22(2) 9(2) 2(2) 7(2) 
C(2) 22(2) 18(2) 2S(2) 2(2) 4(2) 3(2) 
C(3) 18(2) 17(2) 32(3) 3(2) 4(2) 6(2) 
C(4) 16(2) 18(2) 29(2) 10(2) S(2) 7(2) 
C(S) 16(2) 17(2) 19(2) 1(2) 2(2) 6(2) 
C(6) 18(2) 23(2) 24(2) 10(2) 4(2) 7(2) 
C(7) 20(2) 20(2) 22(2) 7(2) 3(2) 6(2) 
C(8) 33(3) 19(2) 22(2) 1(2) -1(2) 11(2) 
C(9) 38(3) 34(3) 2S(3) 11(2) 13(2) 16(2) 
C(1O) 19(2) 27(3) 34(3) -2(2) -1(2) 7(2) 
C(11) 2S(2) 28(3) 24(2) 10(2) 4(2) lS(2) 
C(l2) 34(3) 3S(3) 32(3) 19(2) 13(2) 18(2) 
C(13) 2S(2) 30(3) 30(3) 13(2) 10(2) 14(2) 
C(14) 20(2) 28(2) 24(2) 9(2) 2(2) 12(2) 
C(lS) 20(2) 19(2) 23(2) 6(2) 1(2) 9(2) 
C(16) 20(2) 18(2) 2S(2) 6(2) 4(2) 10(2) 
C(17) 22(2) 2S(2) 23(2) 10(2) 2(2) 8(2) 
C(18) 28(3) 68(4) 37(3) 26(3) 13(2) 22(3) 
C(19) SO(3) 28(3) 30(3) 16(2) -1(2) 12(3) 
C(20) 2S(2) 32(3) 24(2) 10(2) -1(2) 10(2) 
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Table A36. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb317repro55. 
x y z U(eq) 
H(l) 3606 5439 5738 14(12) 
H(2) 3445 3192 5157 39(17) 
H(3) 4626 2327 6253 12(11) 
H(4) 6050 3778 7853 22(13) 
H(8A) 8332 9067 9730 40 
H(8B) 8641 9651 10891 40 
H(8C) 6899 8750 10225 40 
H(9A) 6318 7034 11220 47 
H(9B) 8038 7933 11918 47 
H(9C) 7422 6297 11399 47 
H(10A) 9785 6827 10619 45 
H(lOB) 10389 8440 11203 45 
H(lOC) 10172 7977 10043 45 
H(ll) 3811 6997 9129 37(16) 
H(12) 1450 5844 9502 40(17) 
H(13) -892 5363 8411 26(14) 
H(l4) -816 6056 6970 11(11) 
H(18A) 2992 8238 4035 62 
H(18B) 2449 6790 4298 62 
H(l8C) 3576 8232 5127 62 
H(19A) 791 9543 5529 56 
H(19B) 2043 10055 4908 56 
H(l9C) 2544 9818 5935 56 
H(20A) -933 7532 4006 42 
H(20B) -358 6419 3527 42 
H(20C) 362 7957 3404 42 
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Crystal color, shape 
Crystal size 




Completeness to theta = 29.02° 
Completeness to theta = 26.32° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb3221tb 






a = 12.78166(14) A 
b = 9.19192(9) A 






thin yellow plate 
0.37 x 0.34 x 0.02 rom3 
3.38 to 29.02° 
-17<=h<=16, -12<=k<=11, -26<=1<=26 
31818 
3043 [R(int) = 0.0463] 
94.4 % (final refinements) 
99.6% 
SCALE3 ABSPACK 
0.998 and 0.187 
Full-matrix least-squares on F2 
3043/1/189 
l.022 
R1 = 0.0222, wR2 = 0.0628 
Rl = 0.0274, wR2 = 0.0647 
l.955 and -l.461 e.A-3 
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Table A38. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb322ltb. U(eq) is defined as one third of the trace of the orthogonalized uij 
tensor. 
x y z U(eq) 
Pt(I) 5000 0 5000 12(1) 
1(1) 5628(1) 2081(1) 5761(1) 19(1) 
0(1) 5899(2) 3027(2) 2858(1) 25(1) 
N(I) 6343(2) 234(2) 4476(1) 14(1) 
N(2) 5444(2) 1640(3) 3731(1) 18(1) 
C(I) 7234(2) -396(3) 4699(2) 17(1) 
C(2) 8176(3) -230(3) 4393(2) 20(1) 
C(3) 8217(2) 618(3) 3837(2) 19(1) 
C(4) 7331(2) 1263(3) 3601(2) 17(1) 
C(5) 6389(2) 1056(3) 3928(1) 14(1) 
C(6) 5226(2) 2568(3) 3224(2) 16(1) 
C(7) 4063(2) 2969(3) 3172(1) 18(1) 
C(8) 3742(3) 3773(4) 3794(2) 23(1) 
C(9) 3917(3) 3961(4) 2582(2) 28(1) 
C(10) 3399(3) 1600(4) 3095(2) 23(1) 
Table A39. Anisotropic displacement parameters (A2x 103) for rmb322ltb. The anisotropic 
displacement factor exponent takes the form: -202[ h2 a*2Ull + ... + 2 h k a* b* U12] 
Ull lJ22 U33 UZ3 U13 U12 
Pt(I) 10(1) 13(1) 12(1) 2(1) 1(1) 1(1) 
1(1) 19(1) 18(1) 20(1) -4(1) 3(1) -3(1) 
0(1) 22(1) 31(1) 21(1) 11(1) 4(1) -2(1) 
N(I) 14(1) 14(1) 13(1) 1(1) 2(1) 0(1) 
N(2) 11(1) 25(1) 18(1) 9(1) 5(1) 0(1) 
C(1) 15(1) 19(1) 18(2) 4(1) 1(1) 1(1) 
C(2) 12(1) 24(1) 23(2) -2(1) 0(1) 5(1) 
C(3) 13(1) 21(1) 24(2) -2(1) 4(1) -6(1) 
C(4) 17(1) 19(1) 15(1) 1(1) 3(1) -2(1) 
C(5) 15(1) 14(1) 12(1) 0(1) 0(1) -1(1) 
C(6) 18(1) 14(1) 17(2) 0(1) 2(1) -2(1) 
C(7) 18(1) 19(1) 17(2) 4(1) -2(1) 2(1) 
C(8) 22(2) 22(2) 26(2) -2(1) 1(1) 5(1) 
C(9) 25(2) 30(2) 29(2) 12(2) 0(1) 6(2) 
C(1O) 20(2) 21(2) 29(2) 1(1) -8(1) 0(1) 
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Table A40. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb322ltb. 
x y z U(eq) 
H(2N) 5010(20) 1510(40) 3957(15) 15(9) 
H(1) 7190(30) -980(40) 5036(15) 18(9) 
H(2) 8690(30) -530(40) 4558(19) 32(10) 
H(3) 8850(20) 750(30) 3645(15) 13(8) 
H(4) 7360(30) 1760(40) 3265(17) 20(9) 
H(8A) 3840(40) 3170(50) 4180(20) 43(13) 
H(8B) 4200(30) 4590(50) 3851(19) 28(9) 
H(8C) 3040(30) 4000(40) 3777(17) 24(9) 
H(9A) 4190(30) 3500(40) 2227(19) 29(10) 
H(9B) 3210(40) 4040(50) 2510(20) 57(15) 
H(9C) 4260(20) 4760(40) 2659(16) 7(8) 
H(10A) 3430(30) 1030(50) 3440(20) 45(12) 
H(lOB) 3550(30) 1040(40) 2731(18) 28(9) 
H(10C) 2740(30) 1870(40) 2991(17) 26(10) 
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Completeness to theta = 28.99° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff peak and hole 
rmb3191tn 





P 1 211c 1 
a = 6.0476(2) A 
b = 13.5698(5) A 






0.38 x 0.36 x 0.34 mm3 
3.38 to 28.99° 
-7<=h<=8, -18<=k<= 18, -16<=1<= 15 
32994 
2484 [R(int) = 0.0574] 
96.2% 
Semi-empirical from equivalents 
1.00000 and 0.53725 
Full-matrix least-squares on F2 
2484/0/176 
1.038 
RI = 0.0193, wR2 = 0.0477 
RI = 0.0289, wR2 = 0.0499 
2.251 and -0.925 e.A-3 
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Table A42. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for rmb319LTn. U(eq) is defmed as one third of the trace of the orthogonalized uij 
tensor. 
x y z U(eq) 
Pt(I) 5000 5000 5000 10(1) 
0(1) 4760(3) 3557(2) 4736(2) 21(1) 
N(1) 2376(4) 4963(1) 5946(2) 13(1) 
N(2) 1934(4) 3173(2) 5895(2) 18(1) 
C(1) 1384(5) 4106(2) 6227(2) 14(1) 
C(2) -427(5) 4138(2) 6904(3) 17(1) 
C(3) -1210(5) 5014(2) 7290(3) 16(1) 
C(4) -180(5) 5885(2) 6994(3) 17(1) 
C(5) 1557(5) 5825(2) 6333(3) 16(1) 
C(6) 3442(4) 2974(2) 5218(2) 15(1) 
C(7) 3816(4) 1877(2) 4973(3) 16(1) 
C(8) 4825(6) 1739(2) 3841(3) 25(1) 
C(9) 5424(5) 1498(2) 5952(3) 24(1) 
C(10) 1634(5) 1314(2) 4934(3) 22(1) 
Table A43. Anisotropic displacement parameters (A2x 103) for rmb319LTn. The anisotropic 
displacement factor exponent takes the form: -202[ h2 a*2Ull + ... + 2 h k a* b* UI2] 
UII tJ22 tF3 tJ23 Ul3 UI2 
Pt(1) 11(1) 7(1) 13(1) -1(1) 2(1) 0(1) 
0(1) 25(1) 7(1) 32(1) -2(1) 12(1) 0(1) 
N(I) 13(1) 10(1) 15(1) -1(1) 2(1) 2(1) 
N(2) 26(1) 9(1) 20(1) 0(1) 3(1) 3(1) 
C(1) 17(1) 13(1) 12(1) 1(1) 0(1) 1(1) 
C(2) 18(1) 14(1) 20(2) 1(1) 6(1) -1(1) 
C(3) 15(1) 19(2) 15(1) -1(1) 4(1) 0(1) 
C(4) 19(1) 13(1) 19(2) -4(1) 5(1) 2(1) 
C(5) 17(1) 12(2) 22(2) -1(1) 6(1) -2(1) 
C(6) 18(1) 11(1) 15(1) 0(1) -2(1) -2(1) 
C(7) 19(2) 10(1) 20(2) -2(1) 5(1) 1(1) 
C(8) 35(2) 14(2) 27(2) -4(1) 12(2) 1(1) 
C(9) 26(2) 12(2) 32(2) 5(1) -2(1) 1(1) 
C(10) 28(2) 13(2) 25(2) -4(1) 7(1) -1(1) 
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Table A44. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for nnb319L Tn. 
x y z U(eq) 
H(2) -1170(60) 3510(30) 7000(30) 40(11) 
H(3) -2430(80) 5034(16) 7720(40) 23(11) 
H(4) -590(60) 6540(30) 7270(30) 32(10) 
H(5) 2270(60) 6220(30) 6130(30) 33(12) 
H(8A) 3870(50) 2070(20) 3190(30) 32(9) 
H(8B) 6460(40) 2008(19) 3890(20) 14(7) 
H(8C) 4990(50) 1070(30) 3630(30) 34(10) 
H(9A) 6800(50) 1810(20) 6000(30) 15(7) 
H(9B) 5860(50) 860(30) 5790(30) 40(10) 
H(9C) 4780(50) 1510(20) 6720(30) 25(9) 
H(lOA) 1890(50) 650(30) 4760(30) 33(9) 
H(10B) 920(50) 1390(20) 5590(30) 19(8) 
H(IOC) 570(50) 1520(20) 4300(30) 26(9) 
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Crystal color, habit 
Crystal size 




Completeness to theta = 29.05° 
Completeness to theta = 26.32° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(l)] 
R indices (all data) 
Largest diff. peak and hole 
rmb32ltmpp 1 bar 






a = 8.5986(3) A 
b = 11.1609(4) A 







0.34 x 0.23 x 0.20 mm3 
3.31 to 29.05° 
(1.= 77.623(2)°. 
~= 85.944(2)°. 
y = 72.662(3)°. 
-10<=h<=11, -15<=k<=15, -16<=1<=16 
15524 




1.000 and 0.791 
Full-matrix least-squares on F2 
5644/0/374 
1.086 
Rl = 0.0160, wR2 = 0.0390 
R1 = 0.0180, wR2 = 0.0393 
1.744 and -0.522 e.A-3 
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Table A46. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for rmb32ltmpPlbar. U(eq) is defined as one third of the trace of the orthogonalized 
uij tensor. 
x y z U(eq) 
C(1) 9397(3) 5424(2) 7682(2) 18(1) 
C(2) 10212(3) 4179(2) 8119(2) 20(1) 
C(3) 9798(3) 3686(2) 9126(2) 18(1) 
C(4) 8607(3) 4439(2) 9657(2) 15(1) 
C(5) 7827(3) 5703(2) 9175(2) 13(1) 
C(6) 5762(3) 6318(2) 10542(2) 16(1) 
C(7) 4620(3) 7534(2) 10849(2) 16(1) 
C(8) 5620(3) 8380(2) 11063(2) 20(1) 
C(9) 3713(3) 7143(3) 11842(2) 23(1) 
C(10) 3406(3) 8270(3) 9975(2) 22(1) 
C(ll) 4790(3) 6722(2) 7132(2) 18(1) 
C(12) 3867(3) 6198(2) 6661(2) 21(1) 
C(13) 3995(3) 6313(2) 5592(2) 20(1) 
C(14) 5044(3) 6937(2) 5040(2) 18(1) 
C(15) 5961(3) 7446(2) 5560(2) 14(1) 
C(16) 7777(3) 7975(2) 4121(2) 17(1) 
C(17) 8771(3) 8896(2) 3670(2) 18(1) 
C(18) 10563(3) 8150(3) 3957(3) 33(1) 
C(19) 8277(3) 10132(3) 4089(2) 22(1) 
C(20) 8574(4) 9228(3) 2492(2) 29(1) 
CI(1) 5980(1) 10076(1) 6606(1) 18(1) 
CI(2) 8599(1) 8706(1) 8485(1) 20(1) 
N(I) 5837(2) 7336(2) 6604(1) 13(1) 
N(2) 7018(2) 8114(2) 5058(2) 16(1) 
N(3) 8221(2) 6179(2) 8195(1) 13(1) 
N(4) 6660(2) 6564(2) 9648(1) 15(1) 
0(1) 5900(2) 5240(2) 11019(1) 25(1) 
0(2) 7725(2) 7109(2) 3705(1) 28(1) 
Pt(1) 7152(1) 8015(1) 7456(1) 12(1) 
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Table A47. Anisotropic displacement parameters CA2x 103) for nnb321trnpPlbar. The 
anisotropic displacement factor exponent takes the fonn: -20 2[ h2 a*2U 11 + ... + 2 h k a* b* 
U12 ] 
U" lJ22 Un lJ23 U13 U12 
C(1) 21(1) 20(1) 14(1) -3(1) 2(1) -8(1) 
C(2) 18(1) 19(1) 20(1) -8(1) 0(1) 0(1) 
C(3) 21(1) 13(1) 18(1) -3(1) -5(1) -4(1) 
C(4) 22(1) 15(1) 10(1) -1(1) -2(1) -7(1) 
C(5) 16(1) 15(1) 11(1) -4(1) 0(1) -7(1) 
C(6) 20(1) 19(1) 10(1) -4(1) 2(1) -9(1) 
C(7) 18(1) 17(1) 14(1) -4(1) 2(1) -5(1) 
C(8) 23(1) 21(1) 19(1) -7(1) 4(1) -7(1) 
C(9) 25(1) 28(1) 17(1) -6(1) 5(1) -8(1) 
C(IO) 20(1) 22(1) 20(1) -3(1) -1(1) -4(1) 
C(11) 21(1) 19(1) 13(1) 1(1) 0(1) -6(1) 
C(12) 22(1) 20(1) 21(1) 1(1) -2(1) -9(1) 
C(13) 20(1) 18(1) 22(1) -3(1) -6(1) -5(1) 
C(14) 20(1) 17(1) 15(1) -4(1) -3(1) 1(1) 
C(15) 15(1) 12(1) 12(1) -1(1) -1(1) 1(1) 
C(16) 16(1) 20(1) 13(1) -2(1) 0(1) -1(1) 
C(17) 17(1) 26(1) 13(1) -6(1) 1(1) -8(1) 
C(18) 17(1) 46(2) 38(2) -20(2) 3(1) -4(1) 
C(19) 23(1) 26(1) 22(1) -7(1) 4(1) -11(1 ) 
C(20) 41(2) 38(2) 16(1) -3(1) 3(1) -28(2) 
Cl(1) 24(1) 12(1) 14(1) 0(1) 0(1) -2(1) 
Cl(2) 28(1) 21(1) 15(1) 0(1) -4(1) -13(1) 
N(l) 14(1) 12(1) 11(1) 0(1) -2(1) -2(1) 
N(2) 20(1) 15(1) 12(1) -4(1) 1(1) -5(1) 
N(3) 16(1) 13(1) 11(1) -2(1) -1(1) -5(1) 
N(4) 22(1) 10(1) 12(1) 1(1) 3(1) -4(1) 
0(1) 35(1) 16(1) 20(1) 0(1) 10(1) -8(1) 
0(2) 40(1) 23(1) 24(1) -12(1) 14(1) -13(1) 
Pt(I) 15(1) 12(1) 8(1) 0(1) 1(1) -4(1) 
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Table A48. Hydrogen coordinates (x 104) and isotropic displacement parameters CA2x 10 3) 
for nnb321tmpPlbar. 
x y z U(eq) 
H(I) 9640(30) 5850(20) 6940(20) 21(7) 
H(2) 11030(30) 3710(20) 7710(20) 21(7) 
H(3) 10300(30) 2830(20) 9480(18) 12(6) 
H(4) 8270(30) 4150(20) 10350(20) 17(6) 
H(8A) 6390(30) 7900(20) 11644(19) 14(6) 
H(8B) 4850(30) 9150(30) 11260(20) 24(7) 
H(8C) 6140(40) 8560(30) 10570(20) 27(8) 
H(9A) 3040(30) 7900(30) 12070(20) 27(7) 
H(9B) 3130(30) 6630(30) 11710(20) 29(8) 
H(9C) 4430(30) 6740(30) 12360(20) 24(7) 
H(10A) 3850(30) 8560(20) 9330(20) 21(7) 
H(10B) 2670(40) 8920(30) 10190(20) 30(8) 
H(IOC) 2750(30) 7730(30) 9800(20) 27(7) 
H(ll) 4740(30) 6640(30) 7890(20) 28(7) 
H(12) 3210(30) 5680(30) 7100(20) 26(7) 
H(13) 3370(30) 5960(30) 5250(20) 28(8) 
H(14) 5220(30) 7030(20) 4350(20) 21(7) 
H(18A) 10710(40) 7880(30) 4790(30) 45(9) 
H(18B) 11260(40) 8690(30) 3700(20) 34(8) 
H(18C) 10870(30) 7400(30) 3620(20) 29(8) 
H(19A) 7180(30) 10530(30) 3970(20) 21(7) 
H(19B) 8410(30) 10010(30) 4830(20) 23(7) 
H(19C) 8920(40) 10710(30) 3740(20) 32(8) 
H(20A) 9300(40) 9720(30) 2240(20) 33(8) 
H(20B) 7490(40) 9660(30) 2340(20) 41(9) 
H(20C) 9010(30) 8460(30) 2220(20) 29(8) 
H(2N) 7070(30) 8650(30) 5240(20) 16(8) 
H(4N) 6490(30) 7310(30) 9330(19) 14(6) 
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Crystal color, habit 




Completeness to theta = 28.12° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
rmb272p212121 






a = 4.7998(5) A 
b = 18.Z520(17) A 




3.915 mm- l 
1616 
0.26 x 0.15 x 0.04 mm3 
pale-yellow plate 
1.22 to 28.12° 
0.= 90°. 
f3= 90°. 
y = 90°. 
-6<=h<=6, -23<=k<=24, -54<=1<=53 
31733 
8405 [R(int) = 0.0446] 
97.0% 
SADABS 
0.923 and 0.726 
Full-matrix least-squares on F2 
8405/0/302 
1.313 
R1 = 0.0691, wR2 = 0.1638 
R1 = 0.0745, wR2 = 0.1659 
0.025(19) 
7.429 and -9.333 e.A-3 
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Table A50. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for tmb272p212121. U(eq) is defined as one third of the trace of the orthogonalized 
uij tensor. 
x y z U(eq) 
Pt(I) 7424(1) 5248(1) 7555(1) 11(1) 
0(1) 9013(16) 4660(5) 7920(2) 15(1) 
0(2) 5729(17) 5824(5) 7918(2) 15(1) 
N(I) 8860(20) 4465(6) 7262(2) 14(1) 
N(2) 11430(20) 3495(6) 7120(3) 14(1) 
N(3) 12200(20) 3938(5) 7647(2) 14(1) 
N(4) 6040(20) 5982(5) 7240(2) 12(1) 
N(5) 3660(20) 6989(5) 7095(2) 12(1) 
N(6) 2640(30) 6568(4) 7617(2) 12(1) 
C(1) 8080(20) 4254(6) 6952(3) 15(1) 
C(2) 5960(30) 4486(7) 6748(3) 15(1) 
C(3) 5590(30) 4128(7) 6453(3) 15(1) 
C(4) 7250(30) 3551(5) 6362(2) 15(1) 
C(5) 9360(30) 3286(7) 6571(3) 15(1) 
C(6) 9690(30) 3639(7) 6867(3) 15(1) 
C(7) . 10900(20) 4011(7) 7360(3) 15(1) 
C(8) 11200(30) 4272(7) 7904(3) 15(2) 
C(9) 12660(40) 4147(6) 8218(3) 21(2) 
C(10) 10850(30) 4194(9) 8520(3) 24(3) 
C(ll) 12450(40) 4157(7) 8836(3) 27(3) 
C(12) 10580(30) 4245(10) 9133(3) 31(3) 
C(13) 12120(40) 4214(10) 9453(3) 35(4) 
C(14) 10290(40) 4324(11) 9750(3) 36(4) 
C(15) 11830(30) 4267(11) 10070(4) 42(4) 
C(16) 9950(40) 4392(12) 10362(4) 47(5) 
C(17) 11540(40) 4322(15) 10686(4) 64(7) 
C(18) 7000(20) 6222(6) 6938(3) 17(1) 
C(19) 9130(30) 5949(7) 6745(3) 17(1) 
C(20) 9520(30) 6272(7) 6448(3) 17(1) 
C(21) 7910(30) 6882(6) 6348(3) 17(1) 
C(22) 5800(30) 7164(7) 6540(3) 17(1) 
C(23) 5440(30) 6834(7) 6839(3) 17(1) 
C(24) 4070(30) 6509(7) 7336(3) 17(1) 
C(25) 3590(20) 6244(6) 7883(3) 14(2) 
C(26) 2010(20) 6358(6) 8193(3) 14(2) 
C(27) 3750(30) 6328(7) 8495(3) 20(3) 
C(28) 2060(30) 6377(7) 8805(3) 18(3) 
C(29) 3810(30) 6332(8) 9109(3) 23(3) 
C(30) 2150(40) 6415(7) 9422(3) 24(3) 
C(31) 3930(30) 6364(9) 9728(3) 27(3) 
C(32) 2240(40) 6470(8) 10037(3) 29(3) 
C(33) 3970(40) 6418(9) 10344(4) 33(4) 
C(34) 2230(50) 6531(9) 10652(3) 42(4) 
C(35) 13360(20) 2885(6) 7144(3) 15(3) 
C(36) 1760(20) 7618(7) 7114(3) 20(3) 
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Table A51. Anisotropic displacement parameters (A2x 103) for nnb272p212121. The 
anisotropic displacement factor exponent takes the fonn: -20 2[ h2 a*2U 11 + ... + 2 h k a* b* 
U12 ] 
U" lJ22 U33 lJ23 UB U12 
Pt(1) 8(1) 11(1) 13(1) -1(1) -1(1) 1(1) 
0(1) 12(3) 17(3) 17(3) -1(3) 1(2) 3(2) 
0(2) 12(3) 17(3) 17(3) -1(3) 1(2) 3(2) 
N(I) 12(3) 13(3) 16(3) -1(2) -6(2) 6(2) 
N(2) 12(3) 13(3) 16(3) -1(2) -6(2) 6(2) 
N(3) 12(3) 13(3) 16(3) -1(2) -6(2) 6(2) 
N(4) 13(3) 10(2) 14(3) -3(2) -4(2) -4(2) 
N(5) 13(3) 10(2) 14(3) -3(2) -4(2) -4(2) 
N(6) 13(3) 10(2) 14(3) -3(2) -4(2) -4(2) 
C(1) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(2) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(3) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(4) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(5) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(6) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(7) 17(2) 13(2) 14(2) 3(2) 1(2) -2(2) 
C(8) 18(6) 16(6) 9(6) 1(5) -2(4) -13(5) 
C(9) 20(6) 22(6) 21(6) -1(4) 2(7) -10(8) 
C(10) 23(7) 32(8) 17(7) 2(6) 3(5) 7(6) 
C(11) 24(6) 41(7) 18(6) -3(5) -2(9) -2(10) 
C(12) 28(8) 47(10) 19(7) 3(7) -1(6) 3(7) 
C(13) 27(9) 55(9) 23(7) 0(6) -2(7) 18(8) 
C(14) 44(10) 48(10) 15(7) 2(7) -2(6) 4(8) 
C(15) 29(10) 71(12) 25(8) -2(8) -4(6) 20(8) 
C(16) 60(12) 64(13) 17(8) 6(8) -3(8) 2(10) 
C(17) 59(13) 120(20) 18(8) 12(11) -3(7) 25(13) 
C(18) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(19) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(20) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(21) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(22) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(23) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(24) 16(2) 17(2) 18(2) 1(2) 2(2) -1(2) 
C(25) 11(4) 7(4) 23(4) -5(3) -2(3) 4(3) 
C(26) 11(4) 7(4) 23(4) -5(3) -2(3) 4(3) 
C(27) 22(6) 18(7) 21(7) 2(5) -1(5) -7(5) 
C(28) 18(8) 12(5) 26(6) -2(4) 0(5) 0(5) 
C(29) 24(7) 18(7) 28(8) -4(6) -2(6) 1(5) 
C(30) 22(8) 29(6) 21(6) -2(5) 4(6) 12(7) 
C(31) 31(8) 30(8) 21(8) 1(6) -1(6) 4(6) 
C(32) 24(8) 40(7) 22(6) -1(5) 4(7) 12(8) 
C(33) 42(9) 33(9) 22(8) 2(6) -1(7) -1(7) 
C(34) 44(10) 57(10) 23(7) 0(6) -5(9) 5(11) 
C(35) 17(6) 8(5) 20(6) -3(5) -1(4) 8(4) 
C(36) 11(6) 26(7) 23(7) 1(5) -6(4) 3(4) 
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Table A52. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb272p212121. 
x y z U(eq) 
H(2) 4790 4883 6808 17 
H(3) 4151 4287 6312 17 
H(4) 6974 3327 6157 17 
H(5) 10499 2883 6511 17 
H(9A) 14177 4511 8238 25 
H(9B) 13532 3656 8212 25 
H(1OA) 9796 4660 8513 29 
H(10B) 9483 3789 8515 29 
H(11A) 13880 4547 8838 33 
H(11B) 13419 3679 8849 33 
H(12A) 9603 4721 9118 38 
H(12B) 9156 3854 9130 38 
H(13A) 13585 4596 9453 42 
H(13B) 13055 3733 9471 42 
H(14A) 9406 4812 9736 43 
H(l4B) 8787 3953 9747 43 
H(15A) 13353 4632 10074 50 
H(15B) 12682 3774 10087 50 
H(16A) 8412 4031 10358 57 
H(16B) 9117 4887 10348 57 
H(17A) 12110 3811 10718 96 
H(17B) 10326 4474 10865 96 
H(17C) 13197 4636 10681 96 
H(l9) 10276 5555 6816 20 
H(20) 10894 6081 6306 20 
H(21) 8288 7103 6145 20 
H(22) 4667 7561 6470 20 
H(26A) 536 5980 8208 16 
H(26B) 1072 6841 8183 16 
H(27A) 5107 6737 8491 24 
H(27B) 4818 5864 8496 24 
H(28A) 1025 6846 8806 22 
H(28B) 680 5975 8807 22 
H(29A) 5250 6719 9101 28 
H(29B) 4778 5853 9112 28 
H(30A) 1189 6896 9420 29 
H(30B) 700 6029 9430 29 
H(31A) 4845 5878 9734 33 
H(31B) 5407 6742 9718 33 
H(32A) 1324 6956 10029 35 
H(32B) 752 6093 10045 35 
H(33A) 5464 6792 10337 39 
H(33B) 4874 5930 10354 39 
H(34A) 1349 7015 10645 62 
H(34B) 3435 6497 10842 62 
H(34C) 783 6152 10664 62 
H(35A) 12345 2440 7203 23 





































Crystal color, habit 
Crystal size 




Completeness to theta = 28.97° 
Completeness to theta = 26.32° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data 1 restraints 1 parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb331 p 1 bar 






a = 10.2102(5) A 
b = 10.6491(6) A 




6.136 mm- i 
656 
yellow block 
0.10 x 0.08 x 0.05 mm3 
3.45 to 28.97° 
0.= 70.699(5)° 
13= 76.753(4)° 
y = 79.119(4)° 
-13<=h<=13, -14<=k<=14, -16<=1<=15 
25551 
5829 [R(int) = 0.1178] 
92.2% 
99.4% 
Semi-empirical from equivalents 
1.00 and 0.493 
Full-matrix least-squares on F2 
5829/0/310 
1.072 
R1 = 0.0522, wR2 = 0.0984 
R1 =0.0883, wR2=0.1076 
2.280 and -2.033 e.A-3 
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Table A54. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for rmb331Plbar. U(eq) is defmed as one third of the trace of the orthogonalized Uij 
tensor. 
x y z U(eq) 
Pt(1) 4955(1) 4969(1) 3184(1) 22(1) 
CI(1) 4685(2) 2733(2) 3980(2) 31(1) 
CI(2) 2907(2) 5486(2) 4313(1) 27(1) 
0(1) 8268(5) 860(5) 3483(5) 43(1) 
0(2) 8687(5) 7767(6) 1617(4) 43(1) 
N(1) 6708(5) 4529(5) 2110(5) 22(1) 
N(2) 8639(5) 3423(6) 1504(5) 26(1) 
N(3) 7887(6) 2971(7) 3631(5) 33(1) 
N(4) 5116(5) 6954(5) 2506(4) 21(1) 
N(5) 5735(5) 8940(5) 2228(5) 27(1) 
N(6) 7107(6) 6996(7) 3236(6) 30(1) 
C(1) 7726(6) 3603(7) 2457(6) 27(1) 
C(2) 8169(6) 4247(7) 476(6) 28(1) 
C(3) 8682(7) 4426(7) -718(6) 31(2) 
C(4) 7925(7) 5350(7) -1536(6) 34(2) 
C(5) 6709(7) 6045(7) -1139(7) 34(2) 
C(6) 6210(6) 5876(7) 52(6) 27(1) 
C(7) 6951(6) 4954(6) 877(6) 23(1) 
C(8) 9925(7) 2538(7) 1498(7) 35(2) 
C(9) 7971(7) 1575(7) 4135(7) 33(2) 
C(10) 7678(8) 1081(8) 5470(7) 42(2) 
C(11) 7984(9) -396(9) 5968(8) 55(2) 
C(12) 6017(6) 7597(6) 2675(5) 23(1) 
C(13) 4580(6) 9174(7) 1734(6) 29(2) 
C(14) 3889(7) 10364(7) 1106(6) 33(2) 
C(15) 2761(7) 10242(8) 733(6) 38(2) 
C(16) 2337(7) 9001(8) 932(6) 34(2) 
C(17) 3052(6) 7820(7) 1526(6) 30(2) 
C(18) 4194(6) 7945(7) 1911(6) 27(1) 
C(19) 6426(7) 9933(7) 2373(7) 35(2) 
C(20) 8419(7) 7148(7) 2658(6) 32(2) 
C(21) 9464(6) 6520(7) 3461(6) 30(2) 
C(22) 9327(7) 7218(8) 4403(7) 37(2) 
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Table ASS. Anisotropic displacement parameters (A2x 103) for nnb331Plbar. The anisotropic 
displacement factor exponent takes the fonn: -202[ h2 a*2U 11 + ... + 2 h k a* b* V 12 ] 
Ull lJ22 U33 lJ23 Ui3 U12 
Pt(I) 24(1) 24(1) 14(1) 0(1) -2(1) -2(1) 
CI(I) 36(1) 27(1) 23(1) -1(1) -3(1) -3(1) 
CI(2) 26(1) 29(1) 16(1) 00) 2(1) -2(1) 
0(1) 52(3) 40(3) 33(3) -11(3) -3(2) -3(2) 
0(2) 33(3) 60(4) 16(3) 8(3) 3(2) -1(2) 
N(l) 26(3) 18(3) 15(3) 1(2) 3(2) -4(2) 
N(2) 25(3) 29(3) 16(3) -2(3) 1(2) -1(2) 
N(3) 37(3) 36(4) 21(3) -6(3) -5(3) 6(3) 
N(4) 17(2) 27(3) 14(3) -4(2) -3(2) 3(2) 
N(5) 33(3) 23(3) 21(3) -2(3) 1(2) -6(2) 
N(6) 33(3) 32(4) 17(4) 3(3) 0(3) -9(3) 
C(I) 30(3) 30(4) 20(4) -7(3) -3(3) -2(3) 
C(2) 28(3) 28(4) 20(4) -2(3) 4(3) -4(3) 
C(3) 33(3) 34(4) 25(4) -10(3) 0(3) -4(3) 
C(4) 49(4) 36(4) 11(4) -2(3) 2(3) -8(3) 
C(5) 51(4) 28(4) 28(4) -6(3) -18(3) -6(3) 
C(6) 30(3) 28(4) 16(4) 0(3) 0(3) -3(3) 
C(7) 28(3) 25(3) 14(3) -4(3) 4(2) -7(3) 
C(8) 34(4) 35(4) 23(4) -1(3) 3(3) 5(3) 
C(9) 38(4) 33(4) 23(4) -4(3) -2(3) -6(3) 
C(IO) 38(4) 53(5) 32(5) -11(4) -8(3) 0(4) 
C(11) 68(6) 50(5) 34(5) -7(4) 4(4) 2(4) 
C(12) 27(3) 25(3) 9(3) -1(3) 3(2) -3(3) 
C(13) 29(3) 31(4) 15(3) 0(3) 3(3) 3(3) 
C(14) 37(4) 28(4) 25(4) -3(3) 2(3) 2(3) 
C(l5) 40(4) 42(5) 14(4) 2(3) 2(3) 13(3) 
C(16) 26(3) 47(5) 23(4) -4(3) -7(3) 6(3) 
C(17) 27(3) 39(4) 19(4) -2(3) -3(3) -4(3) 
C(18) 27(3) 32(4) 11(3) 4(3) 3(2) -3(3) 
C(19) 37(4) 32(4) 30(4) -5(4) 0(3) -4(3) 
C(20) 33(4) 34(4) 22(4) -5(3) 1(3) -1(3) 
C(21) 26(3) 35(4) 21(4) -4(3) 1(3) -1(3) 
C(22) 32(4) 43(4) 34(5) -9(4) -11(3) 0(3) 
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Table A56. Hydrogen coordinates C x 104) and isotropic displacement parameters CA2x 10 3) 
for rmb331Pl bar. 
x y z U(eq) 
H(3N) 7500(70) 3410(70) 4020(70) 30(20) 
H(6N) 6960(70) 6590(70) 3790(60) 10(20) 
H(3) 9498 3955 -971 37 
H(4) 8238 5501 -2352 41 
H(5) 6218 6644 -1701 41 
H(6) 5403 6361 302 33 
H(8A) 10208 2327 2253 53 
H(8B) 10602 2980 868 53 
H(8C) 9806 1726 1370 53 
H(10A) 8209 1513 5779 50 
H(lOB) 6728 1344 5746 50 
H(llA) 7409 -832 5722 83 
H(llB) 7825 -642 6826 83 
H(llC) 8916 -670 5679 83 
H(14) 4177 11193 950 40 
H(15) 2258 11014 332 46 
H(16) 1564 8967 663 41 
H(17) 2782 6988 1660 36 
H(19A) 6962 9512 2987 53 
H(19B) 5768 10622 2595 53 
H(19C) 7004 10323 1632 53 
H(21 A) 10365 6571 2977 36 
H(2lB) 9356 5581 3852 36 
H(22A) 9350 8162 4022 55 
H(22B) 10062 6862 4837 55 
H(22C) 8482 7071 4947 55 
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Crystal color, habit 




Completeness to theta = 28.08° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data I restraints I parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb291i21a 






a = 16.7763(13) A 
b = 18.6042(13) A 






0.38 x 0.23 x 0.21 mm3 
orange prism 
2.19 to 28.08°. 
-22<=h<=21, -24<=k<=24, -23<=1<=23 
24271 
6487 [R(int) = 0.0209] 
96.0% 
SADABS 
0.719 and 0.984 
Full-matrix least-squares on F2 
6487/0/378 
1.074 
R1 = 0.0279, wR2 = 0.0688 
R1 = 0.0346, wR2 = 0.0716 
2.979 and -0.813 e.A-3 
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Table A58. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb2911t. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
x y z U(eq) 
Pt(1) 2500 3991(1) 5000 20(1) 
Cl(1) 1545(1) 3114(1) 5070(1) 25(1) 
0(1) 3261(2) 4956(1) 2724(1) 35(1) 
N(l) 3307(2) 4758(2) 4871(2) 21(1) 
N(2) 4150(2) 5386(2) 4324(2) 21(1) 
N(3) 3624(2) 4266(2) 3761(2) 23(1) 
C(l) 3675(2) 4801(2) 4292(2) 21(1) 
C(2) 4081(2) 5764(2) 4965(2) 22(1) 
C(3) 3560(2) 5367(2) 5312(2) 22(1) 
C(4) 3389(2) 5584(2) 5994(2) 27(1) 
C(5) 3765(2) 6211(2) 6306(2) 33(1) 
C(6) 4277(2) 6611(2) 5948(2) 34(1) 
C(7) 4449(2) 6396(2) 5274(2) 28(1) 
C(8) 4698(2) 5560(2) 3826(2) 26(1) 
C(9) 3400(2) 4363(2) 2993(2) 25(1) 
C(10) 3344(2) 3685(2) 2545(2) 24(1) 
C(ll) 3014(2) 3737(2) 1777(2) 30(1) 
C(12) 2936(2) 3120(2) 1335(2) 34(1) 
C(13) 3175(2) 2461(2) 1659(2) 36(1) 
C(14) 3501(2) 2403(2) 2418(2) 32(1) 
C(15) 3595(2) 3018(2) 2861(2) 30(1) 
Pt(2) 7500 3988(1) 10000 20(1) 
Cl(2) 7500 2740(1) 10000 30(1) 
Cl(3) 7500 5234(1) 10000 26(1) 
0(2) 7029(2) 3939(1) 8891(1) 28(1) 
N(4) 6357(2) 4004(2) 10166(2) 22(1) 
N(5) 5017(2) 3863(2) 9862(2) 23(1) 
N(6) 5727(2) 3493(2) 8945(2) 24(1) 
C(16) 5728(2) 3776(2) 9629(2) 22(1) 
C(17) 5194(2) 4186(2) 10565(2) 24(1) 
C(18) 6044(2) 4274(2) 10759(2) 24(1) 
C(19) 6419(2) 4595(2) 11437(2) 27(1) 
C(20) 5909(2) 4820(2) 11898(2) 33(1) 
C(21) 5058(2) 4735(2) 11698(2) 34(1) 
C(22) 4685(2) 4415(2) 11025(2) 30(1) 
C(23) 4207(2) 3664(2) 9438(2) 30(1) 
C(24) 6346(2) 3587(2) 8630(2) 23(1) 
C(25) 6281(2) 3272(2) 7860(2) 24(1) 
C(26) 5590(2) 2889(2) 7533(2) 26(1) 
C(27) 5526(2) 2549(2) 6834(2) 34(1) 
C(28) 6163(2) 2617(2) 6462(2) 30(1) 
C(29) 6844(2) 3027(2) 6783(2) 31(1) 
C(30) 6912(2) 3342(2) 7481(2) 29(1) 
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Table A59. Anisotropic displacement parameters CA2x 103) for rmb2911t. The anisotropic 
displacement factor exponent takes the form: -202[ h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
Ull lJ22 U33 lJ23 UJ3 U12 
Pt(1) 21(1) 23(1) 16(1) 0 4(1) 0 
Cl(1) 28(1) 24(1) 24(1) -3(1) 8(1) -3(1) 
0(1) 43(2) 31(1) 25(1) 5(1) -4(1) 1(1) 
N(1) 23(1) 24(1) 15(1) -1(1) 3(1) 1(1) 
N(2) 19(1) 24(1) 18(1) 2(1) 2(1) 2(1) 
N(3) 29(2) 23(2) 19(2) 0(1) 7(1) -1(1) 
C(1) 20(2) 25(2) 16(2) 2(1) 2(1) 5(1) 
C(2) 17(2) 27(2) 20(2) 0(1) 0(1) 5(1) 
C(3) 19(2) 26(2) 19(2) -3(1) 0(1) 3(1) 
C(4) 23(2) 34(2) 22(2) -4(1) 2(1) 3(1) 
C(5) 27(2) 40(2) 29(2) -14(2) 3(2) 2(2) 
C(6) 30(2) 31(2) 37(2) -12(2) 0(2) -2(2) 
C(7) 20(2) 30(2) 32(2) -1(2) 3(2) -2(1) 
C(8) 23(2) 32(2) 23(2) 7(1) 5(1) 1(1) 
C(9) 21(2) 33(2) 19(2) 0(1) 2(1) 1(1) 
C(10) 21(2) 34(2) 19(2) -2(1) 5(1) -4(1) 
C(1l) 22(2) 45(2) 22(2) 0(2) 5(1) -1(2) 
C(12) 30(2) 56(3) 17(2) -8(2) 4(1) -5(2) 
C(I3) 32(2) 46(2) 30(2) -14(2) 9(2) -5(2) 
C(14) 29(2) 35(2) 31(2) -6(2) 6(2) 1(2) 
C(15) 28(2) 39(2) 21(2) -5(2) 3(1) 2(2) 
Pt(2) 12(1) 34(1) 14(1) 0 2(1) 0 
Cl(2) 23(1) 36(1) 31(1) 0 5(1) 0 
Cl(3) 17(1) 35(1) 25(1) 0 5(1) 0 
0(2) 21(1) 46(2) 16(1) -4(1) 2(1) -6(1) 
N(4) 15(1) 34(2) 18(1) -1(1) 4(1) -2(1) 
N(5) 15(1) 32(2) 22(2) 0(1) 5(1) -1(1) 
N(6) 17(1) 34(2) 20(2) -1(1) 3(1) 1(1) 
C(16) 16(2) 29(2) 21(2) 2(1) 3(1) -1(1) 
C(17) 18(2) 32(2) 22(2) 4(1) 7(1) -2(1) 
C(18) 19(2) 32(2) 21(2) 1(1) 6(1) -2(1) 
C(19) 23(2) 36(2) 23(2) 1(2) 4(1) -2(2) 
C(20) 36(2) 41(2) 21(2) -1(2) 7(2) -1(2) 
C(21) 32(2) 49(2) 25(2) 1(2) 15(2) 8(2) 
C(22) 22(2) 40(2) 32(2) 5(2) 12(2) 1(2) 
C(23) 14(2) 43(2) 32(2) -1(2) 3(1) -6(2) 
C(24) 19(2) 26(2) 22(2) 4(1) 1(1) 2(1) 
C(25) 24(2) 27(2) 21(2) 3(1) 3(1) 4(1) 
C(26) 28(2) 30(2) 23(2) 4(1) 8(1) -3(1) 
C(27) 35(2) 36(2) 30(2) 3(2) 0(2) -6(2) 
C(28) 38(2) 31(2) 22(2) -2(1) 4(2) 6(2) 
C(29) 27(2) 37(2) 30(2) -1(2) 7(2) 5(2) 
C(30) 23(2) 35(2) 29(2) 0(2) 3(2) 1(2) 
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Table A60. Hydrogen coordinates (x 104) and isotropic displacement parameters (Alx 10 3)for 
rmb291lt 
x y z U(eq) 
H(3N) 3590(30) 3910(20) 3920(30) 29(13) 
H(4) 3042 5322 6228 32 
H(5) 3675 6369 6765 39 
H(6) 4507 7034 6171 41 
H(7) 4793 6661 5039 33 
H(8A) 4916 5124 3665 39 
H(8B) 5138 5855 4089 39 
H(8C) 4402 5816 3394 39 
H(Il) 2849 4181 1561 36 
H(12) 2721 3151 821 41 
H(13) 3114 2051 1360 43 
H(14) 3656 1957 2632 38 
H(15) 3827 2984 3371 35 
H(19) 6982 4654 11574 33 
H(20) 6139 5036 12355 39 
H(21) 4739 4896 12023 41 
H(22) 4121 4356 10889 36 
H(23 A) 4245 3498 8948 45 
H(23B) 3854 4075 9389 45 
H(23C) 3990 3288 9698 45 
H(26) 5161 2855 7780 32 
H(27) 5063 2283 6623 41 
H(28) 6134 2390 6002 36 
H(29) 7259 3090 6523 37 
H(30) 7379 3601 7696 35 
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Crystal color, habit 




Completeness to theta = 28.03° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb292ltp21c 






a= 10.4180(9) A 
b = 17.0912(14) A 




5.162 mm- i 
752 
0.20 x 0.20 x 0.10 mm3 
yellow prism 
1.97 to 28.03° 
-13<=h<=13, -22<=k<=21, -10<=1<=10 
12376 
3324 [R(int) = 0.0176] 
96.5% 
SADABS 
0.712 and 0.984 
Full-matrix least-squares on F2 
3324/0/239 
1.043 
R1 = 0.0147, wR2 = 0.0338 
R1 = 0.0186, wR2 = 0.0355 
0.844 and -0.424 e.A-3 
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Table A62. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb292ltP2lc. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
x y z U(eq) 
Pt(I) 10000 0 0 9(1) 
CI(I) 9849(1) 120(1) -2869(1) 14(1) 
0(1) 6301(1 ) 1773(1) 176(2) 25(1) 
N(1) 9880(1) 1171(1) 223(2) 12(1) 
N(2) 9074(2) 2340(1) 762(2) 14(1) 
N(3) 8019(2) 1184(1) 1672(2) 15(1) 
C(1) 8953(2) 1555(1) 873(2) 14(1) 
C(2) 10177(2) 2477(1) -6(2) 14(1) 
C(3) 10688(2) 1744(1) -324(2) 13(1) 
C(4) 11829(2) 1678(1) -1057(2) 16(1) 
C(5) 12423(2) 2366(1) -1444(2) 21(1) 
C(6) 11893(2) 3099(1) -1139(3) 21(1) 
C(7) 10764(2) 3170(1) -421(2) 18(1) 
C(8) 8252(2) 2939(1) 1374(3) 18(1) 
C(9) 6702(2) 1265(1) 1150(2) 17(1) 
C(1O) 5852(2) 681(1) 1866(2) 19(1) 
C(ll) 4523(2) 775(1) 1429(3) 24(1) 
C(12) 3671(2) 220(2) 1927(3) 30(1) 
C(13) 4132(2) -420(1) 2835(3) 32(1) 
C(14) 5453(2) -519(1) 3296(3) 28(1) 
C(15) 6315(2) 33(1) 2823(3) 22(1) 
Table A63. Anisotropic displacement parameters (A2x 103) for nnb2921t. The anisotropic 
displacement factor exponent takes the fonn: -202[ h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
Ull lJ22 U33 lJ23 Ul3 Ul2 
Pt(l) 10(1) 6(1) 12(1) 0(1) 1(1) 0(1) 
CI(I) 20(1) 10(1) 13(1) 1(1) 2(1) 1(1) 
0(1) 19(1) 20(1) 33(1) 2(1) -5(1) 1(1) 
N(I) 13(1) 9(1) 14(1) 1(1) 0(1) -1(1) 
N(2) 17(1) 9(1) 16(1) -2(1) 0(1) 1(1) 
N(3) 13(1) 11(1) 22(1) 1(1) 3(1) 2(1) 
C(1) 15(1) 11(1) 14(1) 0(1) -1(1) 1(1) 
C(2) 16(1) 13(1) 13(1) 0(1) -3(1) -1(1) 
C(3) 16(1) 9(1) 14(1) 2(1) -2(1) -2(1) 
C(4) 17(1) 13(1) 18(1) -1(1) 2(1) -1(1) 
C(5) 20(1) 23(1) 19(1) 1(1) 3(1) -6(1) 
C(6) 28(1) 14(1) 20(1) 3(1) 0(1) -10(1) 
C(7) 26(1) 9(1) 18(1) 2(1) -3(1) -1(1) 
C(8) 20(1) 10(1) 24(1) -3(1) 0(1) 4(1) 
C(9) 15(1) 16(1) 21(1) -5(1) 1(1) 1(1) 





































Table A64. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb292lt 
x y z U(eq) 
H(3N) 8280(20) 769(13) 2170(30) 20(6) 
H(4) 12170(20) 1185(12) -1290(20) 11(5) 
H(5) 13180(20) 2343(13) -1920(30) 23(6) 
H(6) 12310(20) 3549(13) -1410(30) 24(6) 
H(7) 10430(20) 3647(15) -200(30) 27(6) 
H(8A) 7610(20) 3080(13) 480(30) 23(6) 
H(8B) 7830(20) 2736(13) 2320(30) 23(6) 
H(8C) 8750(20) 3391(13) 1690(30) 20(6) 
H(ll) 4240(20) 1237(13) 780(30) 23(6) 
H(12) 2810(30) 269(16) 1630(30) 39(7) 
H(13) 3560(20) -791(14) 3150(30) 29(6) 
H(14) 5750(20) -972(14) 3940(30) 31(6) 
H(15) 7190(30) -52(11) 3160(30) 25(7) 
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Completeness to theta = 29.0° 
Completeness to theta = 26.3° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data 1 restraints 1 parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
rmb332ltb 






a= 17.7393(5) A 
b = 11.4632(3) A 




3.801 mm- l 
1872 
0.31 x 0.20 x 0.08 mm3 
3.25 to 29.00° 
/3= 99.794(3)°. 
-23<=h<=23, -15<=k<=14, -25<=1<=26 
36021 
9266 [R(int) = 0.0407] 
89.5% 
99.7% 
Semi-empirical from equivalents 
0.743 and 0.425 
Full-matrix least-squares on F2 
9266/0/486 
1.068 
Rl = 0.0338, wR2 = 0.0716 
Rl = 0.0486, wR2 = 0.0793 
2.156 and -1.513 e.A-3 
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Table A66. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2x 103) for nnb332ltb. U(eq) is defmed as one third of the trace of the orthogonalized uij 
tensor. 
x y z U(eq) 
Pt(l) 9660(1) 9009(1) 7865(1) 15(1) 
CI(l) 10464(1) 7522(1) 8320(1) 26(1) 
CI(2) 9056(1) 8897(1) 8824(1) 20(1) 
0(1) 9347(2) 6557(2) 5682(1) 28(1) 
0(2) 11006(2) 4957(2) 6717(1) 21(1) 
0(3) 11066(1) 4417(2) 7861(1) 21(1) 
0(4) 9203(2) 13485(2) 8327(1) 26(1) 
0(5) 8101(2) 11715(2) 9523(1) 26(1) 
0(6) 8673(2) 10590(2) 10438(1) 23(1) 
N(I) 10154(2) 9059(2) 6997(2) 15(1) 
N(2) 10509(2) 8435(2) 6016(1) 17(1) 
N(3) 10015(2) 7030(3) 6747(2) 18(1) 
N(4) 9946(2) 4823(3) 7214(2) 20(1) 
N(5) 8926(2) 10293(2) 7469(1) 16(1) 
N(6) 8149(2) 11825(3) 7453(1) 20(1) 
N(7) 9101(2) 11530(3) 8472(2) 18(1) 
N(8) 9395(2) 11678(3) 9870(2) 19(1) 
C(1) 10213(2) 8140(3) 6591(2) 16(1) 
C(2) 10633(2) 9635(3) 6042(2) 18(1) 
C(3) 10898(2) 10383(3) 5575(2) 22(1) 
C(4) 10971(2) 11545(3) 5769(2) 25(1) 
C(5) 10782(2) 11932(3) 6400(2) 25(1) 
C(6) 10504(2) 11191(3) 6856(2) 20(1) 
C(7) 10421(2) 10018(3) 6668(2) 17(1) 
C(8) 10767(2) 7632(3) 5516(2) 25(1) 
C(9) 9586(2) 6285(3) 6280(2) 19(1) 
C(10) 9395(2) 5118(3) 6592(2) 21(1) 
C(ll) 10707(2) 4743(3) 7220(2) 18(1) 
C(12) 11904(2) 4521(3) 8048(2) 21(1) 
C(13) 8618(2) 5276(4) 6813(2) 31(1) 
C(14) 9353(3) 4176(3) 6024(2) 32(1) 
C(15) 12037(2) 4268(4) 8828(2) 28(1) 
C(16) 12285(2) 3595(4) 7665(2) 28(1) 
C{l7) 12162(2) 5755(3) 7919(2) 28(1) 
C(18) 8743(2) 11228(3) 7813(2) 17(1) 
C(19) 7944(2) 11251(3) 6813(2) 19(1) 
C(20) 7387(2) 11505(3) 6245(2) 25(1) 
C(21) 7324(2) 10729(4) 5690(2) 29(1) 
C(22) 7789(2) 9743(4) 5705(2) 25(1) 
C(23) 8351(2) 9504(3) 6274(2) 21(1) 
C(24) 8426(2) 10287(3) 6832(2) 16(1) 
C(25) 7683(2) 12706(3) 7730(2) 23(1) 
C(26) 9263(2) 12636(3) 8714(2) 20(1) 
C(28) 8664(2) 11362(3) 9915(2) 21(1) 
C(27) 9562(2) 12739(3) 9501(2) 21(1) 
C(29) 7964(2) 10082(3) 10605(2) 23(1) 
C(30) 10426(2) 12858(4) 9586(2) 28(1) 

















Table A67. Anisotropic displacement parameters (A2x 103) for rmb332ltb. The anisotropic 
displacement factor exponent takes the form: -2 02[ h2 a*2U 11 + ... + 2 h k a* b* U 12 ] 
Ull UZ2 U33 UZ3 UB UI2 
Pt(l) 17(1) 17(1) 12(1) 0(1) 3(1) 2(1) 
Cl(l) 34(1) 26(1) 15(1) 0(1) 0(1) 13(1) 
Cl(2) 23(1) 23(1) 15(1) 3(1) 6(1) 0(1) 
0(1) 30(2) 35(2) 16(1) 2(1) 0(1) -4(1) 
0(2) 21(1) 26(1) 18(1) -1(1) 4(1) 3(1) 
0(3) 14(1) 30(1) 17(1) 2(1) 0(1) -1(1) 
0(4) 28(2) 26(1) 25(2) 8(1) 5(1) -4(1) 
0(5) 18(1) 33(2) 26(1) 6(1) 3(1) 0(1) 
0(6) 21(2) 28(1) 22(1) 6(1) 6(1) -4(1) 
N(I) 14(2) 17(2) 13(2) 2(1) 0(1) 3(1) 
N(2) 19(2) 19(2) 15(2) -4(1) 3(1) 0(1) 
N(3) 24(2) 17(2) 14(2) 2(1) 5(1) 2(1) 
N(4) 20(2) 21(2) 21(2) 3(1) 5(1) -1(1) 
N(5) 18(2) 18(2) 14(2) 3(1) 5(1) 4(1) 
N(6) 21(2) 24(2) 15(2) 3(1) 6(1) 5(1) 
N(7) 22(2) 20(2) 13(2) 5(1) 5(1) 4(1) 
N(8) 17(2) 23(2) 17(2) 0(1) 4(1) 1(1) 
C(1) 17(2) 20(2) 13(2) -3(1) 3(1) 3(1) 
C(2) 14(2) 21(2) 16(2) 1(1) -1(2) 2(1) 
C(3) 18(2) 28(2) 20(2) 1(2) 3(2) -5(2) 
C(4) 22(2) 24(2) 28(2) 10(2) 2(2) -1(2) 
C(5) 18(2) 19(2) 35(2) -1(2) -2(2) -1(2) 
C(6) 18(2) 20(2) 22(2) -4(2) -2(2) 2(2) 
C(7) 14(2) 20(2) 16(2) 0(1) 3(1) 1(1) 
C(8) 28(2) 25(2) 23(2) -6(2) 10(2) 2(2) 
C(9) 14(2) 23(2) 19(2) -4(2) 2(2) 1(1) 
C(1O) 18(2) 23(2) 21(2) 2(2) 0(2) -1(2) 
C(ll) 19(2) 13(2) 19(2) -4(1) 1(2) 2(1) 
C(12) 16(2) 26(2) 20(2) 0(2) 3(2) 0(2) 
C(13) 19(2) 37(2) 38(2) 11(2) 4(2) 6(2) 
C(14) 29(2) 24(2) 38(3) -5(2) -6(2) 1(2) 
C(15) 18(2) 44(2) 21(2) 1(2) 2(2) -1(2) 
C(16) 23(2) 33(2) 28(2) 1(2) 5(2) 8(2) 
C(17) 24(2) 31(2) 29(2) -6(2) 5(2) -8(2) 
C(18) 19(2) 19(2) 13(2) 4(1) 7(2) 3(1) 
C(19) 19(2) 26(2) 14(2) -1(2) 6(2) -1(2) 
C(20) 23(2) 28(2) 24(2) 6(2) 3(2) 6(2) 
C(21) 21(2) 44(2) 19(2) 2(2) -1(2) 0(2) 
C(22) 24(2) 35(2) 16(2) -4(2) 5(2) 0(2) 
C(23) 19(2) 26(2) 20(2) 1(2) 6(2) 2(2) 
C(24) 16(2) 23(2) 11(2) 4(1) 4(1) 1(1) 
C(25) 20(2) 24(2) 27(2) 0(2) 10(2) 4(2) 
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C(26) 15(2) 22(2) 23(2) 1(2) 7(2) 1(2) 
C(28) 21(2) 25(2) 19(2) -2(2) 8(2) -2(2) 
C(27) 22(2) 18(2) 22(2) 3(2) 1(2) -1(2) 
C(29) 17(2) 33(2) 21(2) 3(2) 10(2) -2(2) 
C(30) 21(2) 37(2) 28(2) 5(2) 7(2) -2(2) 
C(31) 32(2) 25(2) 27(2) -3(2) 9(2) -1(2) 
C(32) 22(2) 33(2) 32(2) 3(2) 4(2) -3(2) 
C(33) 30(2) 39(2) 35(2) 5(2) 21(2) 7(2) 
C(34) 28(2) 40(2) 27(2) 6(2) 14(2) -1(2) 
Table A68. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for rmb332ltb. 
x y z U(eq) 
H(3N) 10050(20) 6860(30) 7150(20) 22 
H(4N) 9770(30) 4650(40) 7490(20) 24 
H(7N) 9180(30) 11090(30) 8720(20) 18(13) 
H(8N) 9770(20) 11430(40) 10200(20) 27(12) 
H(3) 11020 10118 5155 26 
H(4) 11150 12078 5473 30 
H(5) 10846 12717 6516 30 
H(6) 10376 11463 7273 25 
H(8A) 10864 6878 5728 38 
H(8B) 11229 7927 5383 38 
H(8C) 10379 7566 5108 38 
H(I3A) 8439 4537 6953 47 
H(l3B) 8260 5579 6427 47 
H(I3C) 8664 5812 7199 47 
H(14A) 9845 4097 5884 48 
H(14B) 8980 4396 5627 48 
H(14C) 9209 3446 6206 48 
H(I5A) 11752 4812 9058 42 
H(15B) 12572 4343 9014 42 
H(15C) 11872 3489 8906 42 
H(I6A) 12098 2839 7766 42 
H(16B) 12829 3624 7817 42 
H(16C) 12170 3736 7171 42 
H(17A) 12072 5911 7426 42 
H(I7B) 12698 5832 8100 42 
H(17C) 11880 6300 8151 42 
H(20) 7074 12157 6234 30 
H(21) 6959 10870 5295 34 
H(22) 7719 9237 5325 30 
H(23) 8665 8852 6283 26 
H(25A) 7674 12547 8214 34 
H(25B) 7171 12683 7472 34 
H(25C) 7898 13465 7685 34 
H(30A) 10636 12955 10072 43 
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H(30B) 10551 13525 9328 43 
H(30C) 10636 12169 9411 43 
H(31A) 8677 13727 9754 42 
H(31B) 9328 14497 9535 42 
H(31C) 9443 13918 10278 42 
H(32A) 7508 9566 9615 44 
H(32B) 7242 8781 10191 44 
H(32C) 8067 8637 10014 44 
H(33A) 7615 11657 10950 49 
H(33B) 6973 10704 10889 49 
H(33C) 7159 11311 10213 49 
H(34A) 8634 8979 11279 46 
H(34B) 7817 9142 11470 46 
H(34C) 8432 10128 11645 46 
Table A69. Hydrogen bonds for CompoWld 18 [A and 0]. 
D-H d(D-H) d(H .. A) <DBA d(D .. A) A 
N2-H2N 0.911 1.940 172.96 2.846 N6 [ x+ 1, y, z] 
N5-H5N 0.900 1.987 171.01 2.880 N3[x-1,y,z] 
N8-H8N 0.840 2.085 124.99 2.657 03 
N9-H9N 0.823 2.133 145.75 2.852 01 
Table A70. Hydrogen bonds for CompoWld 24 [A and 0]. 
D-H d(D-H) d(H. .A) <DBA d(D .. A) A 
N2-H20 0.768 2.420 152.24 3.121 04 
Table A71. Hydrogen bonds for compoWld 26 [A and 0]. 
D-H d(D-H) d(H .. A) <DBA d(D .. A) 
N2-H2N 0.729 
(H donor with no acceptor) 
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Table An. Hydrogen bonds for compound 28 [A and 0]. 
O-H d(D-H) d(H .. A) <ORA d(D .. A) A 
N2-H2N 0.708 2.599 145.17 3.206 Cll 
N4-H4N 0.827 2.756 131.42 3.361 Cl2 
Table A 73. Hydrogen bonds for compound 41 [A and 0]. 
O-H d(D-H) d(H .. A) <ORA d(O . .A) A 
N3-H3N 0.762 2.565 156.55 3.278 C12 [-x+1, -y+1, -z+l ] 
N6-H6N 0.663 2.612 160.80 3.245 C12 [-x+1, -y+l, -z+l ] 
Table A74. Hydrogen bonds for compound 46 [A and 0]. 
O-H d(D-H) d(H. .A) <ORA d(O .. A) A 
N3-H3N 0.793 2.392 144.38 3.071 Cll 
N4-H4N 0.701 2.440 163.01 3.117 04 [ x, y-1, z ] 
N7-H7N 0.694 2.300 116.03 2.678 N8 
N7-H7N 0.694 2.535 140.04 3.099 Cl2 
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